Consequences of Interstrand Crosslinks in Hematopoiesis: Tipping the balance between senescence and proliferation by Verhagen-Oldenampsen, J.H.E. (Judith)
ConsequenCes of interstrand Crosslinks in hematopoiesis:
tipping the balanCe between senesCenCe  
and proliferation
Judith Verhagen-Oldenampsen
Judith Proefschrift.indb   1 27-12-2012   16:33:08
Consequences of Interstrand Crosslinks in Hematopoiesis: 
Tipping the balance between senescence and proliferation
Copyright © 2013 Judith Verhagen-Oldenampsen, The Netherlands
All rights reserved. No part of this thesis may be reproduced or transmitted in any 
form or by any means, without prior written permission of the author.
ISBN/EAN: 978-94-91602-06-1
Auteur: Judith Hubertina Elisabeth Verhagen-Oldenampsen
Cover design and Lay-out: Janneke de Ronde, http://www.JdR-Design.nl
Printing: Print Service Ede BV, Ede, The Netherlands
 
The work described in this thesis was conducted at the Department of Hematology, 
Erasmus University Medical Center, Rotterdam, The Netherlands. 
This work was funded by Grant EMCR 2005-3314 from the Dutch Cancer Society 
“Koningin Wilhelmina Fonds”.
Financial support for printing this thesis was kindly given by the Dutch Cancer 
Society “Koningin Wilhelmina Fonds”, J.E. Jurriaanse Stichting, CaseMaster:EDC 
– Innovative EDC/eCRF Solutions and Erasmus MC University.
Judith Proefschrift.indb   2 27-12-2012   16:33:09
Consequences of interstrand Crosslinks in hematopoiesis: 
tipping the balance between senescence and proliferation
Consequenties van interstrand crosslinks in hematopoiese: 
Verschuivingen in de balans tussen veroudering en proliferatie
proefschrift
ter verkrijging van de graad van doctor aan de  
Erasmus Universiteit Rotterdam 
op gezag van de rector magnificus  
Prof.dr. H.G. Schmidt
en volgens het besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
dinsdag 26 februari 2013 om 13.30 uur
door
Judith hubertina elisabeth Verhagen-oldenampsen 
geboren te ‘s-Gravenhage
Judith Proefschrift.indb   3 27-12-2012   16:33:09
promotiecommissie
promotor:  Prof.dr. I.P. Touw
overige leden:  Dr. W. Vermeulen
 Dr. E.A.C Wiemer
 Prof.dr. E. van der Schoot
Copromotor: Dr. M.M. von Lindern
Judith Proefschrift.indb   4 27-12-2012   16:33:09
I was up, I was down, 
I felt almost everything. 
I was lost, been around, 
still know hardly anything. 
Get my feet on the ground 
and the heart of everything. 
It’s just the way that I want it.
Tonight’s the night, 
time to leave the pressure behind. 
There’s no surrender.
Voor mijn familie
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1 hematopoiesis
1.1 The hematopoietic system
Hematopoiesis is the process of blood cell formation, schematically 
depicted in Figure 1. Each day, an adult produces around 1011-1012 new 
blood cells. All blood cells are derived from hematopoietic stem cells (HSC) 
that reside in the bone marrow (BM). HSCs have the capacity to either 
self-renew or give rise to daughter cells with limited renewal capacity. 
These cells are indicated as long term repopulating stem cells (LT-HSC) 
and short term repopulating stem cells (ST-HSC), respectively. The ST-
HSC differentiate into multi-potent progenitor cells (MPPs) that undergo 
transient amplifi cation and contribute largely to the quantitative output of 
blood cells from the BM. In the hierarchical model  of hematopoiesis, MPPs 
give rise to common myeloid progenitors (CMPs) and common lymphoid 
progenitors (CLPs), probably through a stochastic mechanism in which 
survival is limited by the growth factors that are present. In turn the CMPs 
and CLPs give rise to the committed cells of the myeloid and lymphoid 
lineages [1-3]. Whereas the CLPs produce both T-, B-, and NK- cells, the 
CMPs give rise to macrophages, granulocytes, erythrocytes and platelets 
(Figure 1). Next to this classical model of hematopoiesis an alternative 
model exists in which lymphoid primed MPPs (LMPPs) exist which have 
both lymphoid and myeloid differentiation potential but lack erythro-
megakaryocyte potential [4]. The identifi cation of these LMPPs suggests 
that at least the granulocyte-macrophage lineage can be generated 
through an alternative mechanism.
The balance between proliferation, differentiation and cell death is tightly 
regulated in hematopoiesis. Disruption of this regulation can lead to a 
survival advantage or an increased replicative potential, which can result 
in leukemia [5]. For example, human chronic myeloid leukemia (CML) is a 
two stage disease of the BM which is caused by chromosomal translocation 
t(9;22). Due to this translocation the BCR-ABL protein is produced. Initially 
this will lead to hyperproliferation of white blood cells, which is the direct 
result of the constitutive kinase activity of BCR–ABL and activation of signal 
transduction pathways. Further mutations can induce the second stage of 
CML (blast crisis), that is characterized by impaired differentiation capacity 
and an increased number of blast cells in the circulation [6].
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Figure 1: Simplified scheme representing hematopoiesis. For details see text.
Acute myeloid leukemia (AML) is a heterogeneous group of leukemias in 
which the majority of the leukemic cells get stuck in an immature blast cell 
stage, representing precursors of early myeloid, erythroid, megakaryocytic, 
granulocytic, or monocytic cell lineages. The prognosis for patients with AML 
is mainly dependent on the genetics of the neoplastic cells [7]. The molecular 
markers with prognostic impact include recurrent translocations, mutations in 
FLT3, NPM1, MLL, WT1, c-KIT, and expression levels of BAALC, NM1, ERG, 
and CXCR4 (reviewed in [8]). Classification of these different AML subtypes 
using molecular markers is relevant because specific abnormalities are 
associated with clinical behavior. Favorable karyotypes with usually a good 
response to therapy include: t(8;21), inv(16) and t(15;17). In contrast, poor 
response is associated with for instance inv(3), or with a normal or complex 
karyotype. Therapy-related AML and AML arising from myeloid dysplastic 
syndrome (MDS) are also associated with poor response to therapy. While 
advances have been made in the understanding of AML, characterized by 
recurrent translocations such as t(8;21) and t(15;17), our understanding of 
poor response leukemia subtypes is still limiting and requires future research.
Bone marrow failure is characterized by impaired hematopoiesis and some 
BM failure syndromes associate with cancer predisposition [9]. It occurs most 
frequently in the elderly population, and at low frequency as congenital BM 
failure syndromes. BM failure occurs more frequently in the East than in the 
West [10]. In Japan and the Far East, the frequency is at least 3 times higher 
than it is in the United States and Europe, even after correction for ethnic 
differences. It has been suggested that environmental factors and persistent 
use of insecticides contribute to the cause of the disease [11]. 
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Although congenital BM failures are rare, the molecular characterization 
of these syndromes may give insight into BM failure in general. The most 
frequent congenital syndromes are described in more detail in the following 
sections. 
1.2 Congenital Bone Marrow Failure Syndromes
1.2.1 Diamond-Blackfan anemia (DBA)
Diamond-Blackfan anemia (DBA) is a congenital aplasia in which 
specifi cally the erythroid compartment is compromised. DBA is a disorder 
of ribosome biogenesis. To date 11 different structural ribosomal proteins 
of both the small and the large ribosomal subunit were found to be affected, 
with mutations in Rps19 being the most frequent aberration [12]. DBA 
usually becomes apparent during the fi rst year of life. Only occasionally 
it evolves into an aplastic anemia or leukemia. DBA is associated with 
craniofacial and thumb abnormalities as well as short stature. Cardiac 
defects are seen in one third of DBA patients. DBA patients are at risk of 
developing solid tumors and hematological malignancies later in life, which 
becomes apparent now that better treatment improves the life expectancy 
of DBA patients [13].  
1.2.2 Shwachmann-Diamond syndrome (SDS)
Shwachmann-Diamond syndrome (SDS) is an autosomal recessive 
disorder. Around 90% of patients carry a mutation in the SBDS gene that 
encodes an enzyme involved in the release of the 60S ribosomal subunit 
from the nuclear-cytoplasmic transport complex. [14]. Failure to release 
the 60S subunit impairs association of the small and large ribosomal 
subunits and inhibits translation initiation. It presents in childhood and is 
characterized by neutropenia that progresses to BM failure. Patients may 
also suffer from pancreatic failure and skeletal abnormalities [15]. SDS is 
associated with a high tendency towards malignant myeloid transformation 
into myelodysplastic syndrome and leukemia [16]. However solid tumors 
are a rare event in SDS, maybe because the patients succumb to the 
disease before solid tumors arise. 
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1.2.3 Dyskeratosis Congenita (DC)
Dyskeratosis Congenita (DC) is a congenital BM failure that is 
characterized by abnormal skin pigmentation, nail dystrophy and mucosal 
leukoplakia [17]. Several subtypes of DC exist: X-linked recessive, 
autosomal dominant and autosomal recessive. BM failure is the major 
cause of mortality with an additional predisposition to malignancy and 
fatal pulmonary complications. Most genes that are affected in DC affect 
a protein complex involved in uridylation of ribosomal RNA and the RNA 
component of the telomerase complex [18]. Other genes associated with 
the disease encode for proteins active in the telomere complex [19]. To 
what extent telomerase dysfunction and ribosome maturation contribute to 
this disease is still subject to controversy [20]. 
1.2.4 Fanconi Anemia (FA)
FA patients often present with a combination of several congenital 
abnormalities including short stature and skin hyperpigmentation [21]. 
Most of the patients that are diagnosed with FA will develop BM failure 
during the first or second decade of life. There is a strong predisposition 
for both solid tumors and hematological malignancies such as MDS or 
AML [22]. Currently 15 FANC genes have been identified that contribute 
to the disease [23-24]. The corresponding proteins function in a DNA 
repair pathway that is also indicated as the Fanconi pathway and is 
involved in DNA repair during DNA replication. At the cellular level, 
the hallmark phenotype of FA cells is pronounced hypersensitivity 
to agents that produce DNA interstrand crosslinks (ICLs) such as 
mitomycin C, diepoxybutane, cisplatin, nitrogen mustard, melphalan, 
cyclophosphamide and furocoumarins in combination with ultraviolet 
(UV) radiation exposure [25].
The clinical variability in congenital abnormalities and the progressive 
BM failure characteristics of FA patients is high [26], which is only 
partially linked to the different genotypes among these patients [27]. 
Mosaicism in the hematopoietic system contributes to this phenomenon 
[28]. In some patients with different mutations on the two alleles of a 
FA gene, one of the 2 mutated FA alleles may revert to its wildtype 
configuration through homologous recombination between the alleles in 
a hematopoietic stem cell. These reverted cells have a selective growth 
advantage over cells carrying 2 mutated FA alleles, and the reverted 
cells repopulate the BM. By consequence, patients have normal blood 
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counts, while they still have an increased risk of FA-related cancers in 
tissues that still carry two mutated alleles. This mechanism resembles 
the strong competitive advantage of non-recombined hematopoietic 
cells in mice carrying a conditional Ercc1 allele (Chapter 3).
1.2.5 Severe Congenital Neutropenia (SCN)
SCN represents a heterogeneous group of inherited disorders that 
are characterized by low neutrophil counts. It is a preleukemic condition 
independent of its genetic subtype. The acquired mutations in the G-CSF 
receptor (CSF3R) are specifi c for SCN and are strongly associated with 
malignant progression. Several causal gene mutations have been identifi ed 
in SCN, such as genes encoding chaperones or proteins involved in the 
unfolded protein response; ELANE [29], GFI1 [30] and HAX1 [29]. The 
clinical diagnosis is usually made shortly after birth or during the fi rst 
months of life, based on recurrent severe infections and severely reduced 
neutrophil count [31]. For most subtypes the underlying mechanism 
is considered to be increased apoptosis of neutrophils and neutrophil 
precursors [32-33].
In summary, the congenital BM failure syndromes affect ribosome 
synthesis, posttranslational quality control of proteins, telomere protection 
and DNA repair. Defects in these processes are sensed by proliferating 
cells and will lead to the activation of tumor suppressor systems with the 
aim to prevent wasting energy on ribogenesis, or permanent DNA damage 
[34]. The activation of tumor suppressor genes may explain the BM 
failure. The selection for cells that escape this repression and which are 
then able to repopulate the BM, may contribute to the subsequent risk for 
leukemic derangement (reviewed in [35]). Zebrafi sh and mouse models 
were generated for DBA and DC that recapitulate the disease. Notably, 
the disease phenotype is abrogated upon deletion of the tumor suppressor 
gene p53 [36-37] (see also section 3 about tumor suppressor genes and 
the DNA damage response). 
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1.3 Acquired Bone Marrow failure
1.3.1 Acquired Aplastic Anemia (Acquired AA)
Aplastic Anemia results from a marked decline of blood cell production 
by the BM. As a result reticulocytopenia, anemia, granulocytopenia, 
monocytopenia and thrombocytopenia arise [38]. Most cases of AA are 
acquired while only a small percentage of patients with AA are the result of 
an inherited disorder, such as Fanconi Anemia and Shwachmann-Diamond 
syndrome. The known causes of acquired AA include autoimmune disease 
[39], but also prolonged exposure to high doses of toxic chemicals 
(e.g. benzene) [40], viral infections (e.g. Epstein-Barr) [41], and distinct 
reactions to certain pharmaceuticals (e.g. chloramphenicol) [42-43]. In the 
latter conditions, acquired AA is most likely caused by the activation of 
tumor suppressor genes. 
1.3.2 Myelodysplastic syndrome (MDS)  
MDS is a HSC disorder characterized by ineffective hematopoiesis, 
various degrees of cytopenia and dysplastic features of peripheral blood 
and BM cells. MDS is distinctly different from acquired AA because the BM 
is not severely hypoplastic. Instead there may even be an excess of blast 
cells, in which case, mutations in these blasts indicate clonal expansion of 
BM progenitors. 
Although MDS is not considered to be a BM failure, there are similarities 
between congenital BM failure and MDS. For instance 5q- MDS includes 
deletion of ribosomal protein RPS14, which suggests that there may be 
similarities between 5q- MDS and DBA. Furthermore, monosomy 7 is 
a common aberration found when MDS or  FA BM undergoes leukemic 
transformation [44]. 
Whereas Fanconi Anemia is due to impaired DNA repair, a subgroup 
of MDS may result from exposure to DNA damaging drugs. This may be 
particularly true for patients that were previously treated for cancer [45-46]. 
For example, patients treated for breast cancer have a 3.5 fold increased 
risk for MDS development [47]. Therapeutic agents which are known to 
predispose for MDS include alkylating agents, topoisomerase II inhibitors 
and epipodophyllotoxins. Also radiation therapy increases the risk of MDS 
and leukemia development. 
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Patients who suffer from MDS, AA or BM failure syndromes are 
at increased risk to develop leukemia. Three possible hypotheses 
are proposed to explain clonal evolution in the context of BM failure. 
1) Acquisition of a genetic defect by one individual HSC can result in 
outgrowth of a leukemic clone via a mechanism independent from the 
underlying MDS/BM failure syndrome. 2) The cytopenia in BM and/or 
peripheral blood may select for a genetic defect that specifi cally overcomes 
the action of tumor suppressor genes. These cells will have a proliferative 
advantage and cause monoclonal hematopoiesis.  3) The BM senescence 
induced by tumor suppressor genes may induce epigenetic changes that 
enable some HSC to proliferate and repopulate the BM. Selection for the 
epigenetic changes that give the best adaptation will give rise to clonal 
hematopoiesis although DNA markers will not be present.
A comparison of MDS transforming to AML with congenital BM failures 
that undergo leukemic transformation suggests that at least part of the MDS 
patients may suffer from a BM failure in which mutations give proliferative 
advantage of the transformed cells over the affected cells in the population 
[48-49].
While several genes and chromosomal regions have been associated with 
MDS, a commonly deleted tumor suppressor gene has not been identifi ed. 
It is possible that haploinsuffi ciency and reduced gene dosage for critical 
genes involved in hematopoiesis are located on chromosome 5q and 7q, 
and may suffi ciently alter the balance between growth and differentiation 
to induce dysplastic hematopoiesis. Alternatively, epigenetic inactivation 
of the remaining allele or alterations in gene expression through loss of 
microRNA (miRNA) loci could also play a role. 
In this thesis we investigate the role of DNA damage and impaired 
repair in BM failure. Currently it is still largely unknown how DNA damage 
affects the hematopoietic system, and which DNA damage-induced tumor 
suppressor genes are involved in BM failure and subsequent leukemic 
progression. A model in which the effect of distinct levels of DNA damage 
on the hematopoietic system can be studied may enable the elucidation 
of specifi c molecular pathways that are involved in the transition from a 
damaged BM environment to leukemia. 
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2 the dna damage response
2.1 DNA damage and its consequences
The genome of every living organism is continuously damaged by 
endogenous and exogenous agents that modify the integrity of the DNA. 
Thereby the genetic information of the DNA is constantly challenged. 
DNA damage is an undesired chemical alteration in the base, sugar or 
phosphate group that alters the properties of the DNA helix. In contrast to 
mutations, that are fixed errors in the coding information of the genome, 
DNA damage can be repaired by specialized mechanisms. 
DNA damage can be induced by exogenous physical agents, 
endogenous chemical genotoxic agents, which are byproducts of 
metabolism such as reactive oxygen species (ROS), or by spontaneous 
chemical reactions such as hydrolysis. The main types of damage, their 
sources and main repair mechanisms are listed in Table 1.
table 1: types and sources of dna damage 
type of dna damage major source of dna damage dna damage repair mechanisms* 
Abasic site Spontaneous or alkylation induced BER
8-oxo-guanine (8-oxo-G) Reactive oxygen species (ROS) BER
6-4-photoproduct ((6-4))-PP) UV light NER
Cyclobutane pyrimidine dimer (CPD) UV light NER
Single strand break (SSB) Reactive oxygen species (ROS) NHEJ, HR, BER
Double strand break (DSB) Ionizing radiation (IR) NHEJ, HR
Mismatch (MM) DNA polymerase infidelity MMR
DNA-protein crosslink DNA topoisomerase enzymatic reaction Direct reversal, NER, HR
Interstrand crosslink (ICL)
Bi-functional alkylating agents/UV 
light/IR
NHEJ, HR
* BER: Base Exchange Repair, NER: Nucleotide Excision Repair, NHEJ: Non-Homologous 
End-Joining, HR: Homologous Recombination, MMR: Mismatch Repair.
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2.1.1 Types of DNA damage
The type and extent of DNA damage determines the fate of damaged cells. 
Some lesions are mainly mutagenic (oxidative lesions such as 8-oxoG), 
whereas others are more cytostatic or cytotoxic (double strand breaks and 
interstrand crosslinks). Most lesions however will have both mutagenic and 
cytotoxic properties varying in ratio depending on location and number of 
lesions as well as cell type, cell cycle stage and differentiation status. 
Mutagenic lesions are usually small changes to the base pairing region 
of DNA bases, including spontaneous deamination, depurination and 
oxidation of bases [50]. These lesions, if left unrepaired, will not block 
DNA metabolic processes such as replication but they infl uence replication 
fi delity. Thereby largely increasing the risk of mutations which in turn may 
contribute to carcinogenesis [51]. However larger helix distorting lesions 
(e.g UV-induced pyrimidin dimers) which do block replication, can also be 
carcinogenic when left unrepaired.
Cytotoxic lesions are chemically diverse, including crosslinks and double 
strand breaks (DSBs). Unrepaired cytotoxic lesions block metabolic 
processes in the cell, ultimately leading to proliferative arrest or cell death. 
The cumulative effect of cytotoxic lesions is therefore very likely to be a 
decrease in functional or proliferative capacity of cells, resulting in aging 
features in the affected tissues or organs.  
2.1.2 Consequences of DNA damage
When damage is infl icted in actively transcribed genes it will block transcription 
and affect protein synthesis. If mutations occur in the DNA due to error-prone 
repair or faulty replication, these will irreversibly change the genetic make-up 
of the cell. These mutations, as well as other changes in the DNA resulting 
from genome instability or miss-segregation (chromosome rearrangements, 
deletions, insertions, duplications and loss of heterozygosity) could lead to 
cancer, inborn defects and overall malfunctioning of cells. Consequently, 
genetic damage has both immediate as well as long term effects.
To protect the genome from the deleterious effects of DNA damage, cells 
are equipped with an arsenal of complementary DNA repair pathways 
([52], Table 1). In addition, cells are able to temporarily block cell cycle 
progression to allow repair before damage is converted in permanent 
mutations during replication [53]. Finally cells may use alternative pathways 
such as apoptosis [54] or senescence [55] when damage levels are too 
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high. The next sections of this introduction will focus on the mechanisms 
that are specifically related to hematological defects and bone marrow 
failure syndromes. These include DNA damage checkpoints (section 2.2), 
double strand break (DSB) repair (section 2.3), nucleotide excision repair 
(NER) (section 2.4) and interstrand crosslink (ICL) repair (section 2.5). 
2.2 DNA damage checkpoints
Maintaining genomic stability is of vital importance to cells. Any change 
to the genomic structure can lead to uncontrollable proliferation or cell 
death. To ensure correct genetic transfer throughout generations, cells have 
a set of surveillance and DNA repair mechanisms that prevent damaged 
DNA from being converted into heritable mutations. These surveillance 
mechanisms are called DNA damage checkpoints. They act as signal 
transduction pathways triggered by DNA damage and will result in inhibition 
of cell cycle progression and/or DNA replication (Figure 2, [56]).  They also 
induce efficient removal of lesions and an increased resistance to future 
lesions [57]. At the top of the checkpoint cascades are two protein kinases of 
the PIKK family, Ataxia Telangiectasia mutated (ATM) kinase and ATM and 
Rad3 related (ATR) kinase. ATM responds mostly to double strand breaks 
while ATR responds to replication stress, but both respond to a variety of 
other DNA lesions [58]. There is also crosstalk between these two pathways, 
for instance because single strand breaks (SSBs) can become DSBs when 
stalled replication forks collapse.
Upon DSB induction, the MRN complex consisting of Mre11, Rad50 and 
Nbs1 binds to the DSB [59]. The MRN-DSB complex recruits ATM to the 
breakage site.  The exact mechanism of ATM activation is still not clear, 
there are several proposed mechanisms such as autophosphorylation of 
ATM [60], activation via the MRN complex [61] and chromatin alterations 
[60]. Upon interaction of ATM with the MRN complex, other DNA damage 
response proteins are recruited to the DSB site. These DNA damage 
response proteins include (among others); MDC1, 53BP1 and BRCA1. 
Simultaneously ATM phosphorylates core histon 2AX (H2AX; referred to 
as γH2AX when phosphorylated), this histone is part of the nucleosome 
structure around which the DNA is wrapped. γH2AX is believed to stabilize 
the interaction of DSB response proteins at the breakage site and serves 
as a platform to facilitate accumulation of DNA repair proteins onto the 
damaged DNA [62]. ATM also phosphorylates and activates Chk2 which in 
turn phosphorylates and stabilises the tumor suppressor protein p53. The 
increase in p53 inhibits cell cycle progression (via p21/Cyclins) and induces 
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apoptosis (via PUMA/BAX/NOXA). Failure to repair DSBs prolongs the 
activation of ATM. For cells that are in G1 or S-phase of the cell cycle this 
will result in a G1 arrest due to activation of the cell cycle checkpoint kinase 
Chk2. If cells are in the G2 phase of the cell cycle Chk1 will be activated, 
resulting in mitotic arrest.
ATR can be activated by many different types of damage, including stalled 
replication forks. The immediate consequence of stalled replication forks is 
an increase in single stranded DNA (ssDNA), which is the primary signal 
for ATR activation [63]. The ssDNA is coated by RPA, and this complex 
recruits the ATR interacting protein (ATRIP) which is constitutively bound 
to ATR [64]. The binding of the ATRIP-ATR complex to the ssDNA-RPA site 
does not yet activate ATR. This is done by TopBP1 which is recruited to the 
ssDNA-RPA site by the 9-1-1 complex [65]. Activated ATR phosphorylates 
Chk1 [66], which phosphorylates and stabilize p53 in a context of persisting 
damage and results in inhibition of cell cycle progression and induction 
of apoptosis [67]. This pathway is critical for the induction of senescence 
in conditions with persisting DNA damage such as in the DNA repair 
defi ciency syndrome Fanconi Anemia [68-70]. The role of p53 downstream 
of ATR is supported by the fact that prolonged ATR activation, even in the 
absence of DNA damage, can promote p53-dependent senescence [71]. 
Activation of ATM and ATR also induces expression of the Cdnk2a locus 
that encodes p16 (mouse and human), p19 (mouse) and p14 (human). 
The mechanisms involved in activation of p53 and p16, and their role in 
hematopoiesis are described in part 3 of this introduction. 
In this thesis we employed Ercc1-defi cient mice to investigate how DNA 
repair defi ciency impacts on hematopoiesis. Ercc1 is well known for its 
function in nucleotide excision repair (NER), but it is also involved in ICL 
repair at the replication fork where it functions in the Fanconi pathway [72]. 
Defective ICL repair requires effi cient repair of double strand breaks and 
non-homologous end joining as a salvage pathway. The next paragraph 
will introduce these mechanisms. 
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Figure 2: Major signal transduction pathways upon replication fork stalling, 
double strand break induction and cellular stress, focusing on cell cycle 
kinases and p53. 
Upon stalling of replication forks ATR kinase is activated, while DSB activate 
ATM. In turn, ATR and ATM phosphorylate H2AX, p38 and Chk1. Via p38 and 
ATF2 cell growth and differentiation is regulated. Upon phosphorylation of Chk1 
either DNA repair is initiated by activating Ku/DNA-PK and FANC proteins or p53 
is phosphorylated which in turn can result in senescence induction, cell cycle 
inhibition via p21 or induction of apoptosis via PUMA/NOXA/BAX. In case of DSB 
induction, ATM is activated which phosphorylates H2AX and Chk2. Chk2 in turn 
phosphorylates p53 which can result in senescence induction, cell cycle arrest or 
apoptosis (as described above). Senescence can also be induced via the p16/Rb 
pathway. However, it is not exactly known how this pathway is activated.
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2.3 Double Strand Break Repair (DSB)
Double strand breaks (DSBs) may arise from ionizing radiation (IR), 
X-rays, free radicals, chemicals and during replication of a single strand 
break (SSB) or interstrand cross links (ICLs). Of all types of DNA damage, 
DSBs are the most harmful since a single unrepaired DSB can cause 
cell death [73].  Eukaryotic cells also produce DSBs themselves. During 
meiosis, DSB repair is essential for accurate chromosome segregation 
because meiotic recombination is initiated by the formation of DSBs [74]. 
DSB formation is essential for producing a diverse immune system in the 
context of V(D)J  and class-switch recombination in lymphocytes [75]. 
B- and T cells recognize foreign pathogens via B- and T cell receptors 
respectively (reviewed in [76]). By rearranging the regional genes of the 
lymphocyte DNA it is possible to generate a great variety in antibody 
repertoire.  
DSB repair occurs primarily by 2 pathways: nonhomologous end joining 
(NHEJ) and homologous recombination (HR) (Figure 3).
NHEJ repairs DSBs by joining the 2 DSB ends together. It is a powerful 
pathway to repair DSBs because it can ligate all DSB ends without the 
requirement of a homologous sequence. By consequence, it is error-prone 
and may generate small insertions and deletions [77-78]. NHEJ plays a 
major role in DSB repair during the G1 phase of the cell cycle since HR is 
not effi cient in this phase due to the lack of sister chromatids [79]. 
HR is a more error-free pathway which uses DNA homology to guide 
DNA repair. A DSB can be accurately repaired by using the undamaged 
sister chromatid strand as a template for the repair of the broken sister 
chromatid strand. Two intact DNA copies are yield from the ligation of the 
DNA strands and the separation of the joined molecules [80]. 
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Figure 3: Mechanisms of HR and NHEJ. 
The DSB signalling is initiated by ATR-ATRIP and/or ATM. In NHEJ, the Ku70/80 
heterodimer binds the damaged DNA ends. This facilitates the recruitment of the 
DNA-PK catalytic subunit to the DSB. The sequential binding of these proteins 
leads to the phosphorylation of DNA-PKc and the Ku heterodimer. DSB ends 
may need to be processed before ligation to obtain fitting ends. Artemis removes 
unpairable bases after which Pol λ/µ will fill in the remaining gaps after pairing of 
complementary overhangs . The DNA ligase IV-XRCC4-XLF complex then ligates 
the juxtaposed DNA ends together. In HR the 5’ DSB end resection is initiated by 
CtIP, Artemis and the MRN complex. Subsequently BLM complexes and EXO1/
DNA2 nucleases are recruited. End resection is completed by EXO1-BLM and BLM-
DNA2 subpathways. Then RPA will bind the single strand overhangs of the DSB 
which will function as a substrate for Rad51 filament formation. BRCA1 recruits the 
BRCA2-Rad51 complex to the damaged site, after which BRCA2 loads Rad51 onto 
the RPA coated ssDNA.If ends are already fully compatible after resection, direct 
single strand annealing (SSA)  will take place between complementary sequences 
(shown in red). The unpaired ssDNA overhangs are removed by ERCC1/XPF and 
the ends are ligated by DNA ligase III. If ends are not fully compatible, strand 
invasion will take place in the sister chromatid (homology search) and a D-loop 
will be formed. If elongation of the invasive strand takes place this will lead to 
displacement of the original homologous duplex sequence and extension of the D 
loop. Hereby the second DSB can be captured by annealing. This end can than 
also be elongated by Pol ζ (shown in dotted green) and gap filling and ligation 
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by DNA Polymerase III will lead to formation of a  Holliday junction. Resolution 
of this structure by SLX1/SLX4 will lead to the formation of newly repaired DNA 
strands which, depending on which strand is nicked, either can lead to crossover 
(C) or non-crossover (NC) products. Holliday junction dissolution performed by the 
dissolvasome (BLM-Top3α-RMI) will specifi cally lead to non-crossover products. 
In case of Synthesis-Dependent Strand Annealing (SDSA), newly synthesized 
DSB ends that stick out of the D loop can be re-annealed. Sequences which 
are not involved in annealing are cleaved and repair can be completed by gap 
fi lling synthesis and ligation. This repair pathway always results in non-crossover 
products. 
2.3.1 Dissease associated with defective DSB repair
Chromosomal instability is a hallmark of numerous tumor types and several 
diseases are linked to defective DSB repair. Defi ciencies in NHEJ most 
often lead to an increased risk of cancer (e.g. hematological malignancies, 
lymphomas and ovarian cancer [81]), with enhanced chromosomal instability, 
including translocations which are also reported in lymphoid malignancies. 
Nijmegen breakage syndrome (NBS) and Bloom syndrome (BS) are inborn 
errors of DSB repair. Both syndromes are characterized by a high sensitivity 
to radiation, growth retardation and immunodefi ciency, as well as by genomic 
instability and a high risk to develop cancer [82-83]. 
NBS cells lack a normal ATR-mediated response to DNA damage and fail 
to undergo G1/S or G2/M arrest [84]. Over 90% of all NBS cases is caused 
by a single hypomorphic 5 bp deletion in Nbs1 (NBS1-657del5) which leads 
to two truncated fragments of nibrin; the expected 26 kD fragment (p26-nibrin) 
and a 70 kD protein (p70-nibrin). The nibrin protein is part of the trimeric MRN 
complex which consists of nibrin, Mre11 and Rad50. The MRN complex is 
a primary sensor for DSBs and it is required for the monomerisation and 
autophosphorylation of ATM [85]. The interaction between nibrin and ATM 
can explain the similarities which are found between A-T and NBS (see also 
paragraph 2.6). 
BS is caused by mutations in BLM, a helicase that plays a key role in HR-
dependent DNA repair [86]. It is part of the “dissolvasome” consisting of BLM, 
Top3α and RMI which seperates double Holiday junctions that can arise during 
DSB DNA repair. BLM belongs to the RecQ helicases which are involved in 
the separation of DNA single strands and is responsible for the maintenance 
of genomic stability [87]. The clinical phenotype of NBS and BS show overlap 
with Fanconi Anemia (see section  1.2.4), and the protein complexes that 
harbor the BLM or NBS1 proteins also contain FA proteins [88-89]. 
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2.4 Nucleotide excision repair (NER)
ERCC1 is an endonuclease that functions in nucleotide excision repair 
(NER). It is involved in the repair of bulky and helix distorting lesions. NER is 
extremely versatile since it can repair various types of lesions such as UV-
induced crosslinks and pyrimidine dimers [90]. The NER pathway consists 
of 2 separate mechanisms (Figure 4). Global genome NER (GG-NER) 
scans the entire genome for lesions that distort the DNA helix (e.g. bulky 
lesions) [91] whereas transcription coupled NER (TC-NER) only operates 
on lesions in actively transcribed genes [92]. The basic steps of NER are 
(1) damage recognition, (2) DNA unwinding and lesion verification, (3) 
incision of the lesion and release of the incised DNA patch, (4) repair of 
the created gap and (5) ligation of the newly synthesized fragment. Both 
pathways are described in  detail in the legend to Figure 4.
2.4.1 Diseases related to defective nucleotide excision repair
At least 3 human syndromes are associated with inborn defects of 
NER; Xeroderma Pigmentosum (XP), Cockayne syndrome (CS), and 
Trichothiodystrophy (TTD). These disorders are all characterized by 
extreme sun sensitivity [94]. UV light induces covalent bonds between 
adjacent pyrimidines on the same DNA strand. The main induced lesions 
are cyclobutane pyrimidine dimers (CPD) and (6 – 4) pyrimidine pyrimidine 
photoproducts ((6 – 4)-PP).
2.4.1.1 Xeroderma Pigmentosum (XP)
XP was the first human disorder identified as a DNA repair defect [95]. It 
is an autosomal recessive genetic disorder in which the ability to repair UV-
induced photoproducts is impaired due to mutations in XPA, XPB, XPC, XPD, 
XPE, XPF and XPG. The primary clinical manifestation of XP patients is a 
1000-fold increase in predisposition for skin carcinoma [96]. In addition, 
progressive neurological degeneration is seen although this progression 
is highly variable between patients [97]. Clinical manifestation of this 
degeneration is seen as abnormal gait, sensorineural deafness and lack of 
deep tendon reflexes. 
The increased cancer incidence can be attributed to an accumulation 
of mutations in the genome of actively replicating cells. In contrast, the 
degenerative symptoms (e.g. skin atrophy or neuron death) are probably the 
result from the accumulation of lesions in transcribed genes, either because 
they cause the inactivation of essential genes, or because they trigger 
apoptosis [96].
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Figure 4: Mechanism of nucleotide excision repair. 
This fi gure shows the molecular mechanism of nucleotide excision repair (NER) 
and its 2 subpathways, global genome NER (GG-NER) and transcription coupled 
NER (TC-NER). In GG-NER, XPC (complexed to HR23B) and XPE recognize the 
helix distorting lesion while in TC-NER stalled RNA polymerase II is the trigger 
for activation of CSA and CSB proteins. In both pathways the recognition step is 
followed by recruitment of the TFIIH complex (containing XPB and XPD) which 
unwinds the helix around the damaged site to form an open complex. This complex 
is stabilized by XPG. Next XPA verifi es the lesion and RPA stabilizes the open 
intermediate structure by binding single-stranded DNA. XPA acts as a scaffold for 
binding to TFIIH, RPA and ERCC1/XPF [93]. The structure specifi c endonucleases 
XPG and ERCC1/XPF are recruited and cleave 3’ and 5’ of the lesion respectively, 
thereby releasing a 24-32 nucleotide fragment which contains the lesion. The 
remaining single-strand gap is fi lled by regular replication machinery (consisting of 
PCNA and DNA polymerase (recruited to the site by RFC)) and the resulting nick is 
sealed by ligase I or ligase III (adapted from Hoeijmakers, Nature 2001).
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2.4.1.2 Cockayne syndrome (CS) 
CS is an autosomal recessive disorder. It is caused by mutations in either 
CSA or CSB and patients are impaired in the TC-NER pathway of actively 
transcribed genes. CS patients exhibit extremely short stature, ataxia 
and progeroid appearance. The disease results in a severe reduction of 
lifespan but there is no link to increased cancer incidence [98]. 
2.4.1.3 Trichothiodystrophy (TTD)
Like XP and CS , TTD is an autosomal recessive disorder characterized 
by brittle hair and skin disorders [99-100]. Up to now four responsible 
genes have been identified for TTD; XPB, XPD, TTDA and TTDN1. 
TTD patients fall into three complementation groups that correspond to 
mutations in subunits of the  general transcription factor TFIIH: TTD-A, 
XPB, and XPD [101]. The function of TTDN1 is still unknown. Patients 
often have an unusual facial appearance with protruding ears and a 
receding chin. Mental abilities range from the low end of the normal range 
to severe retardation [102]. Several categories of TTD can be recognized 
based on cellular responses to UV damage and the affected genes. 
Photosensitive cases of TTD involve mutations in XPB, XPD or TTDA. The 
non-photosensitive form of TTD is genetically heterogeneous with about 
18% of cases relatable to a mutation in the TTDN1 gene [103]. Although 
patients with TTD do not exhibit increased incidences of skin cancer, mice 
with a human TTD mutation do show increased incidences of UV-induced 
skin cancer [104-105].
2.4.2 NER mouse models
For almost all NER factors mouse models have been generated [106-
107] in which the NER disease phenotype is accurately preserved although 
cancer predisposition is more pronounced and neurological complications 
are milder [108]. Mice also show signs of premature aging [109]. Whether 
aging of the hematopoietic model occurs has only rarely been investigated. 
In a mouse model of TTD it has been shown that there is a progressive 
loss of BM progenitors while the HSC levels are preserved  [110].  Analysis 
of the HSCs showed that they have impaired repopulation ability in a 
competitive BM transplantation setting compared to wildtype HSCs. 
This directly shows that HSC function is compromised in XpdTTD mice. 
Previously we have shown that 3 week old Ercc1 knockout mice exhibited 
multilineage cytopenia and fatty replacement of bone marrow [111]. In 
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addition to these features we saw a reduction in stress erythropoiesis and 
early hematopoietic progenitors which was not seen in XPA defi cient mice. 
These data suggest that spontaneous ICLs contribute to the functional 
decline of the hematopoietic system which is associated with aging.
2.5 Interstrand crosslink repair (ICL)
Interstrand crosslinks (ICLs) are very toxic to cells. Already a small 
number of 40 unrepaired ICLs can kill a repair defi cient cell [112]. ICLs 
can be repaired by different DNA repair pathways, depending on how 
they are recognized. In the context of non replicating DNA, the distortion 
of the helical structure will recruit proteins involved in GG-NER. In case 
of RNA polymerase II stalling during transcription, TC-NER will become 
activated. When ICLs are detected during replication (Figure 5), it will lead 
to recruitment of the Fanconi Anemia pathway of ICL repair. 
Stalled replication forks locally increase single strand DNA which results 
in activation of  ATR kinase (see section 2.2), phosphorylation of Chk1 
and subsequent triggering of S phase checkpoints. When ICLs result in a 
stalled replication fork, ATR kinase is activated, which results in association 
of the Fanconi core complex (FANC-A, -B, -C, -E, -F, -G, -L and -M) and its 
translocation to the nucleus where it associates with several other Fanconi 
proteins. FANC-M can also function independently of the core complex and 
has a role in replication fork progression and stabilisation [113]. FANC-M 
associates with FAAP24 and has an essential role in accumulating and 
phosphorylating RPA at the damaged site [114]. It is also thought that 
FANC-M can recognise the ICL [115].
ATR simultaneously phosphorylates FANCI, which recruits the ubiquitin 
ligase FANCL and leads to monoubiquitination of FANCD2 [116]. The 
ubiquitination of FANCD2 results in  translocation of the FANCD2/FANCI 
complex to the nucleus where it colocalizes with several downstream FA 
proteins among which are FANCD1 (BRCA2), FANCN, FANCJ, FANCP 
and FANCO, together with DNA repair proteins among which BRCA2, 
Rad51, γH2AX and PCNA. Together these proteins form the so-called DNA 
repair foci [117]. The FANCD2/FANCI complex is involved in the incision 
step to remove and repair  the ICL. The endonuclease FAN1 interacts 
with the mono-ubiquitinated form of FANCD2 and thereby is recruited 
to the damaged site [118]. The SLX4 protein (FANCP) coordinates the 
action of FAN1 as well as that of the endocnucleases MUS81/EMR1 and 
ERCC1/XPF. While FAN1 and/or MUS81/EME1 nicks the 5’ side of dsDNA, 
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Figure 5: Schematic representation of replication coupled ICL repair. 
ICLs physically block replication. When a replication fork encounters an ICL it will 
stall in front of it. A). ATR will become activated and will phosphorylates Chk1, 
thereby inducing checkpoint activation. Simultaneously the FANCM-FAAP24 
complex recognizes the ICL and FANCM is phosphorylated by ATR. B). ATR 
simultaneously phosphorylates FANCI which leads to recruitment of FANCL and 
assembly of the FA core complex. FANCL monoubiquitinates FANCD2, which 
results in the nuclear translocation of the FANCD2/FANCI complex. There the 
endonuclease FAN1 associates with FANCD2. The ubiquitinated form of FANCD2 
interacts with several downstream proteins such as FANCD1 (BRCA2), FANCJ 
(BRIP1), FANCN (PALB2), FANCO (Rad51c), BRCA1 and Rad51 to form DNA 
repair foci. C). Endonuclease FAN1 interacts with ubiquitinated FANCD2, whereas 
the action of endonucleases ERCC1/XPF and MUS81/EME1 is coordinated by 
FANCP (SLX4). The endonucleases incise the crosslink and unhook it from the 
DNA strand. The resulting DSB can be repaired by HR.
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ERCC1/XPF makes an incision at the junction of dsDNA and ssDNA thereby 
unhooking the ICL. Due to ICL unhooking a DSB is formed which can then 
be repaired by HR as described in section 2.3. Interestingly, mice which 
lack Slx4 have a defect in the recruitment of ERCC1/XPF onto chromatin 
which indicates a role for ERCC1 in FA mediated ICL repair [119-120]. 
Genetic evidence also indicates that the endocnulease ERCC1/XPF 
participates in the same ICL repair pathway as the FA proteins [121]. First, 
Xpf and FancD2 are genes that suppress each other’s effect which makes 
them likely to function in a similar pathway [122]. Second, it has been shown 
that in the absence of the endonuclease ERCC1/XPF complex, cells show 
a defect in FANCD2 recruitment to the damaged chromatin [121]. Thirdly, 
the phenotype of Ercc1 knockout mice has signifi cant overlap with FA 
features [111, 123-124]. 
2.6 Linking defi cient DNA repair to disease phenotypes
The DNA damage response (DDR) operates in a variety of biological 
situations outside of its core business of DNA repair. Such as generation 
of immune diversity via V(D)J recombination, genetic diversity generation 
via sexual reproduction and regulation of telomere homeostasis. A tight 
regulation of the DDR is thus of critical importance for the cell to maintain its 
genomic integrity. Inherited DDR defects commonly predispose patients to 
cancer, contribute to mutations and may allow for survival benefi ts of tumor 
cells despite the presence of genomic instability (see Figure 6 for a schematic 
representation). 
Ataxia Telangiectasia (A-T; caused by mutations in ATM [125]) and Ataxia 
Telangiectasia Related (Seckel syndrome, caused by mutations in ATR [126]) 
cover many aspects of the syndromes discussed in the previous paragraphs, 
because the surveillance role of the mutated proteins functions at the top of 
the DNA repair cascade. The central role of the MRN complex in the ATM 
dependent DSB response is exemplifi ed by  the human disorders caused 
by defects in the MRN complex that are regarded as ‘A-T-like’ conditions 
(A-T-LD [127]). In fact, NBS and A-T-LD exhibit a similar DSB repair defect 
to that of A-T [128]. A-T-LD is caused by hypomorphic defects in the Mre11 
component of the MRN complex [129]. Clinically, A-T-LD manifests as a 
mild/attenuated version of A-T but without cancer predisposition [127]. It is 
very likely that mutations in specifi c DNA repair pathways will lead to specifi c 
disease phenotypes. However it is still not exactly clear which specifi c 
mutations underlie the phenotype of DNA repair related diseases. 
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Figure 6: Cancer versus aging in the hematopoietic system. 
Extensive DNA damage in the presence of an intact DDR can lead to either 
apoptosis or senescence depending on the type of damage. This in turn can lead 
to depletion of the hematopoietic system and eventually in bone marrow aplasia. 
Limited damage in the context of an impaired DDR can lead to mutations which can 
be propagated in either HSCs or progenitors. Additional hits can then lead to clonal 
expansion and eventually to leukemia development.
2.6.1 Cancer
Cancer predisposition is often associated with DDR deficiencies. For 
instance, Fanconi Anemia patients have defects in ICL repair and an 
increased risk of hematological malignancies. XP patients have defects 
in NER and are therefore hypersensitive to UV induced damage and 
therefore predisposed to skin cancers. A defect in mismatch repair 
(MMR), functioning in correcting mismatched bases generated during 
DNA replication, leads to predisposition to colorectal cancers in patients 
with hereditary non-polyposis colon cancer. Other syndromes with 
cancer predisposition have defects in cell cycle checkpoint activation 
such as AT patients, which have mutations in ATM. Besides an 
increased cancer risk, they also display neurodegenerative disease. 
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Most cancers do not show germline mutations in DNA repair genes, 
but they fail to cope with the mutational pressure on the cells. Tumor 
progression is highly correlated to a progressive impairment of DDR 
[130]. It is also likely that during the pre-malignant tumor state, increased 
oncogene-induced proliferation will lead to replicative stress. In this case 
replication forks will stall, resulting in DNA breaks (mostly DSBs) and 
constitutive activation of the DDR [131]. Unrepaired damage in genes 
(including those in DDR) will cause further genetic instability. 
2.6.2 Premature aging   
Organismal aging is generally characterized by a declining regenerative 
ability, increasing homeostatic imbalance and an increase in age related 
diseases such as cancer [132]. Three hypothesis are proposed to explain 
this relationship. The fi rst suggests that longer exposure to carcinogens 
will ultimately lead to a higher cancer risk [133]. The second proposes 
that internal shifts in the organism homeostasis may favor induction 
of cancer or outgrowth of latent malignant cells [134]. This hypothesis 
includes senescence inducing mechanisms [135]. The last hypothesis is 
that cancer and aging are linked to the accumulation of DNA damage over 
time combined with increased epigenetic gene silencing [136].
Mutations in repair pathways lead to specifi c segmental progeroid 
syndromes [137-138]. For instance, mice defective in nucleotide excision 
repair (NER) display features commonly observed in premature aging 
syndromes including runted appearance, ruffl ed fur and shortened life 
span. 
A consequence of insuffi cient DNA repair in HSCs is stem cell failure. 
Stem cell function can be impaired due to increased senescence or 
apoptosis in response to rapid tissue regeneration attempts, such as blood 
cell production in a hypoplastic BM. This effect is seen to variable degrees 
in mice defective in the Fanconi Anemia pathway, NER, MMR and NHEJ 
[110, 139-141].
Spontaneous and/or endogenous DNA damage limits stress-
hematopoiesis by diminishing the ability of HSCs to proliferate and 
self-renew. HSCs are mostly quiescent and thus replication induced 
damage is not likely.  Progenitor cells have a higher proliferation rate 
compared to HSCs and are therefore more prone to DNA damage induced 
by replication. These cells will be preferentially lost upon damage induction 
while the HSCs will remain and accumulate more damage. Damaged 
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HSCs will respond to their extensive DNA damage load by entering a 
senescent state or undergoing apoptosis. In either case, the BM becomes 
hypocellular and BM failure will be inevitable.
Genetic pathways regulating longevity respond to accumulating DNA 
damage by influencing the rate of DNA damage accumulation and 
thereby its impact on cancer and aging [142].  The cellular response to 
accumulation of DNA damage is thought to be upregulation of antioxidant 
mechanisms, activating genome maintenance pathways and suppression 
of the IGF-1/GH somatotrophic axis. Active metabolism produces reactive 
oxygen species (ROS) which can damage the DNA [143]. The conserved 
IGF-1 pathway modulates the speed of organismal aging by suppressing 
the somatotrophic growth axis and subsequent energy metabolism under 
stress conditions [144-145] . Thereby the formation of ROS is prevented 
and thus the amount of DNA damage is reduced. This will ultimately lead 
to a prolongation of lifespan without excessive formation of mutations and 
minimal loss of tissue homeostasis.
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3  tumor suppressor genes and the dna
 damage response
Human tumor formation is promoted by mutations in 3 classes of genes: 
oncogenes, DNA repair genes and tumor suppressor genes (TSG). The 
fi rst cancer genes found, were those who could transform cells in a 
dominant way, these genes are now known as oncogenes due to their 
ability to drive oncogenesis. The opposite class of genes is called tumor 
suppressor genes. These genes suppress oncogenesis by regulating cell 
cycle progression and thereby safeguard the fi delity of DNA replication and 
chromosomal segregation. In the following paragraphs several important 
tumor suppressors involved in leukemogenesis will be discussed in more 
detail. 
3.1 p53
p53 is considered to be one of the major guardians of the genome. In 
response to DNA damage p53 induces a transient growth arrest, allowing 
DNA repair. In case of extensive DNA damage, p53 promotes either 
senescence or apoptosis [146-147]. In approximately 50% of human 
cancers mutations are present in the p53 gene.  In the majority of the 
remaining 50%, p53 function is compromised due to deregulation of up- or 
downstream signaling pathways [148]. 
3.1.1 Regulation of p53
The majority of p53 protein is localized in the nucleus which is consistent 
with its function as a transcription factor.  p53 contains several functional 
domains including a N-terminal transactivation domain, a proline-rich domain, 
a central DNA binding domain (DBD), a nuclear localization sequence (NLS), 
a tetramerization domain (TET), a nuclear export sequence (NES) and a 
C-terminal regulatory domain (REG). All domains can be post-translationally 
modifi ed which ensures a rapid adaptation to changing conditions. The 
best known regulator of p53 is mouse double minute 2 (MDM2) which is a 
ubiquitin ligase [149].  MDM2-induced ubiquitination controls nuclear export 
and degradation of the p53 protein. Like p53, MDM2 is subject to intensive 
posttranslational modifi cations including phosphorylation, ubiquitination, 
acetylation and sumoylation. 
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Under normal circumstances, p53 turnover is maintained at a high level by 
the activity of MDM2, which inhibits p53’s function as a transcriptional activator 
and targets p53 for proteasome-mediated degradation. In turn, p53 upregulates 
MDM2 protein levels, forming a negative autoregulatory loop. In addition, the 
p14ARF protein (p19Arf in mouse) stabilizes p53 by inhibiting MDM2-dependent p53 
degradation, thus specifically activating the p53 pathway. Together, these proteins 
maintain p53 at a steady-state level, allowing the cell cycle to be controlled. 
DNA damage induces phosphorylation of MDM2, which prevents it from 
inhibiting p53 function. Similarly, stress signals induce phosphorylation of 
p53, which protects p53 from MDM2-mediated targeting for degradation. By 
consequence, p53 accumulates. As a result of the increased p53 levels, cells 
will not enter the cell cycle until the DNA damage has been repaired. If repair 
fails, p53 will eventually trigger apoptosis [150].
Mutations in p53 can prevent Mdm2 transcription, or binding of MDM2, 
resulting in protection of p53 from degradation which will lead to increased 
cell cycle arrest. [151]. Tumors may also show overexpression of MDM2, 
constitutively suppressing p53 levels and thereby preventing cell-cycle arrest 
and apoptosis levels by MDM2 [152]. In addition, the viral oncoproteins 
SV40 large T antigen and adenovirus E1B can inactivate the regulatory 
functions of wildtype p53 through sequestration of p53 and/or by increasing 
the phosphorylation of p53. As a consequence, transformed cells express 
high levels of functionally inactive p53 [153-154]. In contrast, the human 
papillomavirus E6 oncoprotein functionally inactivates p53 by strongly 
increasing degradation of this protein in a manner similar to MDM2 [155].
3.1.2 p53 and senescence 
Cellular senescence is characterized by an irreversible cell cycle arrest [156-
157]. There are 2 different forms of senescence induction. The first is known 
as replicative senescence and is induced by telomere shortening which is a 
universal mechanism for limiting proliferative potential. Due to cell divisions 
telomeres erode. Dysfunctional telomeres are sensed as DSBs which will 
induce a DNA damage response via ATM/ATR- Chk1/2- p53-p21-Cdk and 
induces growth arrest (as discussed in section 2.2).  [158-159]. Cells that fail 
to senesce in response to critically short telomeres develop chromosomal 
aberrations, which can result in malignant transformation [160]. Senescence 
induced by non-telomeric signaling is called stress induced premature 
senescence (SIPS). In this case other types of stress such as high ROS levels 
[161], DNA damage [162] or abnormal oncogene activity [163] activate ATM 
and ATR, and elicit a senescent phenotype. 
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3.1.3 p53 and apoptosis
Apoptosis is a tightly regulated multistep process which regulates cell 
death. It is characterized by cell shrinkage, chromatin condensation as well 
as nuclear- and cell fragmentation. These features result in the formation 
of apoptotic bodies that are engulfed by neighboring phagocytic cells 
[164-165].  Under a variety of cell-death-inducing conditions (e.g. IR and 
ischemia), p53 rapidly localizes to mitochondria. Once at the mitochondrion, 
p53 induces mitochondrial outer membrane permeabilization (MOMP), 
thereby triggering the release of pro-apoptotic factors (tBid and BAX) from 
the mitochondrial intermembrane space [166]. Mitochondrial p53 can also 
release BAK from inhibitory BAK–MCL-1 complexes, thereby enabling 
BAK-dependent apoptotic cell death [167]. Another possibility is that the 
p53 target PUMA can release p53 from inhibitory p53–BCL-XL complexes 
[168]. Cytosolic p53 can then promote mitochondrial translocation of BAX 
and subsequent apoptosis [169]. p53 can also induce it’s target genes 
PUMA and NOXA via transcriptionally regulated mechanisms [170].
3.1.4 p53 in hematopoiesis and leukemogenesis
p53 mutations in AML are associated with a complex karyotype [171], 
and with shorter survival and resistance to therapy [172]. The incidence of 
p53 mutations in AML varies from 10-15% [173-174]. The incidence with 
which the p53 pathway is compromised is much higher due to deregulation 
of upstream regulatory factors. For example, MDM2 overexpression leads 
to inactivation of p53 without the necessity of mutations in the p53 gene 
[175]. 
Leukemia relapse may occur because currently used therapies eliminate 
mostly proliferating cells that constitute the bulk of the disease, but fail 
to eliminate quiescent leukemic stem cells (LSCs) that can reinitiate 
the disease after a period of latency [176]. By understanding how p53 
regulates the quiescence of HSCs during steady-state hematopoiesis, it 
may be possible to develop therapeutic strategies that could eliminate the 
largely quiescent leukemic stem cell [177].
3.2 p16INK4A/p19Arf locus
The Cdkn2A tumor suppressor locus encodes 2 different tumor 
suppressor proteins namely p16INK4A and p19Arf (p14ARF in human). This 
locus is frequently mutated in human cancers [178]. p16INK4A and Arf 
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function in distinct anti-cancer pathways: p16INK4A regulates Rb while p19Arf 
regulates p53. These tumor suppressor proteins are expressed in response 
to aberrant growth or oncogenic stress and are thought to function as a 
brake by engaging two potent anti-proliferative pathways. Both genes are 
transcribed from distinct, alternate first exons but share common second 
and third exons that are translated in alternate reading frames. 
3.2.1 p16INK4A
The p16INK4A protein inhibits the activity of the cyclin D1-cyclin-
dependent kinase 4 (CDK4) complex that drives cell cycle progression 
by phosphorylating the Rb protein. Rb phosphorylation, in turn, releases 
the E2F transcription factors that induce transcription of genes during the 
S-phase of  cell cycle progression [179].
Control of E2F transcriptional activity also plays a role in myeloid 
differentiation. Through regulation of transcription factors, such as 
C/EPBα and C/EBPε, myeloid cells terminally differentiate [180-
181]. In hematological malignancies, the p16INK4A locus is frequently 
hypermethylated in its promoter region which leads to transcriptional 
silencing of its expression [182]. 
3.2.2 p19Arf/ p14ARF
p19Arf physically interacts with Mdm2 [183], which prevents ubiquitination 
of p53. Deregulation of the ARF-MDM2-p53 pathway is a common feature 
in human cancer either by loss of p14ARF/p53 or by overexpression of 
MDM2 [184]. In addition, p14ARF inhibits E2F target genes such as Cyclin A 
and Cyclin E [185], which also results in cell cycle arrest. 
Interestingly, the tumor suppressor p19Arf may not only inhibit cell cycle 
progression, but also increase DNA repair capacity by upregulation of 
Xpc [186]. p19Arf activates Xpc expression by de-repressing the promoter 
through disruption of the repressor complex of E2F4. It is known that 
mutations in both the Ink4a/Arf locus and the NER pathway contribute to 
melanoma development [187-188]. Since the loss of the INK4A/ARF locus 
is an early event in melanoma, it could directly affect NER to predispose 
individuals to melanoma.
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3.3 Adenomatous polyposis coli (APC)
The adenomatous polyposis coli (APC) gene is a key tumor suppressor 
gene that, when mutated in the germ line, is involved in familial adenomatous 
polyposis (FAP). FAP is characterized by the presence of multiple polyps in 
the intestine [189]. In mice, homozygous APC mutations lead to embryonic 
lethality [190] while conditional mutations lead to a disturbance of tissue 
homeostasis [191-192]. These fi ndings suggest that APC is essential for 
development and homeostasis and that, when it is inactivated, facilitates 
tumorigenesis. 
It has been shown that APC plays a role in the DNA damage response. 
Transcription of the APC gene can be enhanced in response to alkylating 
agents [193]. The transcribed APC can then interact with DNA polymerase 
β and fl ap endonuclease 1 (Fen-1), thereby modulating the BER pathway 
of DNA repair [194]. Taking these 2 discoveries into account, APC may 
play an important role in carcinogenesis by determining whether cells with 
DNA damage survive or undergo apoptosis [195].
APC contains binding sites for numerous proteins including microtubules, 
Wnt pathway components such as β-catenin and axin as well as cytoskeletal 
regulators. Most mutations in APC lead to a C-terminal mutation of the 
protein [196]. This C-terminal part of the protein contains the domains 
required for β-catenin and microtubule binding. β-catenin plays a role in 
cell adhesion via adherens junctions [197] as well as acting as a signal 
transducer for the Wnt signaling pathway. Binding to microtubules is 
involved in cytoskeletal architecture. In the following paragraphs the role 
of β-catenin and Wnt signaling will be discussed in more detail. 
3.3.1 Wnt signaling
There are 19 known Wnt proteins which can be assigned to 2 overlapping 
groups with respect to their function in hematopoiesis [198]. Members of the 
fi rst group, consisting of Wnt-1/2b/3/3a/4/5a/8a/8b/10b, activate signaling 
pathways through the canonical pathway involving β-catenin. Members of 
the second group, consisting of Wnt-3a/4/5a/5b/6/7/11, activate alternative 
non-canonical signaling pathways. The classifi cation of Wnt ligands as 
either canonical or non-canonical is too simple. Recent reports show that 
Wnts can signal through both types of pathways, with opposing outcomes; 
it all depends on the cellular context [199].
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3.3.1.1 Canonical Wnt signaling
The canonical Wnt signaling pathway is the best understood Wnt 
pathway. The proteins involved are highly conserved among species. This 
pathway regulates β-catenin activity and thereby controls transcription of 
specific target genes.
Without Wnt signaling, β-catenin is sequestered in the cytoplasm within a 
degradation complex which is formed by APC, axin and GSK3-β [200]. This 
complex phosphorylates the N-terminus of β-catenin and thereby triggers its 
ubiquitination and subsequent proteosomal degradation. When Wnt protein 
binds to the Frizzled/LRP receptor complex, Disheveled (Dsh) becomes 
phosphorylated and interacts with axin in order to prevent GSK3-β from 
phosphorylating β-catenin. This results in accumulation of β-catenin protein 
and its subsequent translocation to the nucleus [201]. Nuclear β-catenin 
regulates gene expression via TCF/LEF transcription factors [202].  Regulated 
genes include regulators of cellular proliferation, survival, developmental 
control and genes involved in tumorigenesis (The reader is referred to http://
www.stanford.edu/~rnusse/pathways/targets.html for an up to date overview). 
3.3.1.2 Non-canonical Wnt signaling
The most well-recognized categories of non-canonical signaling are the 
planar cell polarity pathway (PCP) and the Wnt calcium signaling pathway.
The calcium pathway involves activation and membrane association 
of phospholipase C (PLC) through GTP binding proteins [203]. PLC 
hydrolyses membrane phospholipids to produce di-acyl glycerol (DAG), 
and inositol 1,4,5-triphosphate (IP3). IP3 induces the release of calcium 
from the endoplasmic reticulum by association with an ATPase pump, this 
in turn increases the expression and activity of calmodulin and calmodulin 
kinases [204]. Increased intracellular calcium can activate protein kinase 
C (PKC), which can also be directly activated by DAG. Activation of PKC 
can influence a range of cellular functions including motility, apoptosis and 
differentiation, which in turn regulate processes such as morphogenesis. 
PKC can also regulate the expression of Wnt5a resulting in a positive 
feedback loop [205].
The PCP pathway is involved in regulation of planar cell polarity in 
Drosophila. In the PCP pathway, Wnt activates Rho/Rac GTPase and 
Jun-N-terminal sequence kinase, which modulate the organization of the 
cytoskeleton and influence gene expression. 
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In addition, Wnt factors may bind the alternative receptors Ryk or Ror. 
Signalling through these receptors inhibits canonical Wnt signaling by 
other Wnt factors.
3.3.1.3 Wnt signaling in hematopoiesis
Hematopoietic tissues express a number of Wnt family members 
including Wnt-2b, -3a, -5a and -10b and their receptors Fzd-3, -4, -5 and 
-7 [206-208]. Wnts are produced by the hematopoietic cells themselves 
as well as by non-hematopoietic components of the BM such as stromal 
cells, which produce Wnt-5a and Wnt-3 [209]. The more primitive CD34+ 
cells also express Wnt-5a [207]. This provides the opportunity for both 
autocrine and paracrine stimulation of HSCs by Wnts within the BM. Wnt 
overexpression increases proliferation of CD34+ cells and it is essential in 
HSC self-renewal [210]. 
The involvement of the Wnt pathway in regulation of hematopoietic 
stem and progenitor cell growth and self-renewal, in combination with its 
oncogenic potential in other cell types suggests that it might be deregulated 
in hematological malignancies. Indeed, aberrant Wnt signaling leads to 
oncogenic growth in both lymphoid (T-ALL, B-ALL, MM, NH-L, CLL)  and 
myeloid malignancies (AML, CML) [211]. Results from several studies 
indicate that high expression of ß-catenin is a common denominator in 
myeloid leukemic cells. Unlike solid malignancies which display activating 
mutations in components of the Wnt pathway, it is more likely that in 
leukemias there is an autocrine stimulation of the Wnt pathway which leads 
to oncogenesis. On the other hand, non-canonical Wnt signaling e.g. by 
Wnt5a, can inhibit proliferation by limiting signaling through the canonical 
pathway of β-catenin–TCF activation [212]. 
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4 exCision repair Cross   
 Complementing-group 1 (erCC1)
4.1 The ERCC1 protein
As described briefly in section 2.4, ERCC1 functions in NER. In NER, 
ERCC1 heterodimerizes with XPF to form an endonuclease involved 
in processing DNA adducts during NER,  DNA replication and meiotic 
recombination [213]. The dimerization with XPF is crucial for the stability 
and catalytic activity of ERCC1 [214].
The human ERCC1 gene is located on chromosome 19q13.2-19q13.3. 
It consists of 10 exons which are spread over 15 kB of the genome. The 
protein contains 2 functional domains; a central domain which preferably 
binds to 5’ ss overhangs [215] and a C-terminal domain which is involved in 
XPF binding [216]. Recently also an XPA binding site is discovered, which 
is located in the central domain and is involved in the proper positioning 
of the ERCC1-XPF complex on the damaged DNA strand [217-218]. The 
N-terminal domain seems to be non essential for NER and is of unknown 
structure [219]. 
The ERCC1 promoter is located about 170 basepairs upstream from 
the transcriptional start site. This region contains an AP-1 like binding site 
which seems to be critically involved in regulating ERCC1 expression [220]. 
The DNA crosslinker cisplatin has been shown to induce a dose- and time 
dependent increase in ERCC1 mRNA and protein expression in ovarian 
cancer cell lines which suggests that DNA repair capacity is correlated to 
expression [221-222]. This would imply that ERCC1 mRNA levels could be 
used as a marker for DNA repair capacity in human tumors. However up 
to now no studies have been published which show that increased ERCC1 
expression also leads to increased DNA repair.
4.2 ERCC1-XPF mutation in humans (XFE)
Although ERCC1-XPF is involved in multiple genomic maintenance 
pathways, patients with mutated XPF usually only show mild XP symptoms 
and only rarely develop skin tumors before adulthood [223-224]. In all 
cases mutations are hypomorphic, therefore residual protein levels are 
present and as a consequence functional endonuclase activity remains. 
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Only recently the fi rst ERCC1 mutation in a patient was discovered, 
although the screening of patients was extensive for over 30 years [225]. 
This patient displayed only mild impairment of NER, comparable to XPF 
patients. However, a severe pre- and postnatal growth defi ciency was 
present and the patient died at the age of 14 months. Genetic screening 
revealed that the patient carried 2 point mutations in the ERCC1 gene,  one 
of which resulted in a premature stop codon. The protein encoded from 
this allele lacked the entire C-terminal domain which is essential for XPF 
binding. Therefore this allele can be expected to function as a complete 
null. The other allele also had a point mutation but this did not seem to 
infl uence enzymatic activity.  It is very likely that the clinical phenotype 
of the patients is a result of the low levels of ERCC1-XPF rather than the 
reduced enzymatic activity. 
4.3 Ercc1 mouse models
In mice, both Ercc1 and Xpf knockout mutants are viable [226-227]. 
However they have a very severe phenotype. Embryonic and early postnatal 
development is mildly retarded in Ercc1 defi cient mice, but in the second 
week of life a dramatic growth arrest develops to which the mice succumb 
between day 19 and 21. Ercc1-/- mice show signs of premature aging in skin, 
liver and BM [111, 124, 228]. In addition they display neurodegeneration, 
renal insuffi ciency, loss of muscle mass and strength, a hunchback spine 
and on a cellular level they suffer from premature replicative senescence 
and oxidative stress sensitivity [145].  Hypomorph Ercc1 (Ercc1-/d) mice 
harbor a C-terminally truncated allele expressing an Ercc1 protein that fails 
to heterodimerize with Xpf. Ercc1-/d mice display a similar phenotype as 
Ercc1-/- but as a result of their residual DNA repair capacity they survive 
somewhat longer (~6 months).
Unlike all other NER models, Ercc1 mice display hematopoietic defects 
similar to FA defi cient cells [111]. In addition they display severe organismal 
aging together with ICL hypersensitivity. The hematopoietic defect is related 
to accelerated aging of the BM causing loss of HSCs within 3 weeks after 
birth. Accelerated aging of the BM is also seen in mice which are defective 
in the FA pathway, but to a lesser extent [140]. In FA patients and mouse 
models there are also other reminiscent premature aging features such 
as growth hormone defi ciency and premature gonadal failure leading to 
infertility [229-231].  
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Because Ercc1-Xpf is proposed to function in several distinct pathways 
of DNA repair it is necessary to be able to segregate it’s function. In NER, 
it is Xpa that recruits Ercc1 to the site of damage by interacting with it [217, 
232], while it is thought that in ICL repair this is done by Slx4 [119-120]. 
This is supported by the fact that Xpa deficiency leads to an increase in UV 
sensitivity while ICL sensitivity is not affected [145]. In contrast, loss of Slx4 
leads to an increase in ICL sensitivity and does not affect UV sensitivity 
[233].
Although Ercc1 is not exclusively required for activation of the FA 
pathway (as defined by continuing presence of Fancd2 monoubiquitination 
in the absence of Ercc1) it does affect the kinetics of Fancd2 ubiquitination. 
In the absence of Ercc1, prolonged ubiquitination of Fancd2 is seen 
which hints that Ercc1 functions downstream of Fancd2 and that it has an 
essential function in incising the crosslinked DNA during ICL repair and in 
subsequent DNA damage response termination. 
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5  sCope of this thesis
The molecular processes that drive leukemogenesis from senescent 
bone marrow are largely unknown. The aim of tis thesis is to understand 
the molecular basis of BM senescence in response to DNA damage, and 
how these steps subsequently contribute to leukemogenesis. 
Ercc1 defi cient mice are defi cient in both NER and ICL repair and display 
signs of prematur e aging in the BM. Because Ercc1 is involved in the FA 
pathway of ICL repair we used this model to investigate the molecular 
mechanisms of BM failure and subsequent leukemogenesis as seen in 
FA. Important questions in this respect are: (i) Is BM failure specifi c to 
defective ICL repair, or to the overall aging phenotype (Chapter 2), (ii) what 
is the infl uence of Ercc1 levels on senescence in the hematopoietic system 
(Chapter 3), (iii) which tumor suppressor mechanisms are responsible for 
BM failure as seen in Ercc1 defi cient mice (Chapter 4), and (iv) is the poor 
response to Epo specifi c to the lack of Fanconi proteins or secondary to 
senescence (Chapter 5). Finally, we investigated whether activation of p53 
counteracts Wnt signaling (Chapter 6). In order to address these questions 
we analyzed FA defi cient erythroblasts isolated from fetal liver (Chapter 5), 
compared the phenotypes of Ercc1-/-, Ercc1-/d and Ercc1d/d mice (Chapter 
3), generated double knockout mice which lack either the tumor suppressor 
gene Cdkn2A (p16INK4A/p19Arf) or p53 in an Ercc1 hypomorph background 
(Chapter 4) and analyzed the effect of the Wnt signaling pathway in primary 
erythroblasts derived from fetal livers (Chapter 6).
Judith Proefschrift.indb   45 27-12-2012   16:33:13
Chapter 146
referenCes
1. Akashi, K., et al., A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. 
Nature, 2000. 404(6774): p. 193-7.
2. Kondo, M., et al., Lymphocyte development from hematopoietic stem cells. Curr Opin Genet Dev, 
2001. 11(5): p. 520-6.
3. Kondo, M., I.L. Weissman, and K. Akashi, Identification of clonogenic common lymphoid progenitors 
in mouse bone marrow. Cell, 1997. 91(5): p. 661-72.
4. Adolfsson, J., et al., Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic 
potential a revised road map for adult blood lineage commitment. Cell, 2005. 121(2): p. 295-306.
5. Warner, J.K., et al., Concepts of human leukemic development. Oncogene, 2004. 23(43): p. 7164-77.
6. Ernst, T. and A. Hochhaus, Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and 
other lesions associated with disease progression. Semin Oncol, 2012. 39(1): p. 58-66.
7. Estey, E. and H. Dohner, Acute myeloid leukaemia. Lancet, 2006. 368(9550): p. 1894-907.
8. Motyckova, G. and R.M. Stone, The role of molecular tests in acute myelogenous leukemia treatment 
decisions. Curr Hematol Malig Rep, 2010. 5(2): p. 109-17.
9. Shimamura, A. and B.P. Alter, Pathophysiology and management of inherited bone marrow failure 
syndromes. Blood Rev, 2010. 24(3): p. 101-22.
10. Gordon-Smith, E.C. and S. Issaragrisil, Epidemiology of aplastic anaemia. Baillieres Clin Haematol, 
1992. 5(2): p. 475-91.
11. Chatterjee, S., et al., Pesticide induced marrow toxicity and effects on marrow cell population and on 
hematopoietic stroma. Exp Toxicol Pathol, 2011.
12. Farrar, J.E. and N. Dahl, Untangling the phenotypic heterogeneity of Diamond Blackfan anemia. 
Semin Hematol, 2011. 48(2): p. 124-35.
13. Lipton, J.M., et al., Improving clinical care and elucidating the pathophysiology of Diamond Blackfan 
anemia: an update from the Diamond Blackfan Anemia Registry. Pediatr Blood Cancer, 2006. 46(5): 
p. 558-64.
14. Boocock, G.R., et al., Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat 
Genet, 2003. 33(1): p. 97-101.
15. Aggett, P.J., et al., Shwachman’s syndrome. A review of 21 cases. Arch Dis Child, 1980. 55(5): p. 
331-47.
16. Hayes, R.B., et al., hprt mutation frequency among workers exposed to 1,3-butadiene in China. 
Toxicology, 1996. 113(1-3): p. 100-5.
17. Vulliamy, T. and I. Dokal, Dyskeratosis congenita. Semin Hematol, 2006. 43(3): p. 157-66.
18. Jack, K., et al., rRNA pseudouridylation defects affect ribosomal ligand binding and translational 
fidelity from yeast to human cells. Mol Cell, 2011. 44(4): p. 660-6.
19. Garcia, C.K., W.E. Wright, and J.W. Shay, Human diseases of telomerase dysfunction: insights into 
tissue aging. Nucleic Acids Res, 2007. 35(22): p. 7406-16.
20. Bellodi, C., N. Kopmar, and D. Ruggero, Deregulation of oncogene-induced senescence and p53 
translational control in X-linked dyskeratosis congenita. EMBO J, 2010. 29(11): p. 1865-76.
21. Glanz, A. and F.C. Fraser, Spectrum of anomalies in Fanconi anaemia. J Med Genet, 1982. 19(6): p. 
412-6.
Judith Proefschrift.indb   46 27-12-2012   16:33:13
General Int roduct ion 47
C
h
a
p
te
r 
1
22. Butturini, A., et al., Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia 
Registry study. Blood, 1994. 84(5): p. 1650-5.
23. Cybulski, K.E. and N.G. Howlett, FANCP/SLX4: A Swiss Army knife of DNA interstrand crosslink 
repair. Cell Cycle, 2011. 10(11).
24. Kitao, H. and M. Takata, Fanconi anemia: a disorder defective in the DNA damage response. Int J 
Hematol, 2011.
25. Sasaki, M.S. and A. Tonomura, A high susceptibility of Fanconi’s anemia to chromosome breakage 
by DNA cross-linking agents. Cancer Res, 1973. 33(8): p. 1829-36.
26. Kutler, D.I., et al., A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood, 
2003. 101(4): p. 1249-56.
27. Faivre, L., et al., Association of complementation group and mutation type with clinical outcome in 
fanconi anemia. European Fanconi Anemia Research Group. Blood, 2000. 96(13): p. 4064-70.
28. Gross, M., et al., Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-
correction. Cytogenet Genome Res, 2002. 98(2-3): p. 126-35.
29. Klein, C., et al., HAX1 defi ciency causes autosomal recessive severe congenital neutropenia 
(Kostmann disease). Nat Genet, 2007. 39(1): p. 86-92.
30. Person, R.E., et al., Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2. 
Nat Genet, 2003. 34(3): p. 308-12.
31. Badolato, R., et al., Congenital neutropenia: advances in diagnosis and treatment. Curr Opin Allergy 
Clin Immunol, 2004. 4(6): p. 513-21.
32. Ancliff, P.J., et al., Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in 
congenital neutropenia. Blood, 2006. 108(7): p. 2182-9.
33. Dale, D.C. and D.C. Link, The many causes of severe congenital neutropenia. N Engl J Med, 2009. 
360(1): p. 3-5.
34. Bartek, J., J. Bartkova, and J. Lukas, DNA damage signalling guards against activated oncogenes 
and tumour progression. Oncogene, 2007. 26(56): p. 7773-9.
35. Rodier, F. and J. Campisi, Four faces of cellular senescence. J Cell Biol, 2011. 192(4): p. 547-56.
36. Jaako, P., et al., Mice with ribosomal protein S19 defi ciency develop bone marrow failure and 
symptoms like patients with Diamond-Blackfan anemia. Blood, 2011. 118(23): p. 6087-96.
37. Pereboom, T.C., et al., A zebrafi sh model of dyskeratosis congenita reveals hematopoietic stem cell 
formation failure resulting from ribosomal protein-mediated p53 stabilization. Blood, 2011. 118(20): 
p. 5458-65.
38. Marsh, J.C., et al., Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol, 
2009. 147(1): p. 43-70.
39. Baranski, B.G. and N.S. Young, Autoimmune aspects of aplastic anemia. In Vivo, 1988. 2(1): p. 91-4.
40. Smith, M.T., Overview of benzene-induced aplastic anaemia. Eur J Haematol Suppl, 1996. 60: p. 
107-10.
41. Baranski, B., et al., Epstein-Barr virus in the bone marrow of patients with aplastic anemia. Ann Intern 
Med, 1988. 109(9): p. 695-704.
42. Smick, K.M., et al., Fatal Aplastic Anemia. An Epidemiological Study of Its Relationship to the Drug 
Chloramphenicol. J Chronic Dis, 1964. 17: p. 899-914.
Judith Proefschrift.indb   47 27-12-2012   16:33:13
Chapter 148
43. Kaufman, D.W., et al., Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J 
Haematol Suppl, 1996. 60: p. 23-30.
44. Kearns, W.G., et al., Genomic instability in bone marrow failure syndromes. Am J Hematol, 2004. 
76(3): p. 220-4.
45. Hershman, D., et al., Acute myeloid leukemia or myelodysplastic syndrome following use of 
granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer 
Inst, 2007. 99(3): p. 196-205.
46. Valagussa, P., et al., Second acute leukemia and other malignancies following treatment for 
Hodgkin’s disease. J Clin Oncol, 1986. 4(6): p. 830-7.
47. Renella, R., et al., Increased risk of acute myeloid leukaemia after treatment for breast cancer. 
Breast, 2006. 15(5): p. 614-9.
48. Sloand, E.M., et al., Granulocyte colony-stimulating factor preferentially stimulates proliferation of 
monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci U S A, 2006. 103(39): p. 
14483-8.
49. Sloand, E.M., et al., CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) 
express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic 
proteins. Blood, 2007. 109(6): p. 2399-405.
50. Lindahl, T., Instability and decay of the primary structure of DNA. Nature, 1993. 362(6422): p. 709-15.
51. Lehmann, A.R., Replication of damaged DNA in mammalian cells: new solutions to an old problem. 
Mutat Res, 2002. 509(1-2): p. 23-34.
52. Hoeijmakers, J.H., DNA repair mechanisms. Maturitas, 2001. 38(1): p. 17-22; discussion 22-3.
53. Bartek, J. and J. Lukas, Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr 
Opin Cell Biol, 2001. 13(6): p. 738-47.
54. Evan, G.I. and K.H. Vousden, Proliferation, cell cycle and apoptosis in cancer. Nature, 2001. 
411(6835): p. 342-8.
55. Chen, Z., et al., Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient 
tumorigenesis. Nature, 2005. 436(7051): p. 725-30.
56. Sharma, V.M., et al., Histone deacetylases RPD3 and HOS2 regulate the transcriptional activation of 
DNA damage-inducible genes. Mol Cell Biol, 2007. 27(8): p. 3199-210.
57. Yao, R., et al., Subcellular localization of yeast ribonucleotide reductase regulated by the DNA 
replication and damage checkpoint pathways. Proc Natl Acad Sci U S A, 2003. 100(11): p. 6628-33.
58. Bartek, J. and J. Lukas, DNA damage checkpoints: from initiation to recovery or adaptation. Curr 
Opin Cell Biol, 2007. 19(2): p. 238-45.
59. Paull, T.T. and J.H. Lee, The Mre11/Rad50/Nbs1 complex and its role as a DNA double-strand break 
sensor for ATM. Cell Cycle, 2005. 4(6): p. 737-40.
60. Bakkenist, C.J. and M.B. Kastan, DNA damage activates ATM through intermolecular 
autophosphorylation and dimer dissociation. Nature, 2003. 421(6922): p. 499-506.
61. Lee, J.H. and T.T. Paull, Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 
complex. Science, 2004. 304(5667): p. 93-6.
62. Kinner, A., et al., Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the 
context of chromatin. Nucleic Acids Res, 2008. 36(17): p. 5678-94.
Judith Proefschrift.indb   48 27-12-2012   16:33:13
General Int roduct ion 49
C
h
a
p
te
r 
1
63. Zou, L. and S.J. Elledge, Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. 
Science, 2003. 300(5625): p. 1542-8.
64. Cortez, D., et al., ATR and ATRIP: partners in checkpoint signaling. Science, 2001. 294(5547): p. 
1713-6.
65. Lee, J., A. Kumagai, and W.G. Dunphy, The Rad9-Hus1-Rad1 checkpoint clamp regulates interaction 
of TopBP1 with ATR. J Biol Chem, 2007. 282(38): p. 28036-44.
66. Liu, Q., et al., Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA 
damage checkpoint. Genes Dev, 2000. 14(12): p. 1448-59.
67. Taylor, W.R. and G.R. Stark, Regulation of the G2/M transition by p53. Oncogene, 2001. 20(15): p. 
1803-15.
68. Bartkova, J., et al., Oncogene-induced senescence is part of the tumorigenesis barrier imposed by 
DNA damage checkpoints. Nature, 2006. 444(7119): p. 633-7.
69. Di Micco, R., et al., Oncogene-induced senescence is a DNA damage response triggered by DNA 
hyper-replication. Nature, 2006. 444(7119): p. 638-42.
70. Mallette, F.A., M.F. Gaumont-Leclerc, and G. Ferbeyre, The DNA damage signaling pathway is a 
critical mediator of oncogene-induced senescence. Genes Dev, 2007. 21(1): p. 43-8.
71. Toledo, L.I., et al., ATR signaling can drive cells into senescence in the absence of DNA breaks. 
Genes Dev, 2008. 22(3): p. 297-302.
72. Rich, T., R.L. Allen, and A.H. Wyllie, Defying death after DNA damage. Nature, 2000. 407(6805): p. 
777-83.
73. Keeney, S. and M.J. Neale, Initiation of meiotic recombination by formation of DNA double-strand 
breaks: mechanism and regulation. Biochem Soc Trans, 2006. 34(Pt 4): p. 523-5.
74. Soulas-Sprauel, P., et al., V(D)J and immunoglobulin class switch recombinations: a paradigm to 
study the regulation of DNA end-joining. Oncogene, 2007. 26(56): p. 7780-91.
75. Dudley, D.D., et al., Mechanism and control of V(D)J recombination versus class switch recombination: 
similarities and differences. Adv Immunol, 2005. 86: p. 43-112.
76. Moore, J.K. and J.E. Haber, Cell cycle and genetic requirements of two pathways of nonhomologous 
end-joining repair of double-strand breaks in Saccharomyces cerevisiae. Mol Cell Biol, 1996. 16(5): 
p. 2164-73.
77. Cheng, S.S., D.M. Wilson, and S.R. Munn, Predictors of progression of diabetic nephropathy: 
implication for timing of kidney transplantation. Clin Transplant, 1997. 11(4): p. 334-6.
78. Helleday, T., et al., DNA double-strand break repair: from mechanistic understanding to cancer 
treatment. DNA Repair (Amst), 2007. 6(7): p. 923-35.
79. Agarwal, S., A.A. Tafel, and R. Kanaar, DNA double-strand break repair and chromosome 
translocations. DNA Repair (Amst), 2006. 5(9-10): p. 1075-81.
80. Stiff, T., et al., Nbs1 is required for ATR-dependent phosphorylation events. EMBO J, 2005. 24(1): p. 
199-208.
81. Ellis, N.A., et al., Somatic intragenic recombination within the mutated locus BLM can correct the high 
sister-chromatid exchange phenotype of Bloom syndrome cells. Am J Hum Genet, 1995. 57(5): p. 
1019-27.
82. Kaneko, H. and N. Kondo, Clinical features of Bloom syndrome and function of the causative gene, 
BLM helicase. Expert Rev Mol Diagn, 2004. 4(3): p. 393-401.
Judith Proefschrift.indb   49 27-12-2012   16:33:14
Chapter 150
83. Lehmann, A.R., The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three 
diseases. Genes Dev, 2001. 15(1): p. 15-23.
84. Cleaver, J.E., Xeroderma pigmentosum: a human disease in which an initial stage of DNA repair is 
defective. Proc Natl Acad Sci U S A, 1969. 63(2): p. 428-35.
85. Cleaver, J.E., Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev 
Cancer, 2005. 5(7): p. 564-73.
86. Kraemer, K.H., et al., Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a 
complex genotype-phenotype relationship. Neuroscience, 2007. 145(4): p. 1388-96.
87. Nance, M.A. and S.A. Berry, Cockayne syndrome: review of 140 cases. Am J Med Genet, 1992. 
42(1): p. 68-84.
88. Itin, P.H., A. Sarasin, and M.R. Pittelkow, Trichothiodystrophy: update on the sulfur-deficient brittle 
hair syndromes. J Am Acad Dermatol, 2001. 44(6): p. 891-920; quiz 921-4.
89. Liang, C., et al., Structural and molecular hair abnormalities in trichothiodystrophy. J Invest Dermatol, 
2006. 126(10): p. 2210-6.
90. Hashimoto, S. and J.M. Egly, Trichothiodystrophy view from the molecular basis of DNA repair/
transcription factor TFIIH. Hum Mol Genet, 2009. 18(R2): p. R224-30.
91. Faghri, S., et al., Trichothiodystrophy: a systematic review of 112 published cases characterises a 
wide spectrum of clinical manifestations. J Med Genet, 2008. 45(10): p. 609-21.
92. de Boer, J., et al., A mouse model for the basal transcription/DNA repair syndrome trichothiodystrophy. 
Mol Cell, 1998. 1(7): p. 981-90.
93. de Boer, J., et al., Disruption of the mouse xeroderma pigmentosum group D DNA repair/basal 
transcription gene results in preimplantation lethality. Cancer Res, 1998. 58(1): p. 89-94.
94. Wijnhoven, S.W. and H. van Steeg, Transgenic and knockout mice for DNA repair functions in 
carcinogenesis and mutagenesis. Toxicology, 2003. 193(1-2): p. 171-87.
95. de Boer, J. and J.H. Hoeijmakers, Cancer from the outside, aging from the inside: mouse models to 
study the consequences of defective nucleotide excision repair. Biochimie, 1999. 81(1-2): p. 127-37.
96. Niedernhofer, L.J., Nucleotide excision repair deficient mouse models and neurological disease. 
DNA Repair (Amst), 2008. 7(7): p. 1180-9.
97. Niedernhofer, L.J., Tissue-specific accelerated aging in nucleotide excision repair deficiency. Mech 
Ageing Dev, 2008. 129(7-8): p. 408-15.
98. Rossi, D.J., et al., Deficiencies in DNA damage repair limit the function of haematopoietic stem cells 
with age. Nature, 2007. 447(7145): p. 725-9.
99. Lawley, P.D. and D.H. Phillips, DNA adducts from chemotherapeutic agents. Mutat Res, 1996. 355(1-
2): p. 13-40.
100. Kennedy, R.D. and A.D. D’Andrea, The Fanconi Anemia/BRCA pathway: new faces in the crowd. 
Genes Dev, 2005. 19(24): p. 2925-40.
101. Knipscheer, P., et al., The Fanconi anemia pathway promotes replication-dependent DNA interstrand 
cross-link repair. Science, 2009. 326(5960): p. 1698-701.
102. Liu, T., et al., FAN1 acts with FANCI-FANCD2 to promote DNA interstrand cross-link repair. Science, 
2010. 329(5992): p. 693-6.
103. Crossan, G.P., et al., Disruption of mouse Slx4, a regulator of structure-specific nucleases, 
phenocopies Fanconi anemia. Nat Genet, 2011. 43(2): p. 147-52.
Judith Proefschrift.indb   50 27-12-2012   16:33:14
General Int roduct ion 51
C
h
a
p
te
r 
1
104. Stoepker, C., et al., SLX4, a coordinator of structure-specifi c endonucleases, is mutated in a new 
Fanconi anemia subtype. Nat Genet, 2011. 43(2): p. 138-41.
105. Bhagwat, N., et al., XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair. Mol 
Cell Biol, 2009. 29(24): p. 6427-37.
106. Zhang, X.Y., et al., Xpf and not the Fanconi anaemia proteins or Rev3 accounts for the extreme 
resistance to cisplatin in Dictyostelium discoideum. PLoS Genet, 2009. 5(9): p. e1000645.
107. Hsia, K.T., et al., DNA repair gene Ercc1 is essential for normal spermatogenesis and oogenesis and 
for functional integrity of germ cell DNA in the mouse. Development, 2003. 130(2): p. 369-78.
108. McWhir, J., et al., Mice with DNA repair gene (ERCC-1) defi ciency have elevated levels of p53, liver 
nuclear abnormalities and die before weaning. Nat Genet, 1993. 5(3): p. 217-24.
109. Prasher, J.M., et al., Reduced hematopoietic reserves in DNA interstrand crosslink repair-defi cient 
Ercc1-/- mice. EMBO J, 2005. 24(4): p. 861-71.
110. Riballo, E., et al., A pathway of double-strand break rejoining dependent upon ATM, Artemis, and 
proteins locating to gamma-H2AX foci. Mol Cell, 2004. 16(5): p. 715-24.
111. Stewart, G.S., et al., The DNA double-strand break repair gene hMRE11 is mutated in individuals 
with an ataxia-telangiectasia-like disorder. Cell, 1999. 99(6): p. 577-87.
112. Taylor, A.M., A. Groom, and P.J. Byrd, Ataxia-telangiectasia-like disorder (ATLD)-its clinical 
presentation and molecular basis. DNA Repair (Amst), 2004. 3(8-9): p. 1219-25.
113. Seoane, M., et al., Retinoblastoma loss modulates DNA damage response favoring tumor 
progression. PLoS One, 2008. 3(11): p. e3632.
114. Bartkova, J., et al., DNA damage response as a candidate anti-cancer barrier in early human 
tumorigenesis. Nature, 2005. 434(7035): p. 864-70.
115. Balducci, L. and W.B. Ershler, Cancer and ageing: a nexus at several levels. Nat Rev Cancer, 2005. 
5(8): p. 655-62.
116. Clapp, R.W., M.M. Jacobs, and E.L. Loechler, Environmental and occupational causes of cancer: 
new evidence 2005-2007. Rev Environ Health, 2008. 23(1): p. 1-37.
117. Anisimov, V.N., Insulin/IGF-1 signaling pathway driving aging and cancer as a target for 
pharmacological intervention. Exp Gerontol, 2003. 38(10): p. 1041-9.
118. Campisi, J., Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. 
Cell, 2005. 120(4): p. 513-22.
119. DePinho, R.A., The age of cancer. Nature, 2000. 408(6809): p. 248-54.
120. Subramaniam, M.M., et al., Tissue microarray profi ling of primary and xenotransplanted synovial 
sarcomas demonstrates the immunophenotypic similarities existing between SYT-SSX fusion gene 
confi rmed, biphasic, and monophasic fi brous variants. Virchows Arch, 2006. 449(4): p. 435-47.
121. Andressoo, J.O., J.H. Hoeijmakers, and J.R. Mitchell, Nucleotide excision repair disorders and the 
balance between cancer and aging. Cell Cycle, 2006. 5(24): p. 2886-8.
122. Nijnik, A., et al., DNA repair is limiting for haematopoietic stem cells during ageing. Nature, 2007. 
447(7145): p. 686-90.
123. Navarro, S., et al., Hematopoietic dysfunction in a mouse model for Fanconi anemia group D1. Mol 
Ther, 2006. 14(4): p. 525-35.
124. Reese, J.S., L. Liu, and S.L. Gerson, Repopulating defect of mismatch repair-defi cient hematopoietic 
stem cells. Blood, 2003. 102(5): p. 1626-33.
Judith Proefschrift.indb   51 27-12-2012   16:33:14
Chapter 152
125. van der Pluijm, I., et al., Impaired genome maintenance suppresses the growth hormone--insulin-like 
growth factor 1 axis in mice with Cockayne syndrome. PLoS Biol, 2007. 5(1): p. e2.
126. Lowe, S.W., E. Cepero, and G. Evan, Intrinsic tumour suppression. Nature, 2004. 432(7015): p. 
307-15.
127. Vousden, K.H. and C. Prives, Blinded by the Light: The Growing Complexity of p53. Cell, 2009. 
137(3): p. 413-31.
128. Vousden, K.H. and C. Prives, P53 and prognosis: new insights and further complexity. Cell, 2005. 
120(1): p. 7-10.
129. Harris, S.L. and A.J. Levine, The p53 pathway: positive and negative feedback loops. Oncogene, 
2005. 24(17): p. 2899-908.
130. Stommel, J.M. and G.M. Wahl, Accelerated MDM2 auto-degradation induced by DNA-damage 
kinases is required for p53 activation. EMBO J, 2004. 23(7): p. 1547-56.
131. Hainaut, P. and M. Hollstein, p53 and human cancer: the first ten thousand mutations. Adv Cancer 
Res, 2000. 77: p. 81-137.
132. Esteller, M., et al., p14ARF silencing by promoter hypermethylation mediates abnormal intracellular 
localization of MDM2. Cancer Res, 2001. 61(7): p. 2816-21.
133. Ahuja, D., M.T. Saenz-Robles, and J.M. Pipas, SV40 large T antigen targets multiple cellular 
pathways to elicit cellular transformation. Oncogene, 2005. 24(52): p. 7729-45.
134. Levine, A.J., The common mechanisms of transformation by the small DNA tumor viruses: The 
inactivation of tumor suppressor gene products: p53. Virology, 2009. 384(2): p. 285-93.
135. Howie, H.L., R.A. Katzenellenbogen, and D.A. Galloway, Papillomavirus E6 proteins. Virology, 2009. 
384(2): p. 324-34.
136. Campisi, J., Suppressing cancer: the importance of being senescent. Science, 2005. 309(5736): p. 
886-7.
137. Di Micco, R., M. Fumagalli, and F. d’Adda di Fagagna, Breaking news: high-speed race ends in 
arrest--how oncogenes induce senescence. Trends Cell Biol, 2007. 17(11): p. 529-36.
138. Herbig, U., et al., Telomere shortening triggers senescence of human cells through a pathway 
involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell, 2004. 14(4): p. 501-13.
139. d’Adda di Fagagna, F., et al., A DNA damage checkpoint response in telomere-initiated senescence. 
Nature, 2003. 426(6963): p. 194-8.
140. Maser, R.S. and R.A. DePinho, Connecting chromosomes, crisis, and cancer. Science, 2002. 
297(5581): p. 565-9.
141. Campisi, J. and F. d’Adda di Fagagna, Cellular senescence: when bad things happen to good cells. 
Nat Rev Mol Cell Biol, 2007. 8(9): p. 729-40.
142. von Zglinicki, T., et al., Human cell senescence as a DNA damage response. Mech Ageing Dev, 
2005. 126(1): p. 111-7.
143. Serrano, M., et al., Oncogenic ras provokes premature cell senescence associated with accumulation 
of p53 and p16INK4a. Cell, 1997. 88(5): p. 593-602.
144. Endo, H., A. Saito, and P.H. Chan, Mitochondrial translocation of p53 underlies the selective death 
of hippocampal CA1 neurons after global cerebral ischaemia. Biochem Soc Trans, 2006. 34(Pt 6): p. 
1283-6.
Judith Proefschrift.indb   52 27-12-2012   16:33:14
General Int roduct ion 53
C
h
a
p
te
r 
1
145. Moll, U.M., N. Marchenko, and X.K. Zhang, p53 and Nur77/TR3 - transcription factors that directly 
target mitochondria for cell death induction. Oncogene, 2006. 25(34): p. 4725-43.
146. Mihara, M., et al., p53 has a direct apoptogenic role at the mitochondria. Mol Cell, 2003. 11(3): p. 577-90.
147. Leu, J.I., et al., Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat 
Cell Biol, 2004. 6(5): p. 443-50.
148. Chipuk, J.E., et al., PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science, 
2005. 309(5741): p. 1732-5.
149. Chipuk, J.E., et al., Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization 
and apoptosis. Science, 2004. 303(5660): p. 1010-4.
150. Haferlach, C., et al., Mutations of the TP53 gene in acute myeloid leukemia are strongly associated 
with a complex aberrant karyotype. Leukemia, 2008. 22(8): p. 1539-41.
151. Wattel, E., et al., p53 mutations are associated with resistance to chemotherapy and short survival in 
hematologic malignancies. Blood, 1994. 84(9): p. 3148-57.
152. Seliger, B., et al., Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. Eur J Haematol, 
1996. 57(3): p. 230-40.
153. Jasek, M., et al., TP53 mutations in myeloid malignancies are either homozygous or hemizygous due 
to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia, 2010. 24(1): p. 216-9.
154. Urashima, M., et al., MDM2 protein overexpression inhibits apoptosis of TF-1 granulocyte-
macrophage colony-stimulating factor-dependent acute myeloblastic leukemia cells. Blood, 1998. 
92(3): p. 959-67.
155. Komarova, N.L. and D. Wodarz, Effect of cellular quiescence on the success of targeted CML 
therapy. PLoS One, 2007. 2(10): p. e990.
156. Liu, Y., et al., p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell, 2009. 4(1): p. 37-48.
157. Sharpless, N.E., INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res, 2005. 576(1-2): 
p. 22-38.
158. Pacifi co, A. and G. Leone, Role of p53 and CDKN2A Inactivation in Human Squamous Cell 
Carcinomas. J Biomed Biotechnol, 2007. 2007(3): p. 43418.
159. Pabst, T. and B.U. Mueller, Complexity of CEBPA dysregulation in human acute myeloid leukemia. 
Clin Cancer Res, 2009. 15(17): p. 5303-7.
160. Gery, S., et al., C/EBPepsilon interacts with retinoblastoma and E2F1 during granulopoiesis. Blood, 
2004. 103(3): p. 828-35.
161. Krug, U., A. Ganser, and H.P. Koeffl er, Tumor suppressor genes in normal and malignant 
hematopoiesis. Oncogene, 2002. 21(21): p. 3475-95.
162. Zhang, Y., Y. Xiong, and W.G. Yarbrough, ARF promotes MDM2 degradation and stabilizes p53: 
ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 1998. 
92(6): p. 725-34.
163. Serrano, M., The INK4a/ARF locus in murine tumorigenesis. Carcinogenesis, 2000. 21(5): p. 865-9.
164. Datta, A., et al., ARF directly binds DP1: interaction with DP1 coincides with the G1 arrest function of 
ARF. Mol Cell Biol, 2005. 25(18): p. 8024-36.
165. Dominguez-Brauer, C., et al., ARF stimulates XPC to trigger nucleotide excision repair by regulating 
the repressor complex of E2F4. EMBO Rep, 2009. 10(9): p. 1036-42.
Judith Proefschrift.indb   53 27-12-2012   16:33:14
Chapter 154
166. Sharpless, E. and L. Chin, The INK4a/ARF locus and melanoma. Oncogene, 2003. 22(20): p. 
3092-8.
167. Yang, G., et al., Loss of xeroderma pigmentosum C (Xpc) enhances melanoma photocarcinogenesis 
in Ink4a-Arf-deficient mice. Cancer Res, 2007. 67(12): p. 5649-57.
168. Half, E., D. Bercovich, and P. Rozen, Familial adenomatous polyposis. Orphanet J Rare Dis, 2009. 
4: p. 22.
169. Ishikawa, T.O., et al., Requirement for tumor suppressor Apc in the morphogenesis of anterior and 
ventral mouse embryo. Dev Biol, 2003. 253(2): p. 230-46.
170. Andreu, P., et al., Crypt-restricted proliferation and commitment to the Paneth cell lineage following 
Apc loss in the mouse intestine. Development, 2005. 132(6): p. 1443-51.
171. Gounari, F., et al., Loss of adenomatous polyposis coli gene function disrupts thymic development. 
Nat Immunol, 2005. 6(8): p. 800-9.
172. Beroud, C. and T. Soussi, APC gene: database of germline and somatic mutations in human tumors 
and cell lines. Nucleic Acids Res, 1996. 24(1): p. 121-4.
173. Brembeck, F.H., M. Rosario, and W. Birchmeier, Balancing cell adhesion and Wnt signaling, the key 
role of beta-catenin. Curr Opin Genet Dev, 2006. 16(1): p. 51-9.
174. Malhotra, S. and P.W. Kincade, Wnt-related molecules and signaling pathway equilibrium in 
hematopoiesis. Cell Stem Cell, 2009. 4(1): p. 27-36.
175. Mikels, A.J. and R. Nusse, Wnts as ligands: processing, secretion and reception. Oncogene, 2006. 
25(57): p. 7461-8.
176. Willert, K., et al., Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature, 
2003. 423(6938): p. 448-52.
177. Staal, F.J., et al., Wnt signals are transmitted through N-terminally dephosphorylated beta-catenin. 
EMBO Rep, 2002. 3(1): p. 63-8.
178. Barker, N., et al., The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote 
target gene activation. EMBO J, 2001. 20(17): p. 4935-43.
179. Slusarski, D.C., V.G. Corces, and R.T. Moon, Interaction of Wnt and a Frizzled homologue triggers 
G-protein-linked phosphatidylinositol signalling. Nature, 1997. 390(6658): p. 410-3.
180. Kuhl, M., et al., Ca(2+)/calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled 
homologs and promotes ventral cell fates in Xenopus. J Biol Chem, 2000. 275(17): p. 12701-11.
181. Jonsson, M., K. Smith, and A.L. Harris, Regulation of Wnt5a expression in human mammary cells by 
protein kinase C activity and the cytoskeleton. Br J Cancer, 1998. 78(4): p. 430-8.
182. Austin, T.W., et al., A role for the Wnt gene family in hematopoiesis: expansion of multilineage 
progenitor cells. Blood, 1997. 89(10): p. 3624-35.
183. Van Den Berg, D.J., et al., Role of members of the Wnt gene family in human hematopoiesis. Blood, 
1998. 92(9): p. 3189-202.
184. Reya, T., et al., Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent 
mechanism. Immunity, 2000. 13(1): p. 15-24.
185. Chiba, H., et al., Wnt3 modulates the characteristics and cobblestone area-supporting activity of 
human stromal cells. Exp Hematol, 2004. 32(12): p. 1194-203.
186. Reya, T., et al., A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature, 2003. 
423(6938): p. 409-14.
Judith Proefschrift.indb   54 27-12-2012   16:33:14
General Int roduct ion 55
C
h
a
p
te
r 
1
187. Deshpande, A.J. and C. Buske, Knocking the Wnt out of the sails of leukemia stem cell development. 
Cell Stem Cell, 2007. 1(6): p. 597-8.
188. Liang, H., et al., Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in 
hematopoietic tissue. Cancer Cell, 2003. 4(5): p. 349-60.
189. Bunick, C.G. and W.J. Chazin, Two blades of the [ex]scissor. Structure, 2005. 13(12): p. 1740-1.
190. Tsodikov, O.V., et al., Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA 
structure-specifi c endonuclease XPF-ERCC1. Proc Natl Acad Sci U S A, 2005. 102(32): p. 11236-41.
191. de Laat, W.L., et al., Mapping of interaction domains between human repair proteins ERCC1 and 
XPF. Nucleic Acids Res, 1998. 26(18): p. 4146-52.
192. Tsodikov, O.V., et al., Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair 
complexes by XPA. EMBO J, 2007. 26(22): p. 4768-76.
193. Tripsianes, K., et al., Analysis of the XPA and ssDNA-binding surfaces on the central domain of 
human ERCC1 reveals evidence for subfunctionalization. Nucleic Acids Res, 2007. 35(17): p. 
5789-98.
194. Sijbers, A.M., et al., Mutational analysis of the human nucleotide excision repair gene ERCC1. 
Nucleic Acids Res, 1996. 24(17): p. 3370-80.
195. Altaha, R., et al., Excision repair cross complementing-group 1: gene expression and platinum 
resistance. Int J Mol Med, 2004. 14(6): p. 959-70.
196. Li, Q., et al., Association between the level of ERCC-1 expression and the repair of cisplatin-induced 
DNA damage in human ovarian cancer cells. Anticancer Res, 2000. 20(2A): p. 645-52.
197. Li, Q., et al., Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian 
carcinoma cells. Int J Oncol, 1998. 13(5): p. 987-92.
198. Sijbers, A.M., et al., Homozygous R788W point mutation in the XPF gene of a patient with xeroderma 
pigmentosum and late-onset neurologic disease. J Invest Dermatol, 1998. 110(5): p. 832-6.
199. Kondo, S., et al., Late onset of skin cancers in 2 xeroderma pigmentosum group F siblings and a 
review of 30 Japanese xeroderma pigmentosum patients in groups D, E and F. Photodermatol, 1989. 
6(2): p. 89-95.
200. Jaspers, N.G., et al., First reported patient with human ERCC1 defi ciency has cerebro-oculo-facio-
skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure. 
Am J Hum Genet, 2007. 80(3): p. 457-66.
201. Weeda, G., et al., Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, 
nuclear abnormalities and senescence. Curr Biol, 1997. 7(6): p. 427-39.
202. Tian, M., et al., Growth retardation, early death, and DNA repair defects in mice defi cient for the 
nucleotide excision repair enzyme XPF. Mol Cell Biol, 2004. 24(3): p. 1200-5.
203. Doig, J., et al., Mice with skin-specifi c DNA repair gene (Ercc1) inactivation are hypersensitive to 
ultraviolet irradiation-induced skin cancer and show more rapid actinic progression. Oncogene, 2006. 
25(47): p. 6229-38.
204. Niedernhofer, L.J., et al., A new progeroid syndrome reveals that genotoxic stress suppresses the 
somatotroph axis. Nature, 2006. 444(7122): p. 1038-43.
205. Wajnrajch, M.P., et al., Evaluation of growth and hormonal status in patients referred to the 
International Fanconi Anemia Registry. Pediatrics, 2001. 107(4): p. 744-54.
Judith Proefschrift.indb   55 27-12-2012   16:33:14
Chapter 156
206. Koomen, M., et al., Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9 
null mice. Hum Mol Genet, 2002. 11(3): p. 273-81.
207. Whitney, M.A., et al., Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in 
mice with a targeted disruption of the Fanconi anemia C gene. Blood, 1996. 88(1): p. 49-58.
208. Volker, M., et al., Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell, 2001. 
8(1): p. 213-24.
209. Yamamoto, K.N., et al., Involvement of SLX4 in interstrand cross-link repair is regulated by the 
Fanconi anemia pathway. Proc Natl Acad Sci U S A, 2011. 108(16): p. 6492-6.
Judith Proefschrift.indb   56 27-12-2012   16:33:14
Hematopoiesis is not affected 
in prematurely aged mice that 
lack nucleotide excision repair
2
Judith Verhagen-Oldenampsen a, Jurgen R. Haanstra a, 
Paulina M.H. van Strien, Marijke Valkhof, Ivo P. Touw 
and Marieke von Lindern
a These authors contributed equally
Submitted for publication
Judith Proefschrift.indb   57 27-12-2012   16:33:15
Chapter 258
Abstract
Background
The occurrence of bone marrow failure increases in the elderly 
population and constitutes a risk factor for hematopoietic malignancies. 
Increasing DNA damage is thought to contribute to bone marrow 
failure, but the relation between aging, DNA repair and bone marrow 
failure remained unclear. The Ercc1-/- and Xpa-/-Csbm/m mouse models 
lack nucleotide excision repair and show a comparably severe 
aging phenotype due to suppression of the somatotrophic growth 
axis, reduced Igf-I signalling, and subsequent reduction of energy 
metabolism. The endonuclease Ercc1 is involved in NER, but also 
in interstrand cross link (ICL) repair. We previously showed that the 
colony forming capacity of Ercc1-/- mice is severely impaired. Here 
we investigate whether hematopoiesis is impaired by severe aging 
due to suppression of the somatotrophic growth axes  for which we 
compare hematopoiesis between Xpa-/-,Csbm/m mice that lack NER, and 
Ercc1-/- mice that lack both NER and ICL repair. 
Results
At 16 days of age both mouse models showed a severe growth 
delay. Loss of Ercc1 resulted in loss of hematopoietic stem cells from 
bone marrow (BM) and impaired colony forming ability of progenitor 
cells. The severe growth defect in Xpa-/-,Csbm/m mice, however, was 
not associated with loss of hematopoietic stem cells, or with impaired 
colony formation of myeloid progenitors. 
Conclusions
Premature aging and growth inhibition due to increasing DNA 
damage that ought to be repaired by NER is not associated with loss of 
hematopoietic capacity. The loss of hematopoietic potential is specific 
for Ercc1-deficient mice, which suggests that it is restricted to defective 
ICL-repair.
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baCkground
Aging is associated with an increased occurrence of bone marrow failure 
which constitutes a risk factor for hematopoietic malignancies. DNA damage is 
thought to contribute to bone marrow failure, but the relation between aging, DNA 
repair and bone marrow failure remaines unclear. The cellular response to DNA 
damage consists of the recruitment of damage-specifi c DNA repair enzymes, 
the care-takers, and the activation of proteins that prevent the replication of 
damaged DNA; the gate keepers [1]. Although DNA damage can be expected 
to impair cell growth in general, different DNA repair defi ciencies result in distinct 
phenotypes, which may be due to the activation of distinct gatekeepers.
We previously reported that the BM of mice lacking the endonuclease Ercc1 
ages prematurely [2]. Whereas the peripheral blood of Ercc1-/- mice is still largely 
normal at 3 weeks of age, hematopoietic stem- and progenitor cells (HSPC) in 
the BM are reduced in number, and fail to proliferate in vitro. Ercc1 is involved in 
both NER and the repair of ICLs [3-4]. ICL repair is impaired in the bone marrow 
failure syndrome Fanconi anemia, and the ICL-repair defect of Ercc1-/- mice is a 
valuable model to investigate hematopoietic defects as seen in Fanconi anemia 
[5]. 
The NER pathway is required for the removal of helix-distorting lesions, which 
are typically induced by UV irradiation. NER is initiated by two distinct damage 
recognition pathways, global-genome NER operating throughout the genome 
and transcription coupled excision repair which is activated upon stalling of 
RNA polymerase II [6]. Defects in NER can lead to either highly elevated skin 
cancer susceptibility, as seen in Xeroderma Pigmentosum (XP) patients who 
carry mutations in the NER genes XP-A,B,C,D,E,F or G [7]. On the other hand 
patients with Cockayne syndrome (CS), that carry mutations in the transcription 
coupled-NER specifi c genes CSA or CSB, or with Trichothiodystrophy (TTD), 
caused by mutations in XPD as well as XPF-Ercc1, mainly show progeroid/
premature aging-like phenotypes [8]. Xpa-/-Csbm/m mice develop severe growth 
retardation and accelerated aging and die within three weeks postnatal, shortly 
before Ercc1-/- mice. Growth retardation in Ercc1-/- and Xpa-/-Csbm/m mice 
appeared to be due to suppression of the somatotrophic growth axis, reduced 
Igf-I signalling, and subsequent reduction of energy metabolism [9-10]. To 
distinguish the cause of progeroid features, growth retardation and bone marrow 
failure we investigated hematopoietic parameters in NER defective Xpa-/-Csbm/m 
mice and compared it to the previously studied Ercc1-/- mice. This revealed that 
premature aging and growth retardation associated with defective NER does 
not affect hematopoiesis.
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results and disCussion
Similar to what was shown previously, Xpa-/-Csbm/m mice were severely 
growth retarded at 16 days of age, as exemplified by a 42% reduction in 
body weight compared to wt littermates [11]. Age matched Ercc1-/- mice 
showed a 57% reduction in body weight compared to wt littermate controls 
(Fig. 1A) [12]. Due to premature aging all Xpa-/-Csbm/m mice died before 
they were 19 days old, while Ercc1-/- mice died after postnatal day 21 (data 
not shown). This indicates that both models are very similar in their growth 
retardation with a slightly worse life expectancy for the Xpa-/-Csbm/m mice.
Next, we analysed the HSPC compartment. We could compare 
the frequency of hematopoietic subpopulations because the ratios 
mononuclear cells/animal weight were constant for all genotypes (data 
not shown). The fraction of LSK (lineage-marker negative (lin)Sca1+ckit+) 
cells, representing the HSPC compartment,  in the BM of Ercc1-/- mice 
was reduced to 38% compared to wt littermates. However, there was no 
significant difference in the LSK frequency between Xpa-/-Csbm/m mice and 
their wt littermates (Fig. 1B). 
Figure 1: The effect of  Xpa/Csb-deficiency and Ercc1-deficiency on mouse 
weight and hematopoietic stem cells
(A) Weight of 16 day old mice in grams, and (B) Frequency of LSK cells representing 
the HSPC compartment. Data from 1x106 BM cells were recorded. Genotypes 
are shown below the x-axes. Bars represent the average of at least 3 mice, error 
bars represent standard deviation. Two-tailed student t-tests were performed to 
determine significance *: p<0.05, **: p<0.001
Progenitor frequencies were determined by immunophenotyping 
of common myeloid progenitors (CMP; lin-ckit+CD16/32intCD34+), 
granulocyte-monocyte progenitors (GMP; lin-ckit+CD16/32hiCD34+) and 
MEPs (lin-ckit+CD16/32intCD34low) (Fig 2A-C). This indicated that progenitor 
populations were similar between Xpa-/-Csbm/m mice and wt controls, while 
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they were decreased in Ercc1-/- mice compared to wt littermates although 
with a probability to be similar of 0.057 for CMP, 0.12 for GMP and 0.10 for 
MEP (n≥3). The capacity of Xpa-/-Csbm/m bone marrow progenitors to form 
colonies in vitro was reduced to 30% in presence of G-CSF, but unaffected 
in presence of GM-CSF or Epo/SCF (Fig 2D-F). Ercc1-/-BM, however, failed 
to produce any colonies in presence of G-CSF or Epo/SCF, while colony 
formation was reduced to 66% in the presence of GM-CSF (Fig 2D-F). 
In summary, Xpa-/-Csbm/m and Ercc1-/- mice were both severely growth 
retarded, but only Ercc1-defi cient animals displayed a hematopoietic 
defect. These results indicate that growth retardation in Ercc1-/- mice is 
linked to NER-defi ciency and suggest that the hematopoietic phenotype is 
associated with defi cient ICL repair.
Using Xpa-/- mice, we previously showed that defective NER does not 
reduce HSPCs in the BM [2]. However, Xpa-/- mice are hypersensitive 
to UV-induced carcinogenesis mirroring the skin cancer susceptibility 
of XP patients, but do not develop the growth retardation and progeroid 
phenotypes that are manifested in Ercc1 mutants or in Xpa-/-Csbm/m double 
mutants. The data presented here point to a context-dependent sensitivity to 
different types of DNA damage. Loss of TC-NER as it occurs in Csb-defi cient 
mice suppresses the growth hormone (GH) and insulin-like growth factor 1 
(Igf-I) axis [9], which causes the severe growth retardation in Xpa-/-Csbm/m 
mice. However, hematopoiesis in Xpa-/-Csbm/m mice is hardly affected, and 
therefore we conclude that maintenance of HSPCs is independent of GH 
and Igf-I. The sensitivity of the HSPC compartment to defective ICL repair 
is supported by fi ndings in Brca2∆27/∆27 mice that carry hypomorphic alleles 
of Brca2, also known as Fancd1. Brca2/Fancd1 is required for homologous 
recombination downstream of the FA pathway but has no direct link to 
NER [13-14].  Brca2∆27/∆27 mice have a minor growth defect (body weight is 
85% of wt) but display a prominent hematopoietic phenotype: the colony 
forming capacity of Brca2∆27/∆27 BM is 2- to 4-fold reduced, and HSPCs are 
outcompeted by wt cells in transplantation experiments [15]. In contrast 
to Ercc1-/- mice the Brca2∆27/∆27 mice did not show reduced frequencies of 
HSPCs in the BM. This difference between the two mouse models may be 
attributed to different steps in ICL-repair that are affected by either mutation. 
However, we cannot rule out some synergistic effects of defective ICL and 
NER in the hematopoietic phenotype of our Ercc1-defi cient mice.
Judith Proefschrift.indb   61 27-12-2012   16:33:15
Chapter 262
 
Figure 2: Progenitor frequencies and their colony forming capacity in Xpa/
Csb- and Ercc1-deficient bone marrow
(A-C) Progenitor frequencies were determined using BM cell suspensions: common 
myeloid progenitors (CMP; lin-ckit+CD16/32intCD34+), granulocyte-monocyte 
progenitors (GMP; lin-ckit+CD16/32hiCD34+) and MEPs (lin-ckit+CD16/32intCD34low). 
(D-F): BM cell suspensions were plated at a density of 50.000 cells per ml per dish 
in methyl cellulose medium containing huG-CSF (0.1 µg/ml), muGM-CSF (0.1 µg/
ml), or Epo (4 mU/ml) plus transferrin (0.3 mM), hemin (0.2 mM) and muSCF (0.1 
g/ml). Colonies containing 30 cells or more were scored after 7-8 days of culture. 
Bars show the mean of n≥3 animals. Error bars show standard deviations. Two-
tailed student t-tests were done: *: p<0.05, **: p<0.001
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ConClusions
Aging is associated with an increased occurrence of bone marrow failure 
but the mechanism is unclear. It was previously shown that premature 
aging in NER-defective mice is due to suppression of the somatotrophic 
growth axis, reduced Igf-I signalling, and subsequent reduction of energy 
metabolism, a process that also occurs in mice that age naturally [9-10]. 
Here we show that the hematopoietic compartment of prematurely aging, 
NER-defi cient mice is similar to that of their healthy littermates. Age-
matched mice that also lack ICL repair, however, do show a signifi cant loss 
of HSPC. Thus, bone marrow failure is not related to the hormonal aging 
physiology, but to specifi c types of DNA damage.  
materials and methods
Animals 
Ercc1+/- [12], Csbm/+  [16], Xpa+/- [17], and wt littermates were kept in 
a background of C57/Bl6 or FVB/n at the Animal Resource Center 
(Erasmus MC). Ercc1 experimental animals were generated as F1 in a 
mixed background of C57/Bl6 and FVB/n, Xpa/Csb mice were generated 
as C57/bl6. Ercc1+/- mice displayed a wild type phenotype and were used 
as controls. All animal studies were approved by an independent Animal 
Ethical Committee.
Mice were sacrifi ced by CO2 inhalation. BM cell suspensions were 
obtained by crushing femurs, tibia and sternum in HBSS supplemented with 
5% (v/v) fetal calf serum, 100 units/ml penicillin, 100 μg/ml streptomycin. 
BM, spleen and thymus were passed through a 70 µM fi lter (BD Falcon, 
Bedford, MA) to obtain single-cell suspensions.
Colony forming assays
BM cell suspensions were plated at a density of 50.000 cells per ml per 
dish in triplicate in methyl cellulose medium (Methocult M3234, StemCell 
Technologies SARL, Grenoble, France) containing huGCSF (0.1 µg/ml), 
muGM-CSF (0.1 µg/ml), or Epo (4 mU/ml) plus transferrin (0.3 mM), hemin 
(0.2 mM) and muSCF (0.1 µg/ml). Colonies containing 30 cells or more 
were scored after 7-8 days of culture. 
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Flow cytometry 
Blood and single cell suspensions from BM, spleen and thymus were 
analyzed by flow cytometry using a BD™ LSR II Flow Cytometer System 
with FCS Express Diva software (BD Biosciences., San Jose, California), 
and analyzed by FlowJo (Tree Star, Inc., Ashland, Oregon). Antibodies 
directed against CD3e, CD11b, CD45R/B220, Ly6G and Ly-6C, and 
TER-119 were used together with streptavidin-APC and streptavidin-Cy7 
(BD Pharmingen). Directly labelled antibodies used included CD117-
APC, CD16/32-PE (BD Pharmingen), Sca1-PE-cy7, CD34-pacific 
blue, CD127-pacific blue (ebioscience). 7-AAD (Invitrogen, Breda, the 
Netherlands) selected life cells. Subpopulation were gated as described 
by Wolfler et al [18]: LSK (lineage marker negative, Sca1+, ckit+), long-
term hematopoietic stem cells (LT-HSC): LSK,CD34-Flt3-, short-term (ST) 
HSC: LSK, CD34+Flt3-, multipotent progenitors (MPP): LSK,CD34+Flt3+ 
common myeloid progenitor (CMP): lin-ckit+CD34+CD16/CD32low, 
granulocyte-monocyte progenitor (GMP): lin-ckit+CD34+CD16/CD32high 
and megakaryocyte-erythroid progenitor (MEP): lin-ckit+ CD34-CD16/
CD32low. Data from 1x106 BM cells were recorded to ensure reliable 
analysis of small populations.
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Abstract
The endonuclease complex Ercc1/Xpf is involved in interstrand 
crosslink repair and functions downstream of the Fanconi pathway. 
Loss of Ercc1 causes hematopoietic defects similar to those seen 
in Fanconi Anemia. Ercc1-/- mice die 3-4 weeks after birth, which 
prevents long-term follow up of the hematopoietic compartment. We 
used alternative Ercc1 mouse models to examine the effect of low or 
absent Ercc1 activity on hematopoiesis. Tie2-Cre-driven deletion of 
a floxed Ercc1 allele was efficient (>80%) in fetal liver hematopoietic 
cells. Hematopoietic stem- and progenitor cells (HSPC) with a deleted 
allele were maintained in mice up to 1 year of age in the context of a wt 
allele, but were progressively outcompeted when the deleted allele was 
combined with a knock out allele. Mice with a minimal Ercc1 activity 
expressed by 1 or 2 hypomorphic Ercc1 alleles have an extended life 
expectancy, which allows analysis of HSPC at 10 and 20 weeks of age. 
The HSPC compartment was affected in all Ercc1 deficient models. 
Actively proliferating multipotent progenitors were most affected as 
were myeloid and erythroid clonogenic progenitors. In conclusion, lack 
of Ercc1 results in a severe competitive disadvantage of HSPC and is 
most deleterious in proliferating multipotent progenitor cells.
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1. IntroduCtIon 
The Ercc1/Xpf complex is an endonuclease involved in nucleotide 
excision repair (NER) and in repair of interstrand crosslinks (ICL) [1 - 2]. 
Mice lacking Ercc1 (Ercc1-/-) suffer from severe premature aging, which 
shows as small size, ruffl ed fur, liver polyploidy and loss of hematopoietic 
progenitors from bone marrow (BM), and results in death at 3-4 weeks of 
age [3-6].  Hypomorphic Ercc1 (Ercc1d/d or Ercc1*292) mice that harbor 2 
C-terminally truncated alleles are also small but they survive longer (~6 
months), probably as a result of their residual DNA repair capacity (~4%) 
[1 - 2]. The hypomorphic allele has a 7 amino acid deletion at the C-terminus 
which impairs dimerization with Xpf [1].
The short life span and severe aging phenotype of Ercc1-/- is shared with 
other models of defective NER such as the Xpa-/-Csbm/m mice that die at 3 
weeks of age [7-9]. The hematopoietic defect of Ercc1-/- mice, however, is 
specifi cally linked to defective ICL repair ([5]). The correlation of specifi c 
phenotypes with either NER or ICL repair is likely due to the activation of 
distinct tumor suppressor mechanisms that impact differently on specifi c 
tissues. For instance, persistent DNA damage due to defective NER results 
in deregulation of the growth axis, and is independent of p53 and p16INK4a 
[8]. Hematopoiesis, on the other hand, is particularly sensitive to activation 
of p53 (Haanstra, Verhagen-Oldenampsen in preparation), chapter 4.
Both fi broblasts and hematopoietic cells of Ercc1-/- mice and mice lacking 
Fanconi proteins are hypersensitive to the DNA crosslinker mitomycin 
C (MMC) [1, 5, 10]. Importantly, the endonuclease complex Ercc1/Xpf 
participates in the same ICL repair pathway as the Fanconi Anemia (FA) 
proteins [11]. It associates with FancP/Slx4 and is required for FancD2 
focus formation [12]. Mice lacking for instance the Fancc gene only develop 
hematopoietic defects when challenged with MMC, or when hematopoietic 
cells are cultured at atmospheric oxygen prior to transplantation [10, 13]. 
Mice lacking Ercc1 develop hypoplasia of the BM compartment without 
applying an external challenge similar to FA patients [14] and Fancp/Slx4-
defi cient mice [15]. 
The Ercc1 mice are a useful model to study BM failure in FA, which 
is, however, limited by the short life span of Ercc1-/- mice. The BM of 
Ercc1-/- mice contains fewer progenitors, and the remaining myeloid and 
erythroid progenitors fail to proliferate in vitro [5]. The aim of this study 
was to characterize progression of BM failure in Ercc1 models with an 
extended life span, and to examine how low levels of Ercc1 activity 
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impact on hematopoiesis. We used mice with a single floxed Ercc1 allele 
crossed in to a Tie2-driven Cre recombinase. Tie2 is expressed in the early 
hematopoietic stem cell (HSC) when they dissociate from the hemogenic 
endothelium, and in quiescent adult HSC [16-17]. We show that the Ercc1 
allele recombines efficiently in fetal liver. In presence of an intact Ercc1 
allele the recombination frequency remained stable, while the frequency 
of cells lacking Ercc1 rapidly decreased in BM when the second Ercc1 
allele was lacking. This indicated that Ercc1-deficient hematopoietic cells 
have a severe competitive disadvantage. To investigate how low levels 
of Ercc1 affect hematopoietic stem- and progenitor cells we compared 
hematopoiesis in Ercc1wt, Ercc1d/d, and Ercc1-/d mice at 3, 10 and 20 weeks 
of age. At week 3 we included Ercc1-/- in this comparison. This analysis 
showed that proliferating stem- and progenitor cells decreased, whereas 
the most immature cells within the LSK fraction became less affected 
when these cells became quiescent after week 3 of age. The decrease of 
multipotent progenitors preceded the decrease of committed progenitors 
indicating that the earliest proliferating progenitors are most sensitive to 
defective ICL repair.
2. MatErIaLS and MEthodS 
2.1 Animals
Ercc1+/d, Ercc1+/- [1], Ercc1+/f (obtained from Dr. L. Niedernhofer, 
University of Pittsburgh School of Medicine, Pittsburgh, PA), Tie2-Cre [18], 
and wt littermates were kept in a pure background of C57/Bl6 and FVB/n 
at the Animal Resource Center (Erasmus MC). Experimental animals were 
generated as F1 in a mixed background of C57/Bl6 and FVB/n. Ercc1+/- and 
Ercc1+/d mice displayed a wild type phenotype and were used as controls. 
All animal studies were approved by an independent Animal Ethical 
Committee.  Mice were sacrificed by CO2 inhalation between postnatal 
week 3 and 20. Neonatal mice and embryo’s were sacrificed by decapitation 
on ice. Femurs, tibia and sternum were isolated and BM cell suspensions 
were obtained by crushing the bones in HBSS supplemented with 5% (v/v) 
foetal calf serum, 100 units/ml penicillin and 100 μg/ml streptomycin. Fetal 
livers and neonatal spleens were resuspended by pipetting in the same 
medium.
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2.2 Colony forming unit assays
Bone marrow cell suspensions were plated in methyl cellulose medium 
(Methocult M3234, StemCell Technologies SARL, Grenoble, France) con-
taining huGCSF (0.1 mg/ml), muGM-CSF (0.1 mg/ml), or Epo (4 mU/
ml) plus transferrin (0.3 mM), hemin (0.2 mM) and muSCF (0.1 mg/ml). 
Colonies containing 30 cells or more were scored after 7-8 days of culture.
2.3 Flow cytometry
Single bone marrow cell suspensions were analyzed by fl ow 
cytometry using a BD™ LSR II Flow Cytometer System with FCS 
Express Diva software (BD Biosciences., San Jose, California). FCS 
fi les were analyzed using FlowJo (Tree Star, Inc., Ashland, Oregon). 
Cell were labelled with the following antibodies; mouse biotinylated 
lineage depletion kit, CD16/CD32-PE, CD117-APC, CD135-PE and 
streptavidin-APC-Cy7 (BD Pharmingen), Sca1-PE-Cy7, CD34-pacifi c 
blue and CD127-pacifi c blue (ebioscience) and 7’AAD (Invitrogen).
2.4 Genotyping PCR and Q-PCR 
Genomic DNA was isolated from tail segments, or from blood (NucleoSpin 
Tissue XS, MACHEREY-NAGEL GmbH & Co). Genotypes were determined 
by PCR. Genomic Q-PCR used an Applied Biosystems 7900 instrument 
(Applied Biosystems, Weiterstadt, Germany) and SYBR Green PCR 
Master Mix (Applied Biosystems). Primers used were: HPRT - forward: 
AGCCTAAGATGAGCGCAAGT, reverse: ATGGCCACAGGACTAGAACA; 
Recombined Ercc1 allele - forward:  TGCAGCATGCTCTAGACTCG, 
reverse: CCATGAATTCCGGGATCTCTCGAC; Non-recombined 
Ercc1 allele - forward: TCCACTTCGCATATTAAGGTGA, reverse: 
AACCTGCGTGCAATCCAT; Ercc1 knock out locus - forward: 
TCCTCGTGCTTTACGGTATC, reverse: CAGGATCAGGAGGTACAGGA;
2.5 Histology
Livers were embedded in Tissue-Tek O.C.T (Sakura Finetek, 
Zoeterwoude, Netherlands). 4 µm sections were made using a cryostat 
(Leica) and stained with hematoxylin and eosin. Slides were imaged on 
a Leica DMLB light microscope equipped with Leica application suite 
2.7.1 (Leica Microsystems (Switzerland).
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3. rESuLtS 
 
3.1 Ercc1-deficient hematopoietic stem and progenitor cells 
  have a competitive disadvantage
Ercc1-/- mice have an average lifespan of 3 weeks. Because we aimed 
to study long-term effects of Ercc1-deficiency on hematopoietic stem cell 
function, we used a Cre-lox conditional mouse model expressing Cre-
recombinase from the Tie2 promoter (Tie2-Cre). Tie2 is expressed on 
vascular endothelial cells and HSCs [16-17].  Mice with a single floxed Ercc1 
allele (Ercc1+/f) were crossed with Ercc1+/- Tie2-Cre mice. We compared 
Ercc1-/f and Ercc1+/f mice with and without expression of Tie2-Cre. Because 
the recombination efficiency in Cre-lox mouse models is never 100% [19], 
deletion of the floxed allele was analyzed both pre- and postnatal in the 
most active hematopoietic organ, i.e. fetal liver in the embryo, spleen in 
newborn animals and BM in adult animals. 
The presence of the floxed allele was analyzed by real time genomic 
PCR on DNA isolated from the various tissues. The fraction of cells with 
a deleted floxed allele was calculated by comparing the relative signals in 
tissues with or without Cre. Tie2-Cre/Ercc1+/f mice showed stable deletion 
of the floxed allele in 50% or more of the hematopoietic cells (Figure 1). 
In Tie2-Cre/Ercc1-/f mice the Ercc1 allele was deleted in 80% of fetal liver 
cells at prenatal days E12.5 and E15.5. In newborn Tie2-Cre/Ercc1-/f 
animals (postnatal day 1) ~ 50% of spleen cells carried a deleted floxed 
allele. At ten weeks of age the recombined allele was undetectable or 
present in a low percentage of cells. In Tie2-Cre/Ercc1-/f animals of 1 year 
old the BM contained hardly any cells with a recombined allele (Figure 
1).  Accordingly, blood cell parameters and colony forming progenitors in 
BM were similar in Ercc1-/f mice with or without Tie2-Cre expression at 
10 weeks and 1 year of age (data not shown). This indicates that Ercc1-
deleted cells are outcompeted by cells in which the floxed allele was not 
recombined. The presence of one Ercc1 allele is sufficient to maintain the 
hematopoietic cell compartment at a similar level as in nondeleted animals. 
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Figure 1: Recombination in Ercc1-fl ox Tie2Cre model. 
The fraction of recombined alleles in the presence of Tie2-Cre was calculated after 
measuring the non-deleted fl oxed allele by real time genomic PCR and comparing 
it to the presence of the fl oxed allele in absence of Cre. DNA was isolated from 
fetal livers at embryonic day E12.5 and E15.5, from the spleen of neonatal 
mice, and from bone marrow of 10 and 52 week old mice. Closed triangles: 
Ercc1+/f, open boxes: Ercc1-/f. Each symbol is an independent measurement. 
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Figure 2: Weight and liver cell morphology of mice with distinct levels of   
Ercc1 activity. 
(A-C) Mean body weight of (A) 3 week old Ercc1-/- (n=6), Ercc1-/d (n=7), Ercc1d/d 
(n=4) and wt (n=13) mice. (B) 10 week old Ercc1d/d (n=3), Ercc1-/d (n=3) and wt 
(n=6) mice. (C) 20 week old Ercc1-/d (n=8), Ercc1d/d (n=5) and wt (n=12) mice. (D) 
Hematoxylin- and eosin-stained sections of liver from 3 week old wt, Ercc1-/-, Ercc1-/d 
and Ercc1d/d mice. (E) Quantification of enlarged nuclei (>8μm). Error bars indicate 
standard deviation. * indicates p≤0.05, ** indicates p≤ 0.01 and *** indicates 
p≤0.001.
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3.2 The composition of the hematopoietic stem cell pool is   
 affected by the level of Ercc1 activity
To fi nd a window of Ercc1 expression that allows for the analysis of 
hematopoiesis for several weeks, we compared hematopoiesis in bone 
marrow of Ercc1-/- mice with mice harboring one C-terminally truncated Ercc1 
allele and a knock out allele (Ercc1-/d), or two C-terminally truncated Ercc1 
alleles (Ercc1d/d).  The truncated allele has been described as *293 [1] or as 
delta [20], we adopted delta, indicated as ‘d’ that should not to be confused 
with a recombined fl oxed allele. Three week old mice with low or absent Ercc1 
activity had a dose-dependent decrease in body size (Figure 2A). Ercc1-/- mice 
died between week 3 and 4. The Ercc1d/d and Ercc1-/d mice survived longer, 
but  their low body weight persisted at 10 and 20 weeks of age (Figure 2B,C). 
A comparison of liver morphology of the various Ercc1-defi cient mice at 3 
weeks of age indicated that livers from both Ercc1-/-, Ercc1-/d, and Ercc1d/d mice 
contained cells with enlarged nuclei, compared to wt livers (larger than 8 μm; 
Figure 2D,E) as previously described [20].
To analyze the effect of low levels of Ercc1 on hematopoiesis, we fi rst 
examined the stem- and progenitor cell compartment using fl ow cytometry. 
Hematopoietic stem cells and progenitor cells (HSPCs) were defi ned as 
negative for lineage markers (Lin-) and positive for the surface markers Sca 
(Sca1+) and the SCF receptor cKit (cKit+), indicated as the LSK fraction. The 
stem cell compartment was further subdivided into long term HSC (LT-HSC, 
CD34-, CD-135), short term HSC (ST-HSC, CD34+ CD135-) and multipotent 
progenitors (MPP, CD34+ CD135+) [21].
Because BM cellularity corrected for body weight was comparable between 
the different genotypes at 3, 10 and 20 weeks of age, a comparison of the 
subset ratios was permitted between Ercc1-defi cient mice and their wt 
littermates. The percentage of LSK cells in the total bone marrow of 3 week 
old mice was decreased to 17% of wt for Ercc1-/-, 28% of wt for Ercc1-/d and 
27% of wt in Ercc1d/d mice (Figure 3A). At 10 weeks of age, the percentage 
of LSK cells present in the BM further decreased in Ercc1-/d mice to 10% of 
wt, but stabilized to 50% of wt for Ercc1d/d mice (Figure 3B). At 20 weeks 
the percentage of LSK was 26% of wt for Ercc1-/d and 31% of wt for Ercc1d/d 
(Figure 3C). Thus, the size of the stem cell compartment correlates with Ercc1 
activity, but fl uctuates over time. 
We next investigated how distinct subpopulations within the LSK 
compartment depend on Ercc1 protein activity. The distribution of LT-HSC, 
ST-HSC and MPP displayed relatively minor changes at week 3 (Figure 3D). 
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At 10 weeks of age, the fraction of actively dividing MPP was more than 
3-fold decreased in both hypomorphic models (Figure 3E). The Ercc1-/d BM 
contained predominantly quiescent LT-HSC, while proliferating ST-HSC were 
the most abundant fraction in Ercc1d/d BM (Figure 3E). The enrichment of 
quiescent LT-HSC is in accordance with the further reduction of LSK in Ercc1-/d 
BM. In contrast, the LSK fraction in Ercc1d/d BM partly recovered at week 10, 
which is in accordance to the increase in ST-HSC fraction. At 20 weeks of age 
the distribution of quiescent and dividing subfractions within the population of 
LSK cells remained similar to the distribution at 10 weeks for both Ercc1-/d and 
Ercc1d/d mice (Figure 3F).
To specify the distribution of progenitors that arise from the LSK fraction 
in relation to the remaining Ercc1 activity, we analyzed the following lineage 
committed progenitor subsets: Common Myeloid progenitors (CMP, Lin- 
Ckit+CD34+CD16/CD32int), Granulocyte-Monocyte progenitors (GMP, 
Lin- Ckit+CD34+CD16/CD32hi), Megakaryocyte-Erythroid progenitors (MEP, 
Lin- Ckit+CD34-CD16/CD32low) and Common Lymphoid progenitors (CLP, 
Lin-CD127+Sca1/Ckit_int). At 3 weeks of age the CMP fraction of Ercc1-/- mice 
decreased to 46% of wt, the GMP fraction to 16% of wt, the MEP fraction to 
45% of wt and the CLP fraction to 48% of wt levels (Figure 3G). In Ercc1-/d 
mice the progenitor subsets decreased to respectively 39%, 54%, 88% of 
wt levels and no change in CLP levels (Figure 3G). For Ercc1d/d mice these 
percentages were 23%, 38% and 41% of wt levels and no difference in CLP 
levels (Figure 3G). For all myeloid subsets, except the CMP compartment, the 
numbers increased in Ercc1-/d mice as compared to Ercc1-/- mice. 
At 10 weeks of age, BM of Ercc1-/d mice contained 20% of wt CMP levels, 
29% of wt GMP levels, 49% of wt MEP levels and 87% of wt CLP levels 
(Figure 3H). In Ercc1d/d mice these subsets contained 32%, 27%, 39% and 
74% of wt levels respectively (Figure 3H).  At 20 weeks of age Ercc1-/d BM 
contained 35% of wt CMP levels, 77% of wt GMP levels, 53% of wt MEP 
levels and 67% of wt CLP levels (Figure 3I). In Ercc1d/d mice these subsets 
contained 13%, 23%, 31% and 69% of wt levels respectively (Figure 3I). 
In conclusion, decreased Ercc1 levels reduce all compartments of 
actively proliferating stem- and progenitor cells except for the CLP fraction 
that is only moderately affected. Despite reduced numbers of progenitors 
in BM, we observed normal cell numbers in peripheral blood (data not 
shown). The presence of a hypomorphic Ercc1 allele extends the life span 
of the mice, and marginally improves hematopoiesis in the mice. Also 
in Ercc1d/d mice the number of HSPC remains severely compromised. 
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Figure 3: Ercc1 levels infl uence the composition of the stem and progenitor  
cell pool. 
Whole BM suspensions were stained with surface antigen specifi c antibodies 
for hematopoietic stem cells. (A,D,G) Lin- Sca1+ cKit+ cells as percentage 
of total bone marrow cells. (B,E,H) Distribution of stem cells within the LSK 
fraction (LT-HSC (CD34- CD135-), ST-HSC (CD34+ CD135-) and MPP (CD34+ 
CD135+)). (C,F,I) Distribution of progenitor cells within total bone marrow. 
Common Myeloid progenitors (CMP Lin- Ckit+CD34+CD16/CD32intermediate), 
Granulocyte-Monocyte progenitors (GMP, Lin- Ckit+CD34+CD16/CD32high), 
Megakaryocyte-Erythroid progenitors (MEP, Lin- Ckit+CD34-CD16/CD32low) and 
Common Lymphoid progenitors (CLP, Lin-CD127+Sca1/Ckit intermediate). Mean 
percentages are plotted; error bars indicate standard deviation. * indicates p≤0.05, 
** indicates p≤0.01 and *** indicates p≤0.001.
A
B
C
D
E
F
G
H
I
3 weeks
10 weeks
20 weeks
†
†
Judith Proefschrift.indb   77 27-12-2012   16:33:31
Chapter 378
3.3 Ercc1 deficiency impairs colony formation by hematopoietic  
  progenitors
To assess the colony forming potential of hematopoietic progenitors, 
bone marrow suspensions were plated in semi-solid medium supplemented 
with lineage-specific cytokines. At 3 weeks of age the number of erythroid 
(BFU-E, Figure 4A), granulocytic (CFU-G, Figure 4B) and granulocytic-
macrophage colony forming cells (CFU-GM, Figure 4C) were significantly 
reduced in all Ercc1 deficient models relative to wt (Figure 4A-C). 
Similar results were obtained in BM of 10 and 20 week old mice; Ercc1-/d 
BM formed no BFU-E colonies (Figure 4D,G), no CFU-G colonies (Figure 
4E,H) and only 31% of CFU-GM colonies compared to wt (Figure 4F,I). 
In Ercc1d/d BM the percentages were 0%, 0% and 35% of wt respectively. 
These results imply that the residual Ercc1 activity in Ercc1-/d and Ercc1d/d 
mice is not sufficient to support BFU-E or CFU-G colony formation, whereas 
CFU-GM colony outgrowth is only partly restored.
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figure 4: Colony forming potential of bone marrow progenitors is affected   
in hypomorphic Ercc1 models. 
BFU-E, CFU-G and CFU-GM colonies per 5x104 bone marrow cells derived from 
(A-C) 3 week old Ercc1-/- (n=6), Ercc1-/d (n=7), Ercc1d/d (n=4) and wt mice (n=7) 
(D-F) 10 week old Ercc1-/d (n=3), Ercc1d/d (n=3) and wt mice (n=3) (G-I) 20 week 
old Ercc1-/d (n=3), Ercc1d/d (n=6) and wt mice (n=8) . Error bars indicate standard 
deviation. * indicates p≤0.05, ** indicates p≤0.01 and *** indicates p≤0.001.
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4. dISCuSSIon 
The Ercc1/Xpf endonuclease complex acts downstream of the Fanconi 
pathway in ICL repair [1-2]. The hematopoietic defects in Ercc1-deficient 
mice are reminiscent of the hematopoietic defect of FA patients [22]. Loss 
of HSC is seen when FA mice are challenged with Mitomycin C [23-24]. It 
mostly takes several years before FA patients develop anemia. The fact that 
most mouse models lacking Fanconi genes fail to display overt BM failure 
may reflect the time it takes to develop anemia. An important factor in the 
onset of BM failure and leukemia development may be the level of residual 
DNA repair activity. We employed Ercc1-deficient mouse models to show 
progressive loss of the number of hematopoietic stem and progenitor cells 
dependent on Ercc1 activity. Remaining progenitors were compromised in 
their in vitro proliferation capacity, which was similarly severe in Ercc1-/-, 
Ercc1-/d and Ercc1d/d mice.
 
4.1 Reduced competitiveness of Ercc1-deficient hematopoietic 
 cells 
The conditional knock out model showed that a small percentage of 
hematopoietic stem- and progenitor cells in which the floxed Ercc1 allele 
did not recombine outcompeted the Ercc1-deficient cells in which Cre-
driven deletion had occurred. This progressive loss of Ercc1-deficient 
hematopoietic cells resembles what has been found in a small fraction of 
FA patients. In some FA patients a mutation was reverted, or two mutated 
alleles recombined and yielded an unaffected allele. Such a naturally 
corrected hematopoietic stem cell is able to out-compete the hematopoietic 
cells with two defective alleles resulting in the restoration of BM cellularity. 
In these mosaic patients cells fibroblasts retained two mutated alleles 
[25]. The conditional knock out mice that we used here underscores that 
defective ICL repair mainly affects continuously regenerating tissues 
such as BM and blood hematopoietic cells. It is also in the continuously 
proliferating bone marrow compartment that few cells with an intact allele 
can outcompete cells that lack a functional FA pathway.
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4.2 Reduced hematopoietic reserves with normal peripheral 
 blood levels
The hematopoietic defect in Ercc1-defi cient mice, and in FA is specifi cally 
associated with DNA crosslinks that stall the replication fork. The inability 
to repair spontaneous DNA damage limits stress-hematopoiesis by 
diminishing the ability of HSCs to proliferate and self-renew. During 
embryo development and in young mice (<3 weeks) the HSC compartment 
is continuously expanded, whereas HSC become largely quiescent in adult 
mice [26-27]. These quiescent HSC are less sensitive to replication-coupled 
DNA damage repair defects. Progenitor cells have a higher proliferation 
rate compared to HSC and are therefore more prone to DNA damage 
both during development and in adult mice. Accordingly, we found that 
LSK numbers are 3- to 5-fold decreased compared to their wt littermates 
in Ercc1 defi cient mice. At 3 weeks of age the distribution within the LSK 
compartment hardly shows a tendency towards more primitive cells, most 
likely because all compartments contained proliferative cells. At 10 and 20 
weeks of age, when the mice are adult, there is a signifi cant shift towards 
the more primitive cells in the LSK compartment in the Ercc1-/d and Ercc1d/d 
compared to their wt littermates, indicating that maintenance of the LT-
HSC fraction is less sensitive to DNA damage than the maintenance of the 
proliferative MPP fraction [28].
However, the mice did not develop overt anemia, and peripheral blood 
contained near normal amounts of red and white blood cells. This is 
most likely due to compensatory mechanisms controlled by a network of 
cytokines and hormones:  Only small and transient alterations in local- 
and/or systemic concentrations will be needed to maintain or restore 
homeostasis. Notably, Epo serum concentrations were normal in Ercc1 
defi cient mice  (data not shown), but this result was expected given that 
the mice were not anemic and Epo production in the kidney is activated by 
hypoxia. 
Because cell numbers in peripheral blood are hardly affected, the 
hematopoietic defect in Ercc1-/d mice does not represent overt BM failure 
but can be regarded as a situation prone to such overt BM failure. Also in FA 
patients, reduced stem cell numbers precede overt BM failure and leukemia 
development [29-30]. When challenged for regeneration following insult, 
the Ercc1-defi cient stem- and progenitor cells lack the robustness to do so. 
Analysis of BM and leukemogenesis in FA and in FA mouse models show 
that hypoplasia precedes leukemic transformation [31-32]. Hypoplastic 
compartments are most at risk for leukemic transformation [33].   FA patients 
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mainly develop acute myeloid leukemia (AML) and only very rarely acute 
lymphoid leukemia (ALL) [34].  In the Ercc1 models we also found that 
the myeloid compartment is affected by Ercc1 deficiency while the CLP 
compartment is hardly affected. Therefore, the hypomorphic Ercc1 
mice may be a very useful model to study BM failure mechanisms and 
subsequent leukemogenic transformation in FA.
 
4.3 Comparison of the hematopoietic phenotype of Ercc1-/-, 
 Ercc1-/d and Ercc1d/d mice
In myeloid and erythroid colony forming assays Ercc1 deficient 
progenitors show a 50% (on GM-CSF) to a 100% (on EPO/SCF or G-CSF) 
decrease in colony numbers. In Ercc1-/d and Ercc1d/d mice the decrease 
in colony numbers was not significantly different from those in Ercc1-/- 
mice. This implies that low levels of functional protein cannot repair the 
damage inflicted by the rapid proliferation which occurs in these assays. 
Flow cytometry measurements indicated that the decrease in myeloid and 
erythroid colony forming cell numbers was only moderate in the Ercc1 
deficient models at 3 weeks of age. Thus, the progenitors are present and 
they are able to generate progeny in vivo, but not in vitro. In vitro conditions 
challenge the proliferation capacity more than the in vivo condition and 
may be more mutagenic (e.g. due to higher oxygen levels). 
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Abstract
Defective DNA repair is an important factor in aging and cancer. In 
the hematopoietic system, bone marrow failure indicates a high risk to 
develop acute myeloid leukemia that is rarely associated with recurrent 
translocations. The mechanisms that drive leukemia from bone marrow 
failure, however, are largely unknown. Mice lacking the endonuclease 
Ercc1 show severe loss of hematopoietic stem- and progenitor cells 
(HSPC) due to defective repair of interstrand crosslinks (ICLs). In 
this study we investigate whether the tumor suppressors encoded 
by the Trp53 or Cdkn2a loci are involved in the loss of HSPC from 
bone marrow and the associated leukemogenesis risk. Loss of p53, 
but not loss of the Cdkn2a locus, rescued bone marrow HSPC levels 
and colony formation, but it aggravated NER-dependent segmental 
progeria. In line with the dominant role of p53 in the hematopoietic 
phenotype, Ercc1-deficient bone marrow cells that are heterozygous 
for p53 were prone to develop leukemia.
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introduCtion
Hematopoiesis is dependent on the lifelong maintenance of 
hematopoietic stem- and progenitor cells (HSPCs), which requires tight 
genome surveillance to prevent outgrowth of mutated clones. The cellular 
response to DNA damage consists of the recruitment of damage-specifi c 
DNA repair enzymes, the care-takers, and the activation of proteins that 
prevent the replication of damaged DNA, the gate keepers [1]. Examples 
of gate keepers are the cell cycle inhibitors Chk1 and Chk2 (Checkpoint 
homolog-1 and -2), the Cdnk2a (cyclin-dependent kinase inhibitor 2A) 
locus encoding p16Ink4A and p14ARF/p19Arf, and p53 [1-2]. 
The endonuclease Ercc1 is involved in global and transcription coupled 
nucleotide excision repair (NER), and in the excision of interstrand 
crosslinks (ICL). Mice lacking Ercc1 show severe segmental progeria due 
to defective NER, and premature loss of hematopoietic stem cells due to 
defective ICL repair [3, 20], chapter 3. Growth retardation of Ercc1-/- mice is 
due to suppression of the somatotrophic growth axis, reduced Igf-I signaling, 
and subsequent reduction of energy metabolism [4-5]. Growth retardation 
is independent of the classical gatekeepers Trp53, encoding p53, and 
the Cdnk2a locus encoding p16Ink4A and p14ARF/p19Arf [4-6] Schumacher, 
unpublished). We previously observed that loss of HSPC is not due to the 
severe progeria as it occurs in Xpa-/-Csb-/- mice. Instead, loss of HSPC may 
be due to cellular senescence and may depend on activation of p53 and 
expression of p16Ink4a, events known to result in loss of tissue stem cells 
and tissue degeneration. Whether individual cells undergo cell cycle arrest, 
senescence or apoptosis depends on the activation level of the gatekeepers 
and persistence of the damage [7-9]. p53 and p16Ink4a have distinct roles in 
senescence [10]. In the hematopoietic system, however, activation of both 
gatekeepers has been associated with reduced proliferation of the stem 
cell pool, and loss of either gatekeeper is associated with leukemia. Loss 
of Atm leads to p16Ink4a-dependent loss of hematopoietic stem cells (HSCs) 
[11], and methylation and silencing of Cdkn2a is commonly found in AML 
[12].  Activation of p53 restricts self-renewal of hematopoietic stem cells 
[13-15]. Mutations in Trp53 are found in 10-15% of AML cases at diagnosis 
and are associated with aggressive disease and complex karyotypes [16-
18]. Of note, hematopoietic progenitors lacking p16Ink4a, p19Arf as well as 
p53 were reported to gain repopulation capacity [19]. However, despite 
their documented roles in the regulation of HSPCs expansion, it remains 
unclear whether either or both the cdkn2a locus and p53 are involved in 
the BM failure that arises from persistent ICLs, such as seen in Fanconi 
Anemia.
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We used Ercc1-deficient mice to study how persistent ICL cause loss 
of BM HSPCs. The reduction of HSPCs, but not the growth defect and 
liver degeneration, was reverted by loss of Trp53 in Ercc1-deficient mice. 
In contrast, loss of the Cdkn2a locus did not restore HSPC levels. Ercc1-
deficient BM cells heterozygous for Trp53 (Trp53+/-) give rise to leukemia 
when transplanted in wt recipients. These data establish that hematopoiesis 
is particularly sensitive to ICL-induced p53 activation resulting in a reduction 
of the stem cell pool. Moreover, p53 heterozygosity in ICL-sensitive HSPCs 
predisposes to leukemia. In addition, the selective sensitivity of HSPCs to 
ICL suggests that the specific hematopoietic phenotype of FA is not due to 
functions of FA proteins distinct from DNA repair.
results
Ercc1-/d HSPCs have reduced long term repopulation potential 
We recently showed that HPSCs are reduced in bone marrow of Ercc1-/d 
mice throughout their lifespan [20]. However, Ercc1-/d mice retain normal 
peripheral blood cell values. To study the long-term cell-intrinsic effects of 
Ercc1 deficiency and the associated ICL repair defect on hematopoiesis, 
Ercc1-/d FL or BM cells were transplanted into sublethally irradiated 
recipients.  Recipients of Ercc1+/- control cells survived with a sustained 
(> 1 year) and high (>80%) donor contribution. In contrast, engraftment 
of Ercc1-/d cells was partial and only 4 of 10 transplanted mice showed 
stable engraftment of Ercc1-/d hematopoietic cells 6 months after transplant 
(Figure 1). One of these mice developed donor-derived (Ercc1-/d) leukemia 
42 weeks post-transplant. Under similar conditions, none of the full Ercc1 
knockout (Ercc1-/-) BM cells showed sustained engraftment (Figure 1) 
and neither did BM cells from Tie2-Cre-driven knockout mice, in which 
the Ercc1 gene is conditionally disrupted in the HSPCs [21-23]  (Chapter 
3). These results show that a residual level of Ercc1 is essential for 
engraftment of hematopoiesis in vivo. Thus, loss of Ercc1 severely impairs 
the repopulation ability of Ercc1-deficient HSPC.
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Figure: 1 Ercc1 defi cient BM shows impaired repopulation capacity.
Fetal livers or BM was isolated from Ercc1+/- (wt), Ercc1-/- or Ercc1-/d  E12.5 embryos 
or three week old animals. The total cell suspension from 1 fetal liver or 1x107 BM 
cells were intravenously injected per recipient together with mature spleen cells for 
initial survival. Plotted are overall survival curves for the transplanted genotypes: 
Ercc1-/d (n=21), wt (n=6;) and Ercc1-/- (n=11) 
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Activation of p53, but not induction of p16Ink4A-p19Arf represses 
hematopoiesis in Ercc1-/d mice
To determine which gatekeepers are involved in the reduced stem-and 
progenitor pool of Ercc1-deficient BM we first analyzed expression of the 
Cdkna2 locus and Trp53 as well as downstream target genes in the BM of 
20-week old animals (Figure 2). From the Cdkn2a locus, the expression of 
p16ink4a was 5.0-fold and expression of p19Arf 5.5-fold increased in Ercc1-/d 
BM. Trp53 mRNA levels were unaltered, but the p53 target genes PUMA 
and NOXA were elevated 4.2-fold and 2.1-fold, respectively. 
figure 2: mrna levels of Cdkn2a, Trp53 and downstream targets in bm of 
 20-week old mice.
BM of three Ercc1-/d and three Ercc1+/d mice at 20 weeks of age were analyzed 
for expression of the transcripts indicated by qPCR. Graph shows the 2log of the 
fold-change in transcript levels of Ercc1-/d compared to Ercc1+/d. Error bars indicate 
standard deviations (see also Table 3).
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To investigate to what extent induction of p16Ink4a, p19Arf or p53 contributes 
to BM failure in Ercc1-/d mice, Ercc1-/d mice were crossed with Cdkn2a- and 
Trp53-defi cient mice [24-25]. The number of HSPC was less than half in 
BM of 10 week old Ercc1-/d mice compared to Ercc1 profi cient littermates 
both in presence and absence of the Cdkn2a locus (Figure 3A). The 
number of CMP (common myeloid progenitor) and MEP (megakaryocyte/
erythroid progenitor), 2-fold reduced in Ercc1-/d bone marrow, was not 
altered (Figure 3B-D). Colony formation by the remaining progenitors in 
Ercc1-/d BM was strongly reduced in presence of GM-CSF (Figure 3E) or 
absent in presence of G-CSF or Epo/SCF (Figure 3F,G), and remained low 
or absent upon loss of the Cdkn2a locus (Figure 3E-G). 
Deletion of the Trp53 locus reduced the survival of Ercc1-/d mice from 20 
to 3 weeks. Therefore, these mice and respective controls were analyzed 
at 19 days of age. The fraction of LSK cells in the BM of Ercc1-/dTrp53+/- was 
restored to wt levels (Figure 4A). The levels of progenitor cells in Ercc1-
/d BM as measured by fl ow cytometry did not signifi cantly change upon 
loss of Trp53 (Figure 4B-D), but deletion of Trp53 increased the number of 
GM-CSF-induced colonies 3.3-fold (Figure 4E), G-CSF-induced colonies 
12-fold (Figure 4F) and Epo/SCF responsive colonies 25-fold (Figure 4G) 
compared to Ercc1-/d littermates. Thus, absence of p53, but not p16 or 
p19 restored hematopoiesis in Ercc1-/d mice, indicating that activation of 
p53, but not of p16 or p19 inhibits proliferation of hematopoietic cells upon 
defective ICL repair.
Loss of Trp53 aggravates segmental progeria in Ercc1-/d mice
While loss of Trp53 rescued the hematopoietic phenotype of the Ercc1-/d 
mice, this was not the case for other phenotypic features of these mice. 
First, in addition to their shortened lifespan, Ercc1-/dTrp53-/- animals are 
on average 25% smaller than Ercc1-/d littermates (Figure 5A), whereas 
loss of Cdkn2a has no effect on animal weight of Ercc1-defi cient animals 
(Figure 5B). Second, Ercc1-defi ciency causes prominent liver failure and 
polyploidy of hepatocytes [26-27]. In livers of Ercc1-/dTrp53-/- mice, the 
numbers of polyploidy hepatocytes, characterized by enlarged nuclei, were 
increased relative to Ercc1-/d mice (Figure 5C,D). These results show that 
activation of p53, while responsible for reduced HSPC numbers in Ercc1-/d 
mice, restricted accelerated segmental progeria and hepatocyte damage.
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figure 3: depletion of Cdkn2a does not restore hematopoiesis in 10-week  
old Ercc1-/d mice. 
(A-D) Frequencies of hematopoietic stem- and progenitor cells in total BM as 
determined by flow cytometry . The mouse genotype for Ercc1 and Cdkn2a loci 
is indicated below the bars. The mouse LSK (lineage marker negative, Sca1+ and 
C-kit+ cells) compartment contains the hematopoietic stem cells and multiponent 
progenitors. CMP: common myeloid progenitor, GMP: granulocyte/monocyte 
progenitor, MEP: megakaryocyte/erythrocyte progenitor. (E-G) Number of colonies 
counted 7-8 days after plating 5x104 total BM cells in the presence of the growth 
factor(s) indicated. All bars show the mean of n≥3 animals. Error bars show 
standard deviations (see also Table 2). 
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figure 4: depletion of Trp53 restores hematopoiesis in Ercc1-/d mice.
Mice were analyzed at postnatal day 19. (A-D) Frequencies of hematopoietic 
stem- and progenitor cells in total BM as determined by fl ow cytometry (see also 
legend Figure 2). The mouse genotype for Ercc1 and Trp53 loci is indicated below 
the bars.The mouse LSK compartment contains the hematopoietic stem cells and 
multiponent progenitors. CMP: common myeloid progenitor, GMP: granulocyte/
monocyte progenitor, MEP: megakaryocyte/erythrocyte progenitor. (E-G) Number 
of colonies counted 7-8 days after plating 5x104 total BM cells in the presence of 
the growth factor(s) indicated. All bars show the mean of n≥3 animals. Error bars 
show standard deviations.  Data were analyzed by two-tailed student t-tests: *: 
p<0.05, **: p<0.001.
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Selective p53 dependence of cellular senescence in Ercc1-/d 
mice is cell type specific
To assay the proliferation capacity of hematopoietic progenitors, we 
expanded fetal liver-derived erythroblasts ex-vivo. In line with the in vivo 
results, loss of Trp53 rescued Ercc1-/d erythroblast cultures from growth 
arrest while loss of Cdkn2a did not change erythroblast expansion (Figure 
6A,C). However, when we cultured mouse embryo fibroblasts (MEF), 
both the deletion of the Cdkn2a locus and the Trp53 restored proliferation 
of Ercc1-/d MEFs (Figure 6B,D). This indicates that the involvement of 
gatekeeper(s) in DNA damage responses is not only dependent on the 
type of DNA damage, but also on the cellular context. 
Loss of Trp53 does not reduce MMC sensitivity and H2AX foci 
formation in Ercc1-/d mice
Because loss of p53 largely restored hematopoiesis in Ercc1-/d mice, we 
asked whether loss of p53 may also interfere with the response to ICLs 
induced by Mitomycin C (MMC). Erythroblasts were cultured in absence or 
presence of increasing concentrations MMC and the number of blasts was 
determined 48h following exposure to MMC. Erythroblasts cultured from 
Ercc1-/d fetal livers were hypersensitive to low concentrations of MMC. At 
10nM only 25% of Ercc1-/d erythroblasts survived compared to untreated 
erythroblasts, whereas 80% of wt erythroblasts survived 10nM MMC for 
48h (Figure 7A). Trp53 deletion did not alter the sensitivity to MMC.
Stalling of the replication fork activates ATR, resulting in Histone 2Ax 
(H2Ax) phosphorylation within several kb of DNA flanking the stalled 
replication fork [28]. We determined the number of phospho-H2Ax foci in 
Ercc1-/d and wt erythroblast before and after 24h treatment with 0 to 40 nM 
MMC. The majority of wt erythroblasts had no foci, and treatment of wt cells 
with 40 nM MMC increased the amount of cells with foci to 50% of total 
(Figure 7B,C). In contrast, more than 75% of Ercc1-deficient erythroblasts 
already contained foci in the absence of MMC. Treatment with 40 nM MMC 
induced more than 5 foci in more than 60% of Ercc1-/d erythroblasts. Loss 
of p53 slightly reduced the number of cells with phosphorylated H2Ax, but 
did not abrogate the hypersensitivity of Ercc1-/d cells to MMC. These results 
demonstrate that Ercc1-/dTrp53-/- erythroid cells remained hypersensitive to 
MMC and still elicited the DNA damage response.
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figure 5: deletion of Trp53 does not restore growth defect and liver pathology  
of Ercc1-/d mice.
Mice were analyzed at postnatal day 19 or week 10. (A) Body weight for 19 day old 
animals with the indicated genotypes. Error bars show the mean of n≥3 animals. 
Two-tailed student t-tests was done: *: p<0.05 (B) Body weight of 10 week old 
mice of the indicated genotypes. Error bars show standard deviations of n≥3 (C) 
Light microscopy images of paraffi n-embedded livers stained with hematoxylin and 
eosin.  The enlarged nuclei (arrows) indicate polyploidy, which is most severe in 
the Ercc1-/dTrp53-/- mice. Top panel: pictures taken with 10x objective; lower panel: 
pictures taken with 100x objective.  
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figure 6: selective Trp53 dependence of cellular senescence in ercc1-/d mice  
is cell type specific.
(A) Growth curves of erythroblast cultures. Black lines are Ercc1-proficient cultures, 
grey lines show Ercc1-/d cultures. Dashed lines show cultures (co-)depleted for 
Trp53. (B) Mouse embryonic fibroblasts (MEFs) and were grown from E12.5 
embryos and were seeded in DMEM supplemented with 100 units/ml penicillin, 
100 μg/ml streptomycin and 10% (v/v) FCS. Cell numbers and size distributions 
were determined daily, using an electronic cell counter (CASY-1, Scharfe-System, 
Reutlingen, Germany). Each line shows a separate experiment. Black lines show 
results from Ercc1-proficient MEFs, grey lines are Ercc1-/d MEFs. Dashed lines 
show cultures (co-)depleted for Trp53. (C) Growth curves of erythroblast cultures. 
Black lines are Ercc1-proficient cultures, grey lines show Ercc1-/d cultures. Dashed 
lines show cultures (co-)depleted for Cdkn2a. (D) Mouse embryonic fibroblasts 
(MEFs) and were grown from E12.5 embryos and were seeded in DMEM 
supplemented with 100 units/ml penicillin, 100 μg/ml streptomycin and 10% (v/v) 
FCS. Cell numbers and size distributions were determined daily, using an electronic 
cell counter (CASY-1, Scharfe-System, Reutlingen, Germany). Each line shows a 
separate experiment. Black lines show results from Ercc1-proficient MEFs, grey 
lines are Ercc1-/d MEFs. Dashed lines show cultures (co-)depleted for Cdkn2a.
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figure 7: effect of Trp53 depletion on the dna damage response in Ercc1-/d 
erythroblasts 
(A) Number of erythroblasts (>8 µm) in cultures exposed for 48h to an increasing 
concentration of the DNA crosslinker Mitomycin C (MMC) compared to number of 
blasts at the start of the culture.  Black lines: Ercc1-profi cient cultures, grey lines: 
Ercc1-/d cultures. Dashed lines show cultures (co-)depleted for Trp53 (B) Confocal 
pictures of cells exposed to 2.5 nM MMC for 16 h before they were fi xed and 
stained with a phospho-specifi c H2AX antibody  (C) Relative number of cells with 
a certain amount of H2AX-foci at an increasing concentration of MMC. Foci were 
counted in at least 300 cells and cells were divided in classes with a certain amount 
of foci per cell as indicated.
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Ercc1-/dTrp53+/- HSPCs become leukemogenic in vivo
The activation of p53 inhibits expansion of hematopoietic stem- and 
progenitor cells and may concurrently prevent leukemic transformation of 
Ercc1-/d cells. To investigate the leukemic potential of Ercc1-deficient HSC 
and early progenitors we transplanted BM cells into lethally irradiated wt 
recipients. The presence of the Ercc1 knockout or delta allele in peripheral 
blood was analyzed by genomic real time PCR. We transplanted BM 
of Ercc1-/dTrp53+/- mice into lethally irradiated wt recipients (n=22) in 4 
independent experiments. As controls we injected BM from Ercc1+/-Trp53+/- 
or Ercc1+/dTrp53+/- mice (n=21). Two mice that received Ercc1+/dTrp53+/- BM 
were taken out of the cohort because blood analysis failed to detect donor 
material. All other animals retained between 40-90% of donor cells in 
peripheral blood.
Mice showing signs of discomfort suggestive of hematopoietic disease 
(passive behavior, difficult thread, heavy breathing), were sacrificed and 
hematopoietic organs analyzed. From the 20 mice successfully transplanted 
with Ercc1-/dTrp53+/- BM cells, 2 survived 50 weeks post transplantation, 
whereas all control animals survived more than a year (Figure 8A). 
Ercc1-/dTrp53+/- -engrafted animals that were found dead (6/20) could not 
be diagnosed and appear as censored cases in the Kaplan Meier analysis 
(+ symbols in Figure 8A). Mice transplanted with Ercc1+/-Trp53+/- grafts that 
were sacrificed and analyzed as controls together with sick animals from 
the Ercc1-/dTrp53+/- cohort are also censored in this analysis. Diseased 
mice that were transplanted with Ercc1-/dTrp53+/-BM (12/20) suffered from 
an enlarged spleen (8/12) (Figure 8B and Table I) and/or thymus (6/12) 
(Table I). These symptoms, together with FACS analysis (Table I) and 
the accompanying anemia’s were indicative of leukemia. The average 
latency of leukemia development was 29 weeks post-transplant. In all 
leukemia’s analyzed, we confirmed donor origin in BM and blood samples 
by conventional or RT-PCR for the Ercc1- and Ercc1d allele. Finally, 7 
leukemic samples were screened for expression of p53. Trp53 expression 
was  lost in 3 of 7 samples leukemia samples (Table I). 
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figure 8: transplantation of Ercc1-/dTrp53+/- BM cells yields leukemia.
(A) Kaplan-Meier survival curve for leukemia-free survival. Ercc1-/dTrp53+/-: n=20; 
Ercc1+/dTrp53+/- n= 22. Cases that are censored in this analysis because they were 
sacrifi ced for analysis (Ercc1+/dTrp53+/-) or because they died of unknown cause 
(Ercc1-/dTrp53+/-) are marked by “+”. (B) Spleen from an Ercc1-/dTrp53+/- transplanted 
animal that got ill, and one from an Ercc1+/dTrp53+/- recipient in the same experiment. 
(C) Blood smears from Ercc1-/dTrp53+/- recipients that were ill. Cells were fi xed and 
stained with May-Grunwald Giemsa. First panel was photographed with a 10x 
objective, 2nd and 3rd panel are photographed with a 100x objective. 
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disCussion
The endonuclease Ercc1 is involved in the excision of lesions during global 
and transcription-coupled repair, and in the excision of ICL at the replication fork. 
Maintenance and repopulation ability of hematopoietic stem cells is particularly 
sensitive to ICL and impaired in Ercc1-deficient mice. This sensitivity results 
from activation of p53 and not from induced expression of p16 or p19 from 
the Cdkn2a locus. While loss of Trp53 largely restored in vivo and in vitro 
hematopoiesis in Ercc1-/d mice, it aggravated segmental progeria caused 
by defective NER, which indicates that the function of gatekeepers depends 
on the type of DNA damage. In addition, gatekeepers act cell type specific, 
because loss of the Cdkn2a locus fails to rescue Ercc1-/d hematopoietic 
progenitors. Finally, we demonstrated that loss of one Trp53 allele results in an 
increased leukemogenic potential of Ercc1-/d BM cells upon transplantation in 
wt recipients.
Trp53 has a dominant role in the response of hematopoietic 
cells to ICLs 
Deletion of Trp53 restored the stem- and progenitor cell compartment, colony 
forming capacity of progenitors and in vitro expansion of erythroblasts. Deletion 
of the Cdkn2a locus, on the other hand, did not modify the Ercc1-/d hematopoietic 
phenotype. Interestingly, this also implies that p19Arf is dispensable for p53 
activity in the BM of Ercc1-/d mice. The pronounced role of p53 seems to be 
cell-type and DNA-damage specific. Within the hematopoietic compartment, 
loss of p16Ink4a expression restored the repopulation ability of ATM-deficient BM 
[11] but not in Ercc1-/d mice. Cell type specificity is indicated by the observation 
that loss of Cdkn2a restored the in vitro expansion of Ercc1-/- MEFs, but not of 
Ercc1-/- erythroblasts. Cell type and DNA damage specificity was most obvious 
from the observation that the small, runted phenotype of Ercc1-/d mice, and 
aberrant liver morphology, was even aggravated by the loss of Trp53. The 
Ercc1-/dTrp53-/- animals were smaller and died at 3 weeks of age, compared to 
Ercc1-/d animals that live up to 25 weeks. Most likely, a p53-mediated cell cycle 
delay in the Ercc1-/d mice allows for alternative DNA repair, which decreases 
the load of DNA damage and the suppression of the somatotrophic growth 
axes. Because suppression of the growth axes was shown to be Trp53 and 
Cdkn2a independent ([4, 6]; Schumacher, unpublished), the DNA-damage 
induced growth retardation of Ercc1-/d mice was enhanced in the absence of 
Trp53. Thus, the same DNA repair deficiency initiates distinct responses in the 
different cells and tissues of the body. In addition, distinct types of damage 
activate alternative tumor suppressor mechanisms. This may explain why 
DNA repair deficiencies can result in specific disease syndromes including 
segmental progeroid syndromes that affect some but not all tissues.
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table 1: features of leukemias from Ercc1-/dTrp53+/- bone marrow.
no Exp time
(weeks)
wbC
(x109/L)
rbC
(x1012//L)
spleen
enlarged
thymus
enlarged
p53
mrna
immunophenotype
1
1
38.0 1.3 0.51 +
l i n - S c a 1 + / l i n -
CD127+, CD19+ 
blasts
2 21.4 1.6 1.03 + CD19+ blasts
3* 31.9 9.3 3.31 + + - CD19+ blasts
4 21.4 31.7 3.67 + CD19+ blasts
5
2
37.0 + +
LSKs (1%), 
CD3+CD19+ in 
blood
6 23.0 86.9 1.52 + + Cd3+DP
7
3
24.0 n.d. n.d. + +
T-cell leukemia 
CD8+ (no CD4+, but 
DP)
8
4
27.7 15.3 9.79 + + - BM: no LSK or LK, 
68% T-cell, 50% DP
9 24.7 7.4 9.23 + -
10 30.9 low low +
l i n - c k i t + C D 1 9 + , 
CD19+ cells in all 
organs
11 44.0 2.8 3.76 + +
50% BM is lin-
Ckit+CD71+, many 
LSKs (2.7%)
WBC: peripheral white blood cell count (normal range: 3-15x109/L), RBC: peripheral 
red blood cell count (normal range: 5-12x1012/L), BM: bone marrow, DP: double 
positive T-cells, +: present, -: absent, n.d.: not determined
* This animal also had a neck neoplasm
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Ercc1-/dTrp53+/- BM is prone to leukemia development
To investigate leukemogenesis in an Ercc1-/d background, we transplanted 
Ercc1-/d and Ercc1-/d Trp53+/- BM into wt hosts. Only BM cells deficient in 
Ercc1 and heterozygous for p53 transformed to leukemia. The leukemia’s 
that arose from Ercc1-/dTrp53+/- BM were heterogeneous with respect to their 
phenotype. They were characterized by an enlarged spleen (8/12) and/or 
thymus (6/12) and “lymphoid” markers as CD3e and CD19 were detected 
in many cases. Blood parameters, however, differed substantially as did the 
type of cellular abnormalities that were found by FACS analysis. Loss of 1 
allele of Trp53 most likely increases the chance that a cell completely loses 
Trp53 expression by mutation. Notably, in 3 out of 7 leukemia’s the expression 
of Trp53 was completely lost. Although loss of Trp53 facilitates leukemia 
development, it is in itself not sufficient. We observed that complete loss of 
Trp53 did not alter (i) the direct response to ICLs at the replication fork (e.g. 
H2Ax phosphorylation), or (ii) growth factor dependence and differentiation 
capacity of Ercc1-/dTrp53-/- immortalized erythroblast cultures (data not 
shown). Thus, loss of Trp53 facilitates mutagenesis in an Ercc1-deficient 
background by abrogating the senescence response, but does not directly 
contribute to factor-independent proliferation or block of differentiation. The 
future challenge will be to detect the molecular and cellular processes that 
directly cause the leukemic phenotype in this setting.
The presented data may have implications for understanding the 
pathogenesis of therapy related myelodysplastic syndrome (tMDS) 
and AML (tAML) that may occur secondary to cancer treatment with 
alkylating agents and topoisomerase inhibitors. Alkylating agents induce 
DNA crosslinks, and topoisomerase II inhibitors enhance sensitivity 
to crosslinkers [29]. Whereas the frequency of mutations in TP53 is 
approximately 10% in de novo MDS and AML, it is 25-30% in tMDS/
tAML [30]. p53 activates a plethora of genes involved in stress responses 
and it remains to be established which of these downstream targets are 
critical for controlling responses of HSPCs to sustained ICL damage, 
e.g. in Fanconi Anemia. Notably, mutations in p53 rarely occur in AML 
secondary to Fanconi Anemia. The Ercc1-deficient mouse strains appear 
useful models for identification of these genes and connected regulatory 
pathways. Next generation sequencing of the genomes of HSPCs in these 
models at progressive stages of BM failure and transit to (pre-)leukemic 
stages is expected to provide further insights in these issues.    
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experimental proCedures
Animals
Ercc1+/d, Ercc1+/- [31], Cdkn2a+/- [24] Trp53+/- [25], and wt littermates 
were kept in a background of C57/Bl6 and FVB/n at the Animal Resource 
Center (ErasmusMC). Experimental animals were generated as F1 in a 
mixed background of C57/Bl6 and FVB/n, except for the Csb and Xpa 
mice that are C57/bl6 only. Ercc1+/- and Ercc1+/d mice displayed a wild type 
phenotype and were used as controls. All animal studies were approved by 
an independent Animal Ethical Committee.
Mouse blood was obtained by tail vein puncture, or by heart puncture 
after mice were sacrifi ced by CO2 inhalation, and analyzed on an Animal 
Blood Counter (ABX diagnostics). BM cell suspensions were obtained by 
crushing femurs, tibia and sternum in HBSS supplemented with 5% (v/v) 
fetal calf serum, 100 units/ml penicillin, 100 μg/ml streptomycin. BM, spleen 
and thymus were passed through a 70 µM fi lter (BD Falcon, Bedford, MA) 
to obtain single-cell suspensions.
Cell culture
Erythroblasts were cultured in StemPro34 (Invitrogen, Breda, the 
Netherlands) supplemented with 1U/ml erythropoietin (Epo, Ortho-Biotech, 
Tilburg, The Netherlands), 100 ng/ml stem cell factor (SCF, supernatant of 
CHO producer cells) and dexamethasone (106 M; Sigma) at a density of 
1x106/ml. Cell numbers and size distributions were determined using an 
electronic cell counter (CASY-1, Scharfe-System, Reutlingen, Germany). 
Mitomycin C (MMC; Kyowa Hakko Kogyo, Tokyo, Japan) was dissolved in 
50% DMSO/H2O and added at concentrations indicated in the text.
Colony forming assays
BM cell suspensions were plated at a density of 50.000 cells per ml per 
dish in triplicate in methyl cellulose medium (Methocult M3234, StemCell 
Technologies SARL, Grenoble, France) containing huGCSF (0.1 µg/ml), 
muGM-CSF (0.1 µg/ml), or Epo (4 mU/ml) plus transferrin (0.3 mM), hemin 
(0.2 mM) and muSCF (0.1 µg/ml). Colonies containing 30 cells or more 
were scored after 7-8 days of culture. 
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Flow cytometry 
Blood and single cell suspensions from BM, spleen and thymus were 
analyzed by flow cytometry using a BD™ LSR II Flow Cytometer System 
with FCS Express Diva software (BD Biosciences., San Jose, California), 
and analyzed by FlowJo (Tree Star, Inc., Ashland, Oregon). Antibodies are 
listed in Table 2. 7-AAD (Invitrogen, Breda, the Netherlands) selected life 
cells. 
Selected subpopulation consisted of: LSK (lineage marker negative, 
Sca1+, ckit+), long-term hematopoietic stem cells (LT-HSC): LSK,CD34-
Flt3-, short-term (ST) HSC: LSK, CD34+Flt3-, multipotent progenitors (MPP): 
LSK,CD34+Flt3+ common myeloid progenitor (CMP): lin-ckit+CD34+CD16/
CD32low, granulocyte-monocyte progenitor (GMP): lin-ckit+CD34+CD16/
CD32high and megakaryocyte-erythroid progenitor (MEP): lin-ckit+ CD34-
CD16/CD32low. See Figure 9 for gating strategy. Percentages can be 
compared because in all experiments the ratio (mononuclear cells)/(animal 
weight) was constant over all genotypes at a given age (Figure 10). Data 
from 1x106 BM cells were recorded to ensure reliable analysis of small 
populations.  
 
Figure 9: Gating strategy for the LSK fraction and its subdivision and the committed 
progenitors. Example for mice ten weeks of age.
 
FSC 7’AAD
SSCSSC
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Figure 10: The total number of BM mononuclear cells (MNC) obtained from two 
tibiae and the sternum divided by the body weight of the animals. Shown is the mean 
+/- standard deviation from n=3. When no error bar is given, the average of n=2 is 
shown. The ages of the mice , 10 weeks (A) and 21 days (B). Genotyping PCR and 
Q-PCR Genomic DNA was isolated from tail segments, or from blood (NucleoSpin 
Tissue XS, MACHEREY-NAGEL GmbH & Co). Genotypes were determined by 
PCR. Genomic Q-PCR used an Applied Biosystems 7900 instrument (Applied 
Biosystems, Weiterstadt, Germany) and SYBR Green PCR Master Mix (Applied 
Biosystems). Primers are listed in Table 3.
Histology
Liver and spleen were embedded in Tissue-Tek O.C.T (Sakura Finetek, 
Zoeterwoude, Netherlands). 4 µm sections were made using a cryostat 
(Leica) and stained with hematoxylin and eosin. Slides were imaged on a 
Leica DMLB microscope equipped with Leica Application Suite 2.7.1. 
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Immunofluorescence
Cytospins from cultured erythroblast were fixed in 2% (v/v) 
paraformaldehyde in PBS for 15 min at room temperature. After washing 
in PBST [0.1% (v/v) Triton X-100 in PBS] slides were blocked for 10 min 
in PBS+ (20mM Glycine and 75 mM BSA in PBS). Primary antibody was 
incubated overnight in PBS+ at 4°C in a humidified chamber, and washed 
in PBST and PBS+. Slides were incubated with secondary antibody 
for 1 hour at room temperature in a dark humidified chamber. Slides 
are mounted in VECTASHIELD HardSet mounting medium with DAPI 
(Brunschwig Chemie, Amsterdam, Netherlands) before visualization on an 
immunofluorescent microscope (Leica). For detection of phosphorylated 
g-H2AX we used a rabbit polyclonal antibody (phospho S139) from Abcam 
and goat anti-rabbit IgG conjugated to Alexa Fluor 488 (Invitrogen).
table 2: antibodies used in Flow cytometry.
faCs antibody clone supplier
mouse biotinylated lineage 
depletion kit
145-2C11(CD3e), M1/70 (CD11b), 
RA3-6B2  
(CD45R/b220), RB6-8C5 (Gr-1), 
Ter119 (Ter119)
BD pharmingen
Sca1-PE-cy7 (Ly-6A/E) D7 ebioscience
CD34-pacific blue RAM34 ebioscience
CD16/CD32-PE (FcgIII/II) 2.4G2 BD pharmingen
CD117-APC (Ckit) 2B8 BD pharmingen
CD127-pacific blue A7R34 ebioscience
CD135-PE (Flt3) A2F10.1 BD pharmingen
CD150-PE-cy5 (SLAM) TC15-12F12.2 biolegend
streptavidin-APC-cy7  BD pharmingen
7’AAD  Invitrogen
All antibodies are anti-mouse
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Transplantation assays
12-14 week old mice (F1 Fvb/n x C57/bl6) were irradiated with 9.2 
Gy in a Gammacell-40 with two Cesium-137 sources. Two to four hours 
after irradiation mice were transplanted by tail vein injection with either a 
complete FL or 1x107 total BM cells and 1x105 WT spleen cells in 200 µl 
PBS containing 1% FCS. Animals were given ciprofl oxacin in their drinking 
water post-transplantation. Kaplan-Meier survival curves were made in 
SPSS. 
table 3: qPCr primers.
gene forward primer reverse primer
p16* CGT ACC CCG ATT CAG GTG AT TTG AGC AGA AGA GCT GCT ACG T
p19 CGT GAA CAT GTT GTT GAG GC CGA ATC TGC ACC GTA GTT GA
p53 CCA TCC TGG CTG TAG GTA GC AAT GTC TCC TGG CTC AGA GG
PUMA CCA GAA ATG GAG CCC AAC TA AAG GCT GGC AGT CCA GTA TG
NOXA CCC ACT CCT GGG AAA GTA CA AAT CCC TTC AGC CCT TGA TT
HPRT AGC CTA AGA TGA GCG CAA GT ATG GCC ACA GGA CTA GAA CA
* Taken from [32]
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Abstract
Background
Fanconi anemia (FA) patients have a pronounced anemia and 
frequently develop bone marrow hypoplasia with a high risk of 
leukemic progression. The FA genes act in a pathway involved in 
DNA damage repair. Defects in the FA pathway result in hypersen-
sitivity to interstrand DNA crosslinkers and oxidative stress leading 
to chromosomal instability and stress-induced senescence. 
Design and methods 
To investigate the cause of decreased erythropoiesis and 
insensitivity to Epo that develops in FA, we characterized factor-
dependent expansion and Epo-induced signaling in Fanca-/- and 
Fancg-/- erythroblasts.
Results 
We show that erythroblast expansion capacity and Epo-induced 
phosphorylation of Stat5 and Erk1/2 are impaired in Fanca-/- and 
Fancg-/- erythroblasts only when cultivated at atmospheric oxygen 
levels. SCF-induced signal transduction and Epo-induced phospho-
rylation of the Epo-receptor and Jak2 are not affected, suggesting 
that the signaling defect occurs distal of the Epo-receptor/Jak2 
complex. Inefficient Epo signal transduction was also observed 
in wild type erythroblasts challenged with a sub lethal dose of the 
DNA crosslinker mitomycin C (MMC) in a p53 dependent manner 
and in nucleotide excision repair enzyme Ercc1-/- erythroblasts, 
functioning in the same ICL repair pathway as FA. In contrast, 
loss of nucleotide excision repair did not impair Epo-induced Stat5 
phosphorylation. 
 
   Conclusion 
Together the data suggest that deficient Epo-induced signal trans-
duction in FA is secondary to p53 activation at the stalled replication 
fork, rather than a specific function controlled by Fanconi proteins. 
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baCkground
Fanconi anemia (FA) is a genomic instability syndrome, characterized 
by developmental abnormalities, bone marrow failure, and cancer 
predisposition in particular acute myeloid leukemia (AML) and squamous 
cell carcinoma (SCC). Cells derived from FA patients show spontaneous 
chromosome breakage and are hypersensitive to oxidative stress and DNA 
crosslinking agents such as cisplatin and mitomycin C (MMC) [1-4]. FA is 
caused by bi-allelic inactivation of one of the fi fteen genes that encode 
the so-called FA-pathway [5]. During S-phase interstrand crosslinks 
(ICL) stall the replication fork, activating ATR (Ataxia Telangiectasia and 
Rad3 related). ATR, in turn, activates numerous downstream pathways, 
including phosphorylation of H2AX, phosphorylation and stabilization of 
p53, phosphorylation and activation of Chk2 and p38. Activation of ATR 
also triggers the FA-pathway resulting in the effi cient monoubiquitination 
of FANCD2 and FANCI by the ubiquitin ligase FANCL [6-10]. 
Monoubiquitination of FANCD2 and FANCI relocalizes these proteins to 
DNA-repair foci where they interact with the downstream Fanconi pathway 
components (FANCD1, FANCN, RAD51c (FANCO), FANCP, and FANCJ) 
and additional DNA repair proteins (e.g. BRCA1, FAN1, ERCC1, for review 
see [11]). 
The FA pathway is embedded in a network that includes several proteins 
that are associated with instability syndromes or progeroid syndromes (e.g. 
Bloom syndrome, Nijmegen breakage syndrome and Ataxia Telangiectasia 
[5, 12-13]). Many of the proteins within these complexes have previously 
been identifi ed in a BRCA1-associated genome surveillance complex 
(BASC). This complex stabilizes the replication fork at the site of DNA 
aberrations and allows for recruitment of the repair machinery [14-15]. The 
nucleotide excision repair enzyme ERCC1 is required for excision of the 
ICLs. Notably, mice lacking Ercc1 develop hypoplasia of the bone marrow 
compartment, similar to FA patients and Fancp/Slx4-defi cient mice [16-17].
Mice lacking the FA core complex proteins Fanca, Fancc or Fancg 
display the characteristic sensitivity to DNA crosslinking agents (21-23). 
Fancc-/-Fancg-/- double knockout mice and Fancp-/- mice develop bone 
marrow failure and AML [17-18]. Other Fanconi mouse models develop 
bone marrow failure when challenged: (i) Fancc-/- mice develop bone 
marrow hypoplasia when challenged with DNA crosslinking drugs [19], (ii) 
transplantation experiments showed that Fancc-/- murine stem cells have 
a compromized repopulation capacity and an increased risk for leukemic 
transformation after 4 days of culture at atmospheric oxygen [20-21]. 
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Besides their role in maintaining genomic stability, defects in the 
FA pathway also affect the signal transduction of specific receptors via 
unknown mechanisms. For instance, IL3- and IL6-induced growth and 
differentiation is reduced in CD34+ cells derived from Fancc-/- bone marrow 
compared to wt littermates [22-23]. In addition, hematopoietic cells derived 
from FA patients or Fancc-/- mice are hypersensitive to TNFa and IFNg [24-
26], while IFNg-induced Stat1 tyrosine phosphorylation is severely reduced 
in the same model [27].  
Erythropoiesis is critically dependent on the Epo-receptor and Epo-
induced signal transduction. In synergy with stem cell factor (SCF), and 
glucocorticoids, Epo regulates proliferation of early erythroblasts [28-31]. 
Phosphorylation and nuclear location of Stat5 is an important pathway 
mediating Epo-dependent cell survival [32]. Indeed, Stat5 activation 
enables erythropoiesis in the absence of EpoR and Jak2 [33-34]. Notably, 
FA patients presenting with anemia have high Epo serum levels that fail 
to rescue anemia, suggesting a defect in Epo signal transduction [35-36].
To investigate the cause of decreased erythropoiesis and insensitivity to 
Epo that develops in FA, we characterized factor-dependent expansion and 
Epo-induced signaling in Fanca-/- and Fancg-/- erythroblasts. Erythroblasts 
derived from Fanca-/- and Fancg-/- fetal livers show a progressive loss of 
expansion capacity after 10 days in culture at atmospheric oxygen. We 
found Epo-induced Stat5 and Erk1/2 phosphorylation to be severely 
reduced in an oxygen dependent manner in Fanca-/-, Fancg-/- and Ercc1-/- 
erythroblasts. In addition, the crosslinking agent MMC caused decreased 
Epo-induced Stat5 and Erk1/2 phosphorylation in p53wt but not in p53-/- 
cells. Loss of the Cdkn2a locus did not improve Epo signaling in presence 
of MMC. Together the data suggest that impaired Epo signaling in Fanconi 
anemia is part of a general cellular response to DNA damage dependent 
on p53. This also suggests that similar defects may occur in related DNA 
repair syndromes and upon aging.
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design and methods
Antibodies and growth factors
Rabbit polyclonal anti-Jak2 and mouse monoclonal anti-phospho-Stat5 
(Tyr694-Stat5A; Tyr 699-Stat5B; P-Stat5) were obtained from Upstate 
Biotechnology (Massachusetts, USA). Rabbit polyclonal anti-Epo-
receptor, c-Kit, p44/p42 MAP kinase and anti-PY99 mouse monoclonal 
antibody from Santa Cruz Biotechnology (Heidelberg, Germany); mouse 
monoclonal anti-phospho-p44/p42 MAP kinase (Thr202/Tyr204; P-Erk) 
from New England Biolabs (Frankfurt am main, Germany). Recombinant 
human Epo was a gift from Ortho-Biotech (Tilburg, The Netherlands), 
dexamethasone (dex) was purchased from Sigma (Zwijndrecht, The 
Netherlands) and human SCF was produced by CHO cells (supernatant).
Cell culture
Fanca-/- and Fancg-/- mice were previously described [37-38]. Primary 
fetal liver erythroblasts were obtained from day E12-13 fetal livers and 
cultured to a homogenous erythroblast pool in serum free conditions using 
StemPro-34 medium (Invitrogen, Breda, The Netherlands) supplemented 
with Epo (0.5U/ml), SCF (100ng/ml) and Dexamethasone (1mM, Sigma) 
as described previously [29]. Cell cultures were maintained at 1.5-3x106 
cells/ml and a homogenous erythroblast culture was obtained within 4 
days. All starvation/stimulation experiments were performed with cultures 
expanded for 6 days. In some experiments Mitomycin C (MMC; Kyowa 
Hakko Kogyo, Tokyo, Japan) was added to the cultures (concentrations 
indicated in the fi gure legends). 
Immune-precipitations, Western blotting and electrophoretic 
mobility shift assays (EMSA)
Primary erythroid fetal liver cell cultures or bone marrow preparations 
were growth factor deprived for 4h in plain IMDM (Invitrogen). Erythroblasts 
(40-80x106/ml) were stimulated at 37°C with SCF (1mg/ml; 5’), or Epo (5U/
ml; 10’) as indicated in the fi gures. Cell lysis, immune-precipitations, SDS-
polyacrylamide gel electrophoresis, Western blots, preparation of nuclear 
extracts and Stat5 mobility shift assay were all performed as described 
previously [39-40]. 
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Flow cytometry
To measure Epo-receptor (EpoR) membrane expression, Epo was 
biotinylated following the biotin labeling kit protocol from Sigma (#1418165). 
Erythroblasts (1.0x106 per sample) were growth factor deprived for 4h in 
IMDM, washed, incubated with 0.5 U/ml BioEpo and stained as described 
[41]. To control for specific binding, a 10-fold excess of non-biotinylated 
Epo was added in parallel incubations.
To distinguish between live and dead cells, the cell cycle profile was 
determined. 0.5 to 1.0x106 cells were fixed and permeabilized with ice-
cold methanol (0.5 ml; 30’) washed 2 times with Phosphate buffered saline 
(PBS) and incubated for 30’ with 0.5% w/v RNAse A (Sigma) in PBS under 
constant shaking. DNA was stained with propidium iodide (2 µg/ml in PBS, 
Sigma) and fluorescence was measured by flow cytometry.
Real time PCR 
cDNA synthesis and quantitative RT-PCR were performed using 
Taqman technology and Sybr-green detection of dsDNA as de-
scribed [42]. The primer-sequences used for the amplification are 
given in Table 1. The CT-values of RI were used to normalize the 
values. 
table 1: primer sequences used in RT-PCR (5’ → 3’)
gene direction sequence
 p21  forward  ACCAGAGGGAGCCTGAAGACT 
 reverse ACCAGAGGGAGCCTGAAGACT 
Socs3 forward TCAAGACCTTCAGCTCCA A 
 reverse TCTTGACGCTCAACGTGAAG
Spi2.1 forward ACTGCCTTGGCCCTCCTGTC
 reverse TGCCTGTGCTGATCTGTACC
BclXl forward TGGTCGACTTTCTCTCCTAC
 reverse TCACTACCTGCTCAAAGCTC
Tubulin forward TGCAGCGTGCTGTGTGCATG
 reverse TCCTCTCGAGCCTCAGAGAA 
Gilz forward TGCGGAGTACCTCACAGAG 
 reverse TCCTTGTCAGCGAAAGTACCA
RI forward TCCAGTGTGAGCAGCTGA G
 reverse TGCAGGCACTGAAGCACCA
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results
Fanca-/- and Fancg-/- erythroblasts have a reduced expansion
capacity
To examine expansion and survival of Fanca-/- or Fancg-/- erythroblasts 
under stress conditions, we studied in vitro expansion of erythroblasts 
using a model for stress-erythropoiesis [30-31, 43]. Fetal liver-derived 
erythroblasts from wt and knockout mice proliferated with comparable 
kinetics during the fi rst 9 days of culture. However the proliferation capacity 
of Fanca-/- and Fancg-/- progenitors was severely reduced compared to wt 
from day 10 onward (Figure 1A, B). No increase in cell death was detected 
when the proliferative capacity of Fanca-/- or Fancg-/- cells declined 
(Figure 1C). Instead, the number of large blast-cells, able to undergo 
renewal divisions, decreased sharply around day 10 while the number 
of smaller cells was retained (Figure 1D and morphological analysis not 
shown). This indicates that Fanca-/- and Fancg-/- erythroblasts succumbed 
to differentiation 8 days earlier compared to wt littermates.
Treatment of Fancc-/- mice with the DNA crosslinker MMC, showed that 
the bone marrow compartment is particularly sensitive [19]. To test if this 
sensitivity is refl ected in in vitro expanded erythroblasts, we analyzed cell 
growth in presence of increasing concentrations of MMC. Expansion of wt 
cells was inhibited at 50nM MMC but Fancg-/- progenitors were affected 
at 2nM MMC (Figure 1E). Similar results were obtained for Fanca-/- cells 
(data not shown). The decrease in viable cells refl ected the sensitivity for 
MMC (Figure 1F). Thus, Fanca-/- and Fancg-/- erythroblasts have a reduced 
expansion capacity and are extremely sensitive to genotoxic stress.
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Figure 1: The expansion capacity of Fanca-/- and Fancg-/- erythroblasts is 
reduced compared to wt progenit ors. 
(a, b) Erythroblasts derived from wt (black symbols), heterozygous (grey symbols), 
Fanca-/- (a; open symbols) or Fancg-/- (b; open symbols) fetal livers were cultured 
in serum free expansion medium containing Epo, SCF and dex (symbols represent 
different littermates). Presented data are derived from 1 litter each and are 
representative for other litters analyzed. C) Aliquots of the experiment described 
in B were taken on day 9, 11 and 12 of culture. Cells were fi xed and stained with 
Propidium Iodine to determine the percentage of subG1 fragmented DNA fraction 
by fl ow cytometry, which is indicative for dead cells. d) Relative cell numbers sorted 
for cell size (Casy cell counter) in a typical culture of Fanca-/- erythroblasts (see 
A). Only blastoid cells (>9 µm) are able to undergo expansion divisions. Mature 
erythrocytes generated in culture are at average 4.5 µm in size. e) Erythroblasts 
from wild type and Fancg-/-  fetal livers were expanded in presence of different 
concentrations of MMC as indicated. Total blasts are plotted against time in days. 
f) 2 days following addition of MMC, cells were stained with PI and the percentage 
of living cells was determined by fl ow cytometry. Asterisks indicate statistical 
signifi cance (p<0.05; student T-Test) between wt and Fanca-/- cells at a given MMC 
concentration. 
Epo-induced signal transduction is impaired
We next investigated whether the reduced expansion ability could be 
caused by impaired Epo and/or SCF signaling. We examined signaling in 
cells cultured for 6 days to ensure that we compare erythroblasts before 
the onset of Fanca or Fancg defi ciency-induced differentiation and growth 
defects. Epo-induced phosphorylation of Stat5 and Erk1/2 was severely 
reduced and delayed in the Fancg-/- and Fanca-/- cells (Figure 2 A-C). Not 
only the phosphorylation, also expression of Stat5 is slightly reduced in 
Fanca-/- and Fancg-/- progenitors when related to the Erk1/2 loading control. 
However, Epo-induced phosphorylation is reduced in Fanca-/- and Fancg-/- 
cells also when the lower Stat5 expression is taken into account.
To examine if these signaling defects arise at more physiological 
concentrations of Epo (0.03 to 0.1 U/ml) we exposed erythroblast cultures to 
Epo concentrations ranging from 0 to 30 U/ml. At all Epo concentrations, the 
phosphorylation of Stat5 and Erk1/2 was decreased in Fanca-/- and Fancg-/- 
erythroblasts compared to progenitors derived from wt littermates (Figure 2D).
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Figure 2: Epo-induced phosphorylation of Stat5 and Erk1/2 is reduced in 
Fanca-/- and Fancg-/- erythroblasts. 
(a-C). Wild type (wt or +/+), Fancg-/- (-/-) (A, B) or Fanca-/- (-/-) (C) fetal liver-derived 
erythroblasts were factor deprived for 4h and stimulated with Epo (5U/ml) for the 
indicated time points. Cells were lysed and whole cell lysates were analyzed by 
Western blotting using the indicated antibodies.  d) Wt (+/+), Fanca -/- (-/-) and 
Fancg-/- (-/-) fetal liver erythroblasts expanded for 6 days were factor deprived 
for 4h and stimulated with various concentrations of Epo (0-30U/ml) for 10’. Cells 
were lysed and whole cell lysates were analyzed by Western blotting. (a-d) Blots 
were stained with anti-phospho-tyrosine-Stat5a/b (p-Stat) or anti-phospho-Erk1/2 
(p-Erk). As a loading control the same blots were re-stained with anti-total-Stat5a/b 
(Stat5) or anti-total-Erk1/2 (Erk) as indicated. e) Wt (white bars) and Fancg-/- 
(black bars) erythroblasts expanded for 6 days were factor deprived for 4h and 
stimulated with Epo. At the indicated time points (0, 1, 3h) aliquots were taken 
from the stimulated cells for RNA isolation. mRNA levels of p21, SOCS3, Spi2.1, 
Tubulin, Ribonuclease Inhibitor (RI) and GILZ were determined by real-time-PCR. 
Fold induction of Epo-induced genes was normalized against RI and is depicted 
compared to the specifi c RNA levels of non-stimulated wt cells. Tubulin is an 
additional control for the normalization of values on RI. Values represent mean and 
standard deviation of three experiments and at least 3 independent measurements 
per condition were performed. Asterisks indicate statistical signifi cance (p<0.05; 
student T-Test) between wt and Fancg-/- cells at a given time point. 
Subsequently we investigated whether attenuated Epo-induced signal 
transduction modifi es regulation of known Epo target genes. In accordance 
with previous results [42], Epo induced expression of e.g. p21WAF, Socs3 
(suppressor of cytokine signaling), Spi2.1 (serine protease inhibitor 2.1) and 
repressed expression of Gilz (glucocorticoid induced leucine zipper) in wt 
progenitors. This regulation was absent (p21, Spi2.1) or reduced (Socs3, 
Gilz) in erythroblasts expanded from Fancg-/- fetal livers (Figure 2E). 
Signaling in Fanca-/- and Fancg-/- progenitors is specifi cally 
abrogated downstream of the EpoR/Jak2 complex
Impaired Epo-induced signal transduction could be caused by decreased 
EpoR membrane expression. However, EpoR membrane expression, 
estimated by the amount of Epo binding sites using biotinylated Epo was 
similar in wt, Fanca-/- and Fancg-/- cells (Figure 3A). EpoR signal transduction 
is dependent on the activation of Jak2, which phosphorylates the distal 
tyrosines on the EpoR (for review see [44]). Epo-induced phosphorylation of 
the EpoR was equally effi cient in progenitors expanded from Fanca-/-, Fancg-/- 
and wt fetal livers (Figure 3B, C), and also Jak2 phosphorylation is unchanged 
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suggesting that the signaling defect occurs downstream of Jak2-mediated 
EpoR phosphorylation. To investigate whether signaling defects are specific 
to Epo-induced signaling or applicable to receptor signaling in general, SCF 
signal transduction was investigated. SCF-induced auto-phosphorylation of 
its receptor c-Kit and the phosphorylation of the downstream target Erk1/2 
were not affected in Fanca-/- cells (Figure 3D, E). 
Stat5 activation in vivo is unaffected 
To examine whether Epo-induced Stat5 phosphorylation is also 
affected in vivo, freshly isolated bone marrow cells from wt and Fancg-/- 
mice were stimulated with Epo after a brief (3h) factor deprivation. 
Epo-induced phosphorylation of Stat5 can not be detected by Western 
blot in a heterogeneous mixture of bone marrow cells. Therefore Epo-
induced Stat5 DNA binding to the classical binding site b-casein was 
analyzed. Surprisingly, Stat5 activation in Fancg-/- cells was similarly 
efficient as in wt littermates (Figure 4A). In addition, induction of Stat5 
target genes PIM1 and CIS as assessed by northern blot was also 
unaffected both in Fancg-/- (Figure 4B). This may suggest (i) a difference 
between erythroblasts derived from fetal liver and bone marrow or 
(ii) that reduced signaling efficiency may develop during cell culture. 
Impaired Epo-signaling is restored by erythroid expansion at 
3% oxygen
FA cells are hypersensitive to oxidative stress [45]. Notably, the 
atmospheric oxygen level (20%) during expansion of erythroblasts in vitro 
is cytotoxic particularly for mouse cells [46-47] and is significantly higher 
than physiological levels (~3%). Oxidative stress induces many of the 
DNA lesions with which cells have to cope continuously [48] and cells 
accumulate DNA damage more rapidly at 20% oxygen compared to 3% 
oxygen [47]. FA pathway-deficient cells are particularly sensitive to these 
culture conditions. Therefore we examined whether impaired Epo-induced 
phosphorylation of Stat5 was due to hyperoxic culture conditions and thus 
could originate from prolonged oxidative stress. Fetal livers from Fanca-/- 
mice and wt littermates were split and erythroblasts were expanded for 6 
days at 20% and 3% oxygen. While Epo-induced Stat5 phosphorylation was 
impaired in cells expanded at atmospheric oxygen, Stat5-phosphorylation 
in response to Epo was not affected when progenitors were grown at 3% 
oxygen (Figure 4C). Thus, sensitivity to oxidative stress is involved in 
impaired signal transduction that develops during cell culture.
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Figure 3: Ligand-induced phosphorylation of EpoR, Jak2 and c-Kit is not 
affected in Fanca-/- and Fancg-/- fetal erythroblasts. 
(A) Expression of the EpoR on the surface of wt (dotted line), Fanca-/- (left panel, 
solid line) or Fancg-/- (right panel, solid line) erythroblasts was measured by flow 
cytometry, using biotinylated Epo. Black lines depict cells stained with biotinylated 
Epo, while the grey lines depict cells treated with biotinylated Epo in presence 
of 10 times excess of non-biotinylated Epo as a specificity control. B-E) wt (+/+), 
Fancg-/- (-/-) (B) or Fanca-/- (-/-) (C-E) fetal liver erythroblasts expanded for 6 days 
were factor deprived for 4h and stimulated with Epo (5U/ml; 10’) or SCF (500ng/
ml; 5’) as indicated. Cells were lysed and the EpoR (B, C), Jak2 (C) and c-Kit (B, 
D) were immune-precipitated (IP). Immune-precipitates were analyzed on Western 
blots using the anti-phosphotyrosine antibody PY99 (anti-pY, upper panels) or 
the specific antibodies used in the IP as loading control (lower panels).  E) whole 
cell lysates (WCL) of wt (+/+) or Fanca-/- (-/-) fetal liver derived erythroblasts were 
tested on Western blot for Erk phosphorylation.
Impaired Epo-signaling is a hallmark of defective ICL repair
Cells lacking the NER/ICL-repair enzyme Ercc1 are also extremely 
sensitive to oxidative stress [49-50]. Ercc1-/- mice develop bone marrow 
hypoplasia at 3 weeks of age and have reduced expansion of erythroblasts 
similar to Fancg-/- and Fanca-/- cells [16]. The functions of the Fanconi pathway 
and Ercc1 converge at the ICL [51]. Therefore we investigated whether 
deficient EpoR signaling can more generally result from a deficiency in ICL 
repair. Erythroblasts were expanded from Ercc1-/- fetal livers at atmospheric 
oxygen. Epo-induced Stat5 phosphorylation was significantly decreased in 
all expanded Ercc1-/- progenitors compared to progenitors derived from wt 
littermates (Figure 5A). Surprisingly, Xpa-/-;Csbm/m mice, although having a 
premature aging phenotype and increased tumor risk, were unaffected in 
Epo-induced Stat5 and Erk phosphorylation (Figure 5B) and showed no 
expansion defect [49]. This indicated that defects in nucleotide excision 
repair per se do not lead to attenuation of Epo-signaling. In addition, Epo-
induced signaling was also suppressed in wt erythroblasts treated with a 
low dose of the DNA crosslinking agent MMC (Figure 6A), but agents that 
induce bulky lesions (e.g. daunarubicin) did not affect Epo-induced Stat5 
activation (data not shown). The data suggest that reduced EpoR signaling 
is not specific for defects in the Fanconi pathway, but it may be specific for 
defects in ICL repair.
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Figure 4: Impaired Epo signal transduction is induced by cell culture stress. 
(a) Bone marrow was isolated from wt and Fancg-/- mice, incubated in serum- and 
factor-free medium for 3h and stimulated with Epo (5U/ml), IL-3 (supernatant) or 
GM-CSF (10ng/ml) for 10’. Nuclear extracts were generated and Stat5 binding to 
the b-casein probe by EMSA (electrophoretic mobility shift assay) was tested. b) 
Northern blots for Stat5 target genes PIM-1 and CIS performed on RNA isolated 
from fresh bone marrow samples of wt and Fancg-/- mice stimulated with Epo (5U/
ml) for 0, 1 or 3 hours.  C) Erythroblasts were expanded from wt or Fancg-/- fetal 
livers in 20% (upper panel) or 3% (lower panel) oxygen. After 6 days cells were 
factor deprived (4h) and stimulated with Epo (5U/ml). Lysates were examined on 
Western blots for the presence of Phospho-Stat5 (P-Stat5) and total Stat5. 
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Figure 5: Ercc1-/- erythroblasts are also impaired in Epo-induced Stat5 
phosphorylation. 
(a) Erythroblasts expanded separately from 2 wt and 4 Ercc1-/- fetal livers (5 days) 
were factor deprived (4h) and stimulated with Epo (5U/ml; 10’). Cell lysates were 
analyzed for the presence of phosphorylated Stat5 (P-Stat5) and total Stat5 (Stat5). 
b) Aliquots from Xpa+/-/Csb+/m  and Xpa-/-/Csbm/m erythroblast cultures at day 6 were 
starved (3h) and stimulated with Epo (10U/ml), SCF (100ng/ml), Insulin (Ins; 40ng/
ml) or no factor (NF), lysed and whole cell lysates were subjected to SDS-PAGE 
and western blotting. Blots were stained using antibodies against phosphorylated 
Stat5 (P-Stat5), total Stat5 (Stat5), phosphorylated Erk (P-Erk) and total Erk (Erk). 
No defect in Epo or SCF signal transduction was observed.
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Figure 6: Genotoxic stress impaired Epo-induced Stat5 phosphorylation 
requires p53 but not p16. 
(a) Erythroblasts were expanded for 4 days from wt and p53-/- fetal livers in the 
continuous presence of MMC at different concentrations as indicated. Cells were 
factor deprived (4 h) and stimulated with Epo (5U/ml; 10’). Cell lysates were 
analyzed for the presence of phosphorylated Stat5 (P-Stat5) and total Stat5 (Stat5). 
b) Erythroblasts derived from wt (closed symbols) and p53-/- (open symbols) fetal 
livers were cultured in serum free expansion medium containing Epo, SCF and dex 
in the presence of various concentrations of MMC as indicated (concentration in 
nM). C) Erythroblasts from various p16/p53 heterozygous and knockout mice fetal 
liver culture were incubated with 0, 20 or 40 nM MMC for 24 h. Cells were then 
factor deprived (4h), stimulated with Epo (5U/ml; 10’) and cell lysates were assayed 
by western blot for phosphorylation of Stat5 (P-Stat5) and total Stat5 (Stat5) on the 
same blot (M=protein marker).
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Impaired Epo signaling is rescued by loss of p53
Stalled replication forks result in phosphorylation and stabilization of 
p53, and in activation of the Cdkn2a locus that encodes p19Arf and p16Ink4a, 
causing senescence or apoptosis [52-53]. To examine whether stalled 
replication forks interfere with the efficiency of signal transduction through 
a p53-dependent mechanism, erythroblasts expanded from wt and p53-/- 
fetal livers were exposed to increasing concentrations of MMC for 4 days 
and Epo-induced phosphorylation of Stat5 was examined. Addition of 2 to 
50nM MMC reduced Epo-induced phosphorylation of Stat5 and Erk without 
affecting total Stat5 expression (Figure 6A). The same concentrations of 
MMC did not affect Epo-induced phosphorylation of Stat5 in absence 
of p53 (Figure 6A) and rendered the cells less sensitive to the growth 
inhibitory effect of MMC (Figure 6B). Indeed, p53 deficiency also rescued 
the reduced Epo-induced signaling observed in Ercc1-/- erythroblasts 
(Figure 7). Of note, a sub lethal dose of 2nM MMC during wt erythroblast 
expansion led to the same abrogation of expansion as observed for Fanca-/- 
and Fancg-/- after 10 days (compare Figure 1A, B to Figure 6B, 2nM MMC 
wt curve). Epo-induced phosphorylation of Stat5 in Cdkn2a-/- erythroblasts 
was still attenuated upon treatment with MMC ruling out a role for p16 
in the signaling phenotype (Figure 6C). Together the data suggest that 
the observed signaling defect is part of a general senescence program 
induced upon specific DNA damage which is p53 but not p16 dependent.
figure 7: The reduced Epo-induced signaling observed in Ercc1-/- erythroblasts 
is rescued by p53 deficiency. Erythroblasts were grown from two p53-/- and two 
p53/Ercc1-/delta knockout fetal livers for 6 days. Cells were factor deprived (4h), 
stimulated with Epo (10U/ml; 10’) and cell lysates were assayed by western blot for 
phosphorylated Erk (P-Erk) and total Erk (Erk) on the same blot. 
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disCussion
One of the consistent and early symptoms of Fanconi anemia is bone 
marrow failure. Fancc-/-/Fancg-/- mice develop bone marrow failure and 
leukemia [18], and Fancc/- bone marrow cells grown at atmospheric oxygen 
for 4 days display reduced repopulation ability [21]. Consistent with these 
observations, Fanca-/- and Fancg-/- erythroblasts displayed a reduced in 
vitro expansion capacity and impaired Epo signaling that results in impaired 
Epo-controlled gene regulation. Importantly, the defect in Epo signaling 
is not observed in freshly isolated cells, but develops during in vitro cell 
culture at 20% oxygen. Fanca-/- and Fancg-/- progenitors retain their Epo-
response when cultured at physiological oxygen levels (3%). Impaired 
Epo-induced phosphorylation of Stat5 was also observed in erythroblasts 
lacking the DNA repair enzyme Ercc1, in cells treated with sub lethal doses 
of MMC but not in Xpa/Csb double knockout cells and not in cells treated 
with genotoxic substances that generate bulky lesions (e.g.daunarubicin). 
Induction of the signaling defect by MMC required the presence of p53 but 
was independent of p16. Based on these fi ndings, we suggest that reduced 
responsiveness to Epo in erythroblasts with a defective FA pathway is part 
of a general cellular response to stalled replication forks dependent on 
p53 and not due to a specifi c function of the FA pathway in Jak/Stat signal 
transduction. 
Reduced EpoR signaling in Fanca-/- and Fancg-/- erythroblasts
We observed a reduction in Epo-induced phosphorylation of Stat5 and 
Erk1/2 in Fanca-/- and Fancg-/- erythroblasts expanded at atmospheric 
oxygen, paralleled by impaired regulation of Epo-target genes. In 
contrast, Epo-induced phosphorylation of Jak2 and the EpoR, as well 
as EpoR membrane expression was not impaired. This indicated that 
receptor activation per se is not affected, only the recruitment and/or 
phosphorylation of effectors downstream of the EpoR/Jak2 complex. 
SCF-induced phosphorylation of Erk and auto-phosphorylation of c-Kit is 
also not affected, suggesting that the signaling defect in hematopoietic 
FA knockout cells may be specifi c for Jak-dependent cytokine receptors. 
FA patients that develop bone marrow hypoplasia have high serumlevels 
of Epo [35-36], suggesting that erythroblasts in the bone marrow of FA 
patients fail to respond to Epo, when anemia becomes apparent. 
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Epo-induced Stat5 phosphorylation is also impaired in erythroblasts 
expanded from mice lacking the interstrand crosslink repair enzyme Ercc1, 
and in wt progenitors treated with a sublethal dose MMC, suggesting that 
the signaling defect is not specific for FA. Because the signaling defect 
does not occur in Xpa-/-Csbam/m bone marrow it is not a general DNA 
damage effect. Instead it seems to be the result of replication stress. Mouse 
cells in culture are particularly sensitive to atmospheric oxygen, resulting 
in increased DNA damage [47]. The impaired DNA repair ability of cells 
defective in the FA-pathway will lead to increased chromosomal instability 
at 20% oxygen [54]. Thus, expansion of cells at hyperoxic conditions is 
likely to accelerate accumulation of DNA-damage and hence activation of 
p53 in comparison to in vivo conditions.
At present we do not know the mechanism that is causing the inefficient 
phosphorylation of Stat proteins and other signaling molecules in an 
EpoR but not SCF specific manner. This peculiar specificity rules out a 
general cellular response to genotoxic stress that interferes with signal 
transduction per se. The observation that SCF-induced signal transduction 
is not affected may bear importance because bone marrow failure in FA 
has a high risk of transformation into leukemia. Retained SCF-induced 
signals together with alterations in the signaling network during SIPS may 
be at the basis of cellular transformation leading to tumorigenesis [55 , 56].
Previously it was shown that Stat1 activation by IFNg is impaired in 
FANCC-/- lymphoblastoid cell lines [27]. It was suggested that FANCC 
is directly involved in recruitment of Stat1 to the IFNg-receptor [57]. Our 
data suggest that impaired Epo-induced Stat5 phosphorylation is a more 
general, p53-mediated response to replication stress, which could occur 
in all FA complementation groups as well as in other genomic instability 
syndromes or in wt cells exposed to DNA-damaging drugs. 
Reduced expansion capacity of Fanca-/- and Fancg-/- 
erythroblasts
Fanca-/- or Fancg-/- erythroblasts are initially not affected in their expansion 
rate. Epo-levels were below the detection limit of 20U/l in both Fanca-/- and 
Fancg-/- mice, the number of erythrocytes and reticulocyte in blood was 
normal  and comparable between Fanca-/-, Fancg-/- and wt mice (reticulocytes: 
2-5%; data not shown). Fetal liver size and weight was identical between 
wt and Fanconi-knockout embryo’s (data not shown). Thus, there appears 
to be no defect in in vivo erythropoiesis in these mice. In vitro, however, 
the ability of the erythroblasts to undergo renewal divisions in response 
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to Epo, SCF and Dex is abrogated after circa 9-10 days, while wt cells 
can be expanded for more than two weeks before the cultures succumb 
to complete differentiation. Thus, the signaling defect clearly precedes 
inhibition of proliferation. Purifi cation of Fanca-/- or Fancg-/- progenitors 
during this stage showed that mainly the population of large blastoid cells 
rapidly decreased without an increase in dead cells, suggesting enhanced 
differentiation. Enhanced differentiation at the expense of erythroblasts 
expansion was also observed for wt erythroblasts treated with a critical, 
sublethal dose of MMC, but did not occur in p53-/- erythroblasts. 
Reduced expansion could be due to attenuated Epo-induced activation 
of downstream targets or it could be an independent cellular response 
to DNA damage or a combination of both. We previously demonstrated 
that loss of Btk decreases the effi ciency of EpoR signaling, which lead to 
abrogation of expansion in favor of differentiation [41]. This suggests that 
expansion and differentiation require distinct Epo-signaling thresholds with 
lower Epo signaling resulting in enhanced differentiation. However, also 
increased p53 levels evoked by increasing DNA damage may abrogate 
the potential of erythroblasts to expand. p53 was shown to enhance 
differentiation and to abrogate proliferation of erythroblasts [58-59] and 
loss of p53 is a crucial step in Friend virus-induced erythroleukemia [60].
Notably, p53 is increased in all tissues of Fancc-/- mice [61]. Lack of p53 
also abrogates the hypersensitivity of Fancc-/- cells for MMC, indicating that 
DNA damage-induced p53 is an important mechanism in the FA phenotype 
[61]. Interestingly, reduced phosphorylation of Stat5 induced by MMC, was 
rescued by p53 defi ciency, clearly suggesting a link between p53 and Epo-
induced signaling. The gatekeeper p53 appears to play a major role in 
inducing premature senescence and aging, resulting in a reduction of the 
pool of stem- and progenitor cells [56, 62-63]. The data suggest that during 
hyperoxic culture erythroblasts lacking an intact FA pathway accumulate 
DNA damage and by consequence activate p53, which enhances 
expression of cell cycle inhibitory and differentiation promoting genes. 
If increased differentiation at the expense of renewal is due to impaired 
signaling and/or increased DNA damage due to cell culture, the expansion 
capacity is expected to be retained when Fanca-/- cells are cultured at 3% 
oxygen. However, the expansion of wt as well as Fanca-/- erythroblasts was 
decreased when cultured at 3% oxygen. This observation was surprising, 
since expansion of mouse embryo fi broblasts is much improved at 3% 
oxygen. 
Judith Proefschrift.indb   131 27-12-2012   16:33:58
Chapter 5132
In conclusion, we found that long term erythroblast expansion and Epo 
signal transduction is dependent on the integrity of ICL repair pathways 
in a p53 dependent manner.  This in vitro phenotype may be involved in 
the erythropoiesis defect and the insensitivity to Epo as observed in FA 
patients.
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Abstract
Wnt/β-catenin signaling is intimately involved in main-
tenance and proliferation of stem- and progenitor cells. 
In contrast to Wnt/β-catenin signaling, activation of p53 
induces senescence and abrogates renewal. Permanently 
proliferating cultures of committed mouse erythroblasts 
can be reproducibly established from p53-deficient fetal 
liver or bone marrow in serum-free medium supplemented 
with erythropoietin, stem cell factor and glucocorticoids. 
We observed that p53-/- erythroblasts have increased 
β-catenin levels and decreased spontaneous differen-
tiation rates compared to respective wild-type erythro-
blasts. Expression of β-catenin protein levels inversely 
correlated with expression of the p53 target gene Siah1 
(seven in absentia homologue 1), a ubiquitine ligase 
known to control β-catenin protein stability. Proliferation 
of the established p53-/- erythroblast line I/11 was critically 
dependent on Wnt/β-catenin signaling. Our data suggest 
a mutual antagonistic effect of p53 and Wnt/β-catenin 
signaling on the balance of proliferation and maturation of 
committed erythroblasts.
Judith Proefschrift.indb   138 27-12-2012   16:33:59
Wnt signalling in erythropoiesis 139
C
h
a
p
te
r 
6
introduCtion 
Lifelong production of the appropriate numbers of erythrocytes requires 
a balance between HSC maintenance and erythroid commitment, lineage 
expansion and survival in response to erythropoietin (Epo) [1]. In response 
to hypoxia, erythropoiesis will be promoted because enhanced levels of 
Epo increase survival of erythroblasts [2], as well as via enhanced transient 
amplifi cation of erythroblasts, which involves stem cell factor (SCF) and 
glucocorticoids [3-4]. 
Erythroblasts can be expanded in vitro from mouse fetal liver or bone 
marrow in presence of Epo, SCF and glucocorticoids [5]. These cultures 
display limited self renewal for 10-15 cell doublings, and increasingly 
undergo spontaneous differentiation. Erythroblast cultures derived from 
p53 defi cient mice display less spontaneous differentiation, which allows 
for the establishment of cultures with an apparent unlimited proliferation 
potential [6]. In addition, long-term p53 defi cient cells retain a normal 
diploid karyotype and retain the ability to undergo terminal differentiation 
in presence of Epo and insulin [5-6]. To avoid genetic instability of p53 
defi cient cells under sub-optimal conditions [6], genetically stable cultures 
can be established from wildtype (wt) erythroblasts derived from embryonic 
stem cells (ESEPs [7]) or early fetal livers [8]. These long term cultures 
behave like their freshly isolated fetal liver derived wt counterparts with 
respect to cytokine/hormone requirement and terminal differentiation 
into enucleated erythrocytes, thereby producing cell numbers which are 
suffi cient for complex biochemical studies [9-11].
The Wnt pathway is a highly conserved pathway which plays a crucial 
role in cell fate determination, survival, proliferation and movement in 
a wide variety of tissues [12]. Aberrant expression or function of Wnt 
signaling components is associated with several cancer types [13-16]. Wnt 
signaling cooperates with signals from several receptor tyrosine kinases 
and cytokine receptors to enable proliferation and survival as well as 
renewal of HSCs [17-21]. Multiple Wnts are expressed in hematopoietic 
tissues, raising the possibility of autocrine and paracrine activation of Wnt 
signalling [22]. Cultivation of HSCs in Wnt-conditioned media signifi cantly 
stimulated proliferation and attenuated commitment/differentiation [18, 20]. 
In addition, the Wnt pathway was found to be constitutively activated in 
acute myeloid leukemia (AML) [23] and to be involved in the blast crisis 
of chronic myelogenous leukemia (CML) during progression to AML [24]. 
Moreover, the balance between HSC self-renewal and commitment seems 
to be regulated by Hmgb3 via canonical Wnt signalling [17, 25]. It remains 
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to be established, however, whether Wnts contribute to the renewal of 
hematopoietic progenitors at later stages of their development. This 
raised the question whether the Wnt pathway is also active in committed 
erythroblasts and whether it contributes to the transient amplification within 
the erythroid lineage.
Two independent intracellular signalling pathways have been identified, 
the Wnt/β-catenin (canonical) pathway [26] and the Wnt-Ca2+/PCP 
(noncanonical) pathway [27]. Wnt signals are transduced through 
receptors of the frizzled (Fz) family [28] and coreceptor LRP5/6, which is a 
member of the low density lipoprotein receptor family [29-30]. In addition, 
Wnt factors can bind tyrosine kinase receptors such as Ror2 [31] or Ryk 
[32], which inhibits canonical signaling. Both Wnts and Fzs are members 
of large protein families, currently compromising at least 19 Wnts and 10 
Fzs in the mouse [33]. Each Wnt can bind several Fz-receptors, but the 
specificity of Wnts for Fz-receptors is not yet fully understood. The key 
signal mediator in the canonical pathway is β-catenin, which is rapidly 
degraded in absence of Wnt signals. Wnt signaling stabilizes β-catenin, 
resulting in its translocation to the nucleus and association with members 
of the TCF/LEF family of transcription factors, which triggers transcription 
of target genes [26]. Expression and stability of b-catenin is regulated 
via two different pathways. The general pathway involves glycogen 
synthase kinase 3-β (GSK3-β) and the adenomatosis polyposis coli 
gene product, APC [26]. In the alternative pathway, a complex of Siah-1 
(Seven-In-Absentia homologue-1), SIP (Siah-1-interacting protein SIP), 
Skp1 (S-phase kinase-associated protein 1) and Ebi binds to β-catenin to 
induce its ubiquitination and degradation [34-35]. Within this non-canonical 
pathway, the p53 controlled Siah-1 is the limiting factor [36].
Here we report that loss of p53 decreased Siah-1 expression, and 
increased β-catenin levels in fetal liver- and bone marrow derived 
erythroblasts, and in mouse embryonic fibroblasts. Downregulation of 
β-catenin inhibited proliferation and induced differentiation of p53-deficient 
erythroblasts. These results suggest a mutual antagonistic effect of the 
senescence promoting activity of p53 and Wnt induced “renewal signaling” 
on the balance between proliferation and differentiation. 
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materials and methods 
Cells and cell culture
Primary erythroblasts were isolated and expanded from fetal liver of 
E12.5 mouse embryos as described [5] using serum-free medium (Stem-
Pro-34TM, Invitrogen), supplemented with 1U/ml human recombinant 
erythropoietin (kind gift of Ortho Biotech, Tilburg), 50ng/ml murine 
recombinant SCF (supernatant of producer cells), 10-6M dexamethasone 
(Dex; Sigma) and 40ng/ml insulin-like growth factor 1 (IGF-I; Promega). 
Established erythroid lines (clone I/11 [6], R10, 2C4 [37], and ESEP [7]) 
were cultured under the same conditions. All erythroid cell types were 
expanded by daily partial medium changes and addition of fresh factors, 
keeping cell densities between 2-4 x106cell/ml. Cell number and size 
distribution were determined using an electronic cell counter (CASY-1, 
Schärfe-System). Proliferation kinetics and cumulative cell numbers were 
calculated as described [6]. To induce differentiation, cells were transferred 
to medium containing 10U/ml Epo, 10ng/ml insulin (ins; Actrapid HM), and 
1mg/ml iron saturated human transferrin (Sigma). 
Cytospins and hemoglobin assay
Cytospin preparations and staining with cytological dyes, and hemoglobin 
content was analyzed photometrically as described [38]. Results are the 
average of triplicate measurements after normalization for both cell number 
and volume. 
Western Blot analysis
Erythroid cells were washed twice with ice-cold PBS, centrifuged and the 
pellet lysed in an isotonic buffer containing 10mM HEPES pH=7.5, 40mM 
KCl, 0.2% NP-40, 5% glycerol, 1mM DTT supplemented with proteinase 
inhibitor mix. Cell debris was removed by centrifugation for 5 min at 15.000 
rpm at 4°C. Lysates were resuspended in 4x SDS loading buffer. Sample 
amounts to be loaded were normalized to both cell number and cell volume 
and subjected to Western Blot analysis as described earlier [6]. 
Antibodies used: anti-β-catenin monoclonal antibody (C19220, 
Transduction Laboratories), anti-ERK 1/2 (V1141, Promega), anti-HA 
(MMS-101R, Covance), a polyclonal anti-LRP6 antibody was raised in 
rabbit against the recombinant cytoplasmic tail of LRP6. 
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Proteins were either detected by fluorescently labeled secondary 
antibodies followed by detection using an Odyssey IR Imaging System 
(LI-COR Biosciences) or by probing with horseradish peroxidase-
conjugated species specific antiserum (DAKO A/S, Glostrup,Denmark), 
followed by enhanced chemiluminescence reaction (Du-Pont, Boston, 
MA). Western blot results were quantified by integrating optical densities 
of bands using Gel-Pro Analyzer™ Software (Media Cybernatics, UK) and 
normalized to signals from respective loading controls.
cDNA preparation and PCR analysis
Total RNA was isolated using Tri ReagentÒ-RNA/DNA/Protein Isolation 
Reagent (Molecular Research Center, Inc.) and used for cDNA synthesis 
using SuperScript™ Reverse Transcriptase (Life Technologies, Inc.). 
PCR reactions were performed according to standard procedures: Siah1b 
mRNA expression was analyzed by quantitative PCR using Taqman Q-PCR 
as described [11]. Siah1b levels were normalized against expression of 
RNAse inhibitor. All other real-time PCR reactions were performed using 
the LightCycler® (Roche Diagnostics) in 20µl format using LightCycler 
DNA-Master SYBR Green I (Roche Diagnostics) and normalized against 
β-actin mRNA.
RNAi assays
Double-stranded siRNA oligomers were designed and manufactured by 
Invitrogen (Stealth Select RNAi). b-catenin siRNA sense: 5’-ccc aga aug 
ccg uuc gcc uuc auu a-3’, antisense: 5’-uaa uga agg cga acg gca uuc 
ugg g-3’; non-functional siRNA sense: 5’-cca uug uuu  gug cag uug cuu 
uau u-3’, antisense: 5’-aau aaa gca acu gca caa aca aug g-3’. Wt and 
p53-/- fetal liver derived erythroblasts were transfected with siRNA using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. 
Optimization of transfection conditions was done using a fluorescein-
labeled double-stranded RNA (BLOCK-iT fluorescent oligo, Invitrogen).
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results 
Loss of p53 increases β-catenin levels 
Because Wnt/β-catenin signaling enhances renewal of stem cells or 
multipotent hematopoietic progenitors [19], we compared β-catenin levels 
in long-term cultures of p53-/- versus wt fetal liver-derived erythroblasts. 
The p53-/- clone I/11 displayed signifi cantly elevated levels of cytoplasmic 
β-catenin in comparison to wt erythroblasts (Figure 1A). Moreover, a 
considerable fraction of β-catenin in I/11 cells localized to the nucleus, 
consistent with a function in transcriptional signaling (Figure 1B). To 
analyze whether these high levels of β-catenin were a direct consequence 
of p53 loss or rather a clonal feature of I/11 cells, β-catenin expression 
was measured in independently obtained long-term cultures of p53-/- 
erythroblasts derived fetal livers (FL) or bone marrow (BM), versus p53+/+ 
embryonic stem cell-derived erythroid progenitors (ESEPs; [7, 37]) (Figure 
1C). Both early (7 days) and long-term (up to 60 days) p53-competent ESEP 
cultures showed low levels of β-catenin, whereas all p53-/- established 
erythroblast cell lines exhibited high β-catenin expression, independent of 
clonal background (72a, R10, both from fetal liver) or tissue (2C4, bone 
marrow) of origin (Figure 1C). 
To investigate whether β-catenin levels were already elevated in p53-
defi cient primary cultures or in established cell lines only, β-catenin 
expression was compared between freshly isolated cultures of p53-/- and 
wt fetal liver-derived erythroblasts. These cells were derived either from 
p53-/- or wt animals, or from mice lacking the nucleotide excision repair 
enzyme Ercc1. The cross-link repair defect of Ercc1-/- erythroblasts results 
in p53-dependent reduced proliferation and enhanced differentiation 
(manuscript in preparation). Compared to wt erythroblasts, β-catenin 
expression was enhanced in primary erythroblast cultures derived from 
p53-/- fetal livers, whereas it was undetectable in erythroblast cultures 
(two independent lines) derived from Ercc1-/- mice. 
Analysis of MEFs derived from either p53-/- or wt animals suggested that 
the observed upregulation of β-catenin was a common consequence of 
loss of p53 (Figure 1E) rather than a senescence-related event during 
prolonged cultivation.
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figure 1: β-catenin protein levels are increased by p53-deficiency. 
A-F. Cell lysates were separated by SDS-PAGE and immunoblotted using antibodies 
specific for β-catenin or ERK1/2 (loading control). (a) Cytoplasmic extract of primary 
wt fetal liver-derived erythroblasts (wt-ftl) or the p53-/- erythroid cell clone I/11. (b)
Cytoplasmic and nuclear β-catenin levels in the p53-/- erythroid cell clone I/11. 
(C) Wt embryonic-stem-cell-derived erythroblasts (ESEP; numbers indicate days 
in culture) and different established cultures of p53-/- erythroblasts (ftl 72a, R10: 
fetal-liver-derived erythroblasts; bm 2C4, bone-marrow-derived erythroblasts). 
(d) Erythroblasts freshly expanded from fetal livers of p53-/- mice (p53-/-; numbers 
indicate days the cells were kept in culture; primary wt (p53wt/Ercc1wt) or Ercc1-
deficient erythroblasts (p53wt/Ercc1-/-). (e) wt or p53-/- mouse embryo fibroblasts 
(MEF). (f) Siah1b mRNA expression was quantified in erythroblasts cultivated for 
7 days from wt, p53+/- and p53-/- fetal livers. Numbers identify littermates. Values 
are the average of at least 7 independent experiments; error bars indicate standard 
error of mean (SEM).
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Expression of b-catenin is mainly regulated by ubiquitination and 
proteosomal degradation. Two distinct ubiquitin ligases are involved: 
APC and Siah1, whereby Siah1 expression is controlled by p53 [36]. We 
measured the expression of Siah1b in erythroblasts cultured for 7 days 
from p53-/-, p53+/-, or wt fetal livers of embryos from the same litter by 
quantitative PCR (qPCR). Whereas Siah1b mRNA levels were similar in 
p53+/- and wt cultures, expression was 5-fold lower in p53-/- cultures (Figure 
1F). Expression of Siah1a was not detectable in any of the samples 
analyzed.
Together, these experiments demonstrated a strict inverse correlation 
between β-catenin levels and p53 expression that was not restricted to 
the erythroid lineage but also observed in primary fi broblasts. Further, the 
lack of p53 and increased expression of β-catenin were associated with 
low levels of the p53 target gene Siah1b, that is known to control β-catenin 
degradation.
Table 1: Expression of components of the Wnt signaling pathway in p53-
defi cient (I/11) and wild-type erythroid progenitors during self-renewal and 
differentiation.
Expression of Wnts, Frizzled (Fzd) receptors and Kremen (Km) transcripts was 
analyzed by qPCR. Symbols used: -, no expression; +, weak expression; ++, 
strong expression.
Wnt genes wilt-type p53-/- wilt-type p53-/-
Wnt1, 2 - - - -
Wnt2b - - ++ -
Wnt3, 3a, 4 - - - -
Wnt5a + - - -
Wnt5b, 6, 7a, 7b, 8a, 8b, 9a, 9b, 10a - - - -
Wnt10b - ++ - -
Wnt11 + - - -
Wnt16 - - - -
Frizzled genes
Fzd1, 8 - - - -
Fzd2 ++ - - -
Fzd3 ++ + + -
Fzd4 ++ - + -
Fzd5 + - + -
Fzd6 ++ - ++ -
Fzd7 ++ + + +
Fzd9 ++ + + +
Fzd10 ++ - - -
Kremen genes
Krm1 ++ ++ + +
Krm2 - - - -
Self-renewal Differentiation
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Figure 2: Expression of wnt2b, β-catenin, and LrP6 during differentiation of 
wt versus p53-deficient mouse erythroblasts.
mRNAs prepared from wt fetal liver erythroblasts (wt-ftl) (a) or the p53-/- erythroid 
cell clone I/11 (b) at 0, 8, 12, 24, 36, and 48 hours after induction of differentiation, 
respectively, were used for qPCR using primer pairs specific for Wnt2b and b-actin 
(as constitutive expression control) followed by gel electrophoresis. Cell lysates 
from wt erythroblasts (wt-ftl) (C) or p53-/- I/11 cells (d) were prepared at different 
stages of differentiation, separated by SDS-PAGE, immunoblotted, and detected 
using antibodies specific for b-catenin or ERK1/2 (loading control for normalization). 
Expression levels of LRP6 (e), c-Kit, and Bcl-XL (f), the latter two as controls 
for known changes in expression patterns during erythroid differentiation in I/11 
cells during differentiation measured by qPCR. mRNA was prepared from cells 
harvested at 0, 6, 12, 24, 36, and 48 hours after differentiation induction. Data 
normalized to b-actin mRNA. Error bars: SEM, n=3.
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Expression of Wnt/β-catenin signaling components in 
erythroblasts 
Although reduced Siah1b expression can increase β-catenin levels, the 
pathway still requires activation by Wnt ligand. Therefore we compared 
expression of crucial components of the Wnt signaling pathway in p53+/+ 
versus p53-/- erythroblasts during self-renewal and differentiation.
Using RT-PCR we detected signifi cant amounts of 7 of the 10 known 
Frizzled genes (Fz2, 3, 4, 6, 7, 9, and 10) in wt and 53-defi cient erythroblasts 
(Table 1). Most Fz mRNAs became less abundant during differentiation. 
Expression analysis for the 19 mouse Wnt mRNAs indicated that wt 
erythroblasts cultured under renewal conditions only expressed low levels 
of Wnt5a and Wnt11 mRNAs (Table 1). Surprisingly, Wnt2b expression, 
so far described for its proliferation-promoting role in kidney, eye and liver 
development [39-41], increased massively during differentiation (Figure 
2A,B). All other Wnt transcripts remained undetectable in terminally 
maturing erythroid cells. Only p53-/- I/11 cell clones expressed high levels 
of Wnt10b mRNA, which became downregulated during differentiation 
(Table 1). Most likely, this clone-specifi c genetic event occurred during the 
establishment of the I/11 cell line. 
Besides Fz proteins, Wnt signaling also requires LRP5 and/or LRP6 
(LDL-receptor related protein) co-receptors. LRP6, but not LRP5 mRNA 
was expressed in proliferating erythroblasts, but became rapidly down-
regulated as the cells started to differentiate (Figure 2B). As a control for 
differentiation effi ciency, c-Kit mRNA abundance (SCF receptor; a marker 
for immature hematopoietic cells) and transcript levels of the anti-apoptotic 
gene Bcl-Xl, were used as surrogate markers, showing the expected 
down- and upregulation pattern, respectively [9-10, 42] (Figure 2F). 
Analysis of β-catenin expression during differentiation of erythroblasts 
showed a transient upregulated at 8 hours after differentiation induction 
and decreased to undetectable levels at 24 hours (Figure 2B). This 
time window of elevated β-catenin expression can be explained by the 
upregulation of Wnt2b and concurrent downregulation of Lrp6. 
Finally, also the expression of Kremen1 and Kremen2 mRNAs (receptors 
for Dickkopf-1; negatively regulating canonical Wnt signaling [43]) were 
analyzed by qPCR. Kremen1 mRNA was expressed at comparable levels 
during self-renewal as well as differentiation (Table 1).
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In conclusion, primary erythroblasts proliferating in vitro express 
multiple Fz receptors, low levels of Wnt5a and Wnt11 ligands. Wnt2b 
was specifically expressed during differentiation. Its signaling potential, 
however, appears limited due to the rapid downregulation of LRP6.
Down-regulation of β-catenin by RNAi in p53-deficient 
erythroblasts triggers apoptosis
To investigate whether activation of the canonical Wnt-pathway 
contributes to the expansion capacity of the I/11 erythroblastic cell line, 
β-catenin expression was down-regulated using RNA interference (RNAi). 
A β-catenin-specific shRNA expressed from the retroviral vector pMSCV, 
but not the control shRNA downregulated ß-catenin in mouse L-cell 
fibroblasts expressing Wnt3A (Figure 3A, insert). 
Next the RNAi vectors were introduced into p53-/- I/11 cells. Control cells 
proliferated normally (Figure 3A) and displayed only few dying and/or 
differentiating cells, as deduced from size profiles and cytospins (Figure 
3B,C). In contrast, cells transduced with the β-catenin specific RNAi 
vector proliferated slower and displayed a high proportion of apoptotic or 
abortively differentiated cells (Figure 3B,C). Increased cell death of the 
β-catenin knockdown cells was confirmed by propidium iodide staining 
plus flow cytometry (Figure 3D) and TUNEL-assays (Figure 3E), revealing 
a significantly higher proportion of apoptosis in comparison to cells ex-
pressing the control vector. β-catenin levels were massively reduced by the 
specific shRNA (data not shown). These data indicate that up-regulation of 
β-catenin is required for long-term expansion of p53-/- I/11 erythroid cells.
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figure 3: down-regulation of b-catenin in p53-deficient erythroblasts by rnai. 
Insert in panel a: b-catenin protein levels in L-Wnt3A cells infected with empty vector 
(lane 1) or infected with a pMSCV-based retrovirus bearing either a mismatched 
b-catenin RNAi construct (lane 2) or a functional b-catenin RNAi construct (lane 
3), respectively. Cumulative cell numbers (a) and cell size distributions (b) of 
p53-deficient erythroblasts (I/11) infected with either a mismatched b-catenin 
RNAi construct (mock) or a functional b-catenin RNAi construct (RNAi). Cells were 
cultured under renewal conditions and analyzed every 24 hours. Note impaired 
proliferation (A) and gradual reduction of cell size in cells expressing functional 
b-catenin RNAi (B). (C) Cytospin preparations from aliquots of the above cultures 
72 hours after transduction, were stained with histological dyes plus neutral 
benzidine (to reveal hemoglobin). (d) The proportion of propidium iodide positive 
erythroblasts was determined by flow cytometry in samples taken 24, 48 and 72 
hours after infection. (e) After staining with haematoxylin (blue), apoptotic cells 
(brown/black) infected with empty vector (left panel) or β-catenin RNAi (right panel) 
were detected by TUNEL assay on cytospins.
disCussion 
The Wnt/b-catenin signaling pathway is critically involved in expansion of 
various types of stem and progenitor cells, while activation of p53 restricts 
proliferation. Lack of p53 reduces spontaneous differentiation in fetal 
liver-derived erythroid cultures and allows for establishment of cultures 
with unlimited self-renewal that remain fully dependent on cytokines and 
hormones for proliferation and differentiation [44-45]. Although loss of 
p53 is thought to enable establishment of cell lines by allowing genetic 
instability, we previously showed that p53-/- erythroid cell lines, when 
properly treated, remain diploid and fully competent to differentiate into 
hemoglobinized, enucleated erythrocytes [6, 10]. Here, we demonstrate 
that loss of p53 contributes to enhanced activity of the Wnt/b-catenin 
pathway, which correlated with reduced expression of the p53 target gene 
Siah1b, encoding an E3-ligase for b-catenin. Our findings implicate that 
Wnt/b-catenin signaling does not only maintain renewal in stem cells, but 
also in fully committed progenitors and they suggest mutual antagonistic 
effects between the “senescence factor” p53 and the “renewal pathway” 
induced by Wnt.
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Loss of p53 is associated with upregulation of β-catenin in 
erythroblasts
Primary erythroblasts of different origin undergo renewal divisions in 
response to SCF, Epo and glucocorticoids, [6-7, 10, 46-47]. Moreover, all 
primary wt erythroblasts, including ESEPs [7] and avian erythroblasts [48], 
undergo considerable spontaneous differentiation, even under optimal renewal 
conditions. In primary p53-/- erythroblasts, however, spontaneous differentiation 
is strongly reduced and even absent in established p53-/- cultures. Interestingly, 
all p53-/- cells tested, accumulated increased amounts of β-catenin whereas wt 
erythroblasts had low β-catenin levels, even when they were able to undergo 
long-term renewal (ESEP). This phenotype was not restricted to cells of erythroid 
origin but was also observed in MEFs. Erythroblasts defi cient for the DNA cross-
link repair gene Ercc1 (Ercc1-/-) undergo enhanced differentiation. Although p53 
levels are too low to be detected, this process is p53-dependent as loss of p53 
restores expansion of Ercc1-/- erythroblasts (Chapter 4). This could explain why 
Ercc1-defi cient cells were completely devoid of β-catenin. 
Siah-1b, the mammalian homologue of Drosophila Seven In Absentia, 
is a p53 target gene [34]. Siah-1 recruits E3 ubiquitin ligases and results 
in GSK3-independent degradation of b-catenin [34, 49]. Indeed, low 
Siah1b levels in freshly isolated primary erythroblasts from individual 
mouse embryos correlated with loss of p53 (Figure 1E). Taken together, 
our observations indicate a general mechanism for the inverse relationship 
between p53 activity and b-catenin levels.   
The correlation between lack of p53 and enhanced b-catenin levels also 
sheds new light on the role of p53 in murine erythroleukemia induced by 
Spleen focus forming virus (SFFV) or Friend virus. The SFFV-encoded 
glycoprotein gp55 associates with the Epo-receptor, resulting in Epo-
independent proliferation and polycythemia. Transformation to leukemia 
is critically dependent on activation of the transcription factors PU.1/Spi1 
or Fli-1, combined with loss of p53 [50]. Loss of p53 was assumed to 
induce mutations that cooperate with PU.1 or Fli-1, but other studies 
indicate that it is required to protect cells from apoptosis and promote 
renewal of leukemic cells [51-52]. Our studies suggest that stimulation of 
Wnt/b-catenin signaling may be one of the effects resulting from loss of 
p53 in SFFV-induced erythroleukemia. 
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Recently, the Wnt pathway has also been implicated in human leukemia 
(reviewed in [53]). A large number of AML samples express increased 
levels of b-catenin and forced expression of b-catenin in hematopoietic 
progenitors impairs myelomonocytic differentiation [54]. Furthermore, 
transition of CML to blast crisis was shown to involve nuclear localization of 
b-catenin [55], while the Frat-oncogenes, activated upon retroviral insertion, 
induce T-cell leukemia by inactivation of glycogen synthase kinase 3 and 
b-catenin stabilization [56]. Finally, up-regulation of the Wnt coreceptor 
RYK and ß-catenin itself was found in several cases of myelodysplastic 
syndrome /AML with poor prognosis [57].
Autocrine Wnt/β-catenin signaling
Analysis of Wnt expression in early and established cultures of wt and 
p53-/- erythroblasts, indicated that low levels of several Wnt factors are 
detectable in all cultures. A high expression of Wnt10b was observed 
in established I/11 cells. Inhibition of ß-catenin expression in I/11 
erythroblasts by RNA interference abrogated renewal, suggesting that a 
Wnt10b autocrine loop is required for sustained proliferation of I/11 cells. 
The observation that I/11 cells die instead of differentiate upon the RNAi 
treatment may be due to “conflicting instructions” given by renewal factors 
in the sudden absence of Wnt signaling. The other p53-/- cell lines, however, 
were established independently of significant expression of Wnt10b or any 
other Wnt. This difference between established cultures is not surprising, 
because cultures of p53-deficient erythroblasts go through a brief period 
in which proliferation and spontaneous differentiation balance each other 
before spontaneous differentiation decreases and proliferation increases. 
In I/11 erythro blasts the events leading to establishment of a permanently 
proliferating cell line apparently involved up-regulation of Wnt10b, other 
cultures may have been selected on the basis of distinct additional events. 
Is the Wnt pathway required for in vivo and in vitro 
erythropoiesis?
The broad spectrum of Frizzled receptors (Fz2, 3, 4, 5, 6, 7, 9, and 10) in 
wt erythroblasts suggests that the cells can respond to a variety of Wnts. 
We do not have evidence that wt erythroblasts produce Wnts enhancing 
their renewal. Instead, the cells may respond to paracrine stimulation by 
Wnts from stromal cells in the bone marrow or the spleen [18, 20, 58]. 
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Interestingly, Wnt2 was absent in renewing wt fetal liver erythroblasts 
but strongly upregulated as soon as 8 hours after differentiation induction. 
Simultaneously the Fz-co-receptor LRP6 was down-regulated, which 
may explain the short time window in which Wnt2 could drive b-catenin 
signaling. Possibly this transient Wnt2 signal causes the transient increase 
in proliferation rate during the early “differentiation divisions” observed with 
chicken and mouse erythroblasts [6, 59]. 
The Wnt/β-catenin/TCF4 axis is crucial for proliferation of colon crypt 
stem cells and perturbed activation of TCF4 is a critical step in tumor 
development [60] and leukemia (reviewed in [53]). Recent studies showed 
that Wnt also promotes self-renewal of hematopoietic stem cells [18-19, 21] 
where it has been implicated in the proper balance between self-renewal 
and differentiation [17, 25]. Ablation of β-catenin in the hematopoietic 
system, however, did not show major defects [61]. Alternatively, enhanced 
b-catenin may only be required to counteract stress conditions, such as 
oxidative stress in vitro due to culture at atmospheric oxygen [62]. It is 
also possible that the effects of endogenous Wnt on stem cell renewal 
may only become apparent when the stem cell pool is challenged. Thus, 
in erythropoiesis, the requirement for Wnt/b-catenin signaling in vivo may 
become important when maximum expansion of the erythroid compartment 
is needed, i.e. under prolonged hematopoietic stress [46, 63]. Similar 
situations have been observed for mice expressing glucocorticoid- and Epo 
receptor mutants or defi cient in STAT5, that show little or no hematopoietic 
defects in vivo (unstressed), whereas corresponding fetal liver-derived 
erythroblasts cultured in vitro exhibit decreased renewal and enhanced 
premature differentiation [47].
Stress erythropoiesis, in the mouse, occurs specifi cally in the spleen 
and not in the bone marrow. Expression of BMP4 and sonic hedgehog in 
spleen are important [64-65]. It would be interesting, however, to compare 
Wnt expression by stromal cells in mouse bone marrow and spleen. 
In conclusion, several Wnts may act on erythroid progenitors. Stabilization 
of b-catenin is necessary but not suffi cient to induce erythroblast renewal. 
Wnts cannot substitute for the renewal factors Epo, SCF or glucocorticoids. 
Instead, constitutive expression of Wnt5a allows long-term proliferation of 
wt erythroblasts, as previously observed for p53-defi cient cells. Because 
p53-defi cient cells express high levels of b-catenin, we postulate that 
Wnt/b-catenin signaling and p53 activation are mutually antagonistic. 
To understand the implications of this mutual antagonism under various 
conditions is the next challenge.
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summarY and disCussion
Summary
During the entire life time of an organism, its DNA is exposed to conditions 
that modify nucleotides or break the DNA strands. Defective repair of DNA 
damage causes mutations that may lead to cancer. The various tumour 
suppressor systems block survival and-or proliferation of mutated cells. 
However, protection from cancer causes aging of cells and tissues, and of 
the entire organism. The balance between protection and aging results in an 
increasing cancer incidence with age [1].
Much has been learned from syndromes linked to defective DNA repair. 
Yet little is understood as to why distinct DNA repair defects are linked to 
specifi c disease phenotypes [2]. The DNA damage response (DDR) consists 
of a complex network of proteins that are responsible for damage recognition, 
signal transduction, cell cycle control and DNA repair [3]. This network function 
is balanced between aging and cancer development [4]. Organismal aging and 
cancer development are tightly regulated by the expression level of several 
DDR proteins (such as ATR reviewed in [5]) as well as by the damage load [6].
Our blood contains a variety of cells with a relatively short lifetime and 
maintenance of blood levels requires the continuous generation of blood cells 
from the hematopoietic stem- and progenitor cell (HSPC) compartment in the 
bone marrow. By consequence, the hematopoietic system is very sensitive to 
DNA damaging drugs. The cytotoxic anticancer drugs used for most kinds of 
cancer have several adverse effects on hematopoiesis. For example, long term 
treatment with high dose alkylating agents may lead to progressive depletion 
of HSPCs  and subsequent bone marrow hypoplasia. This hypoplastic 
environment can drive the remaining HSCs into proliferation while mutations 
caused by DNA damage result in a high risk of leukemic development.
The aim of this thesis was to elucidate the molecular mechanism of bone 
marrow failure and the subsequent leukemogenesis as seen in bone marrow 
failure syndromes associated with age or with persistent DNA damage. For this 
we used Ercc1 defi cient mice. Ercc1 is an endonuclease which is involved in 
the excision of nucleotides during global and transcription coupled nucleotide 
excision repair (NER) and it also functions in excision of interstrand crosslinks 
(ICLs) at the replication fork. It has previously been shown that the number 
of hematopoietic stem cells was reduced in the bone marrow of Ercc1-/- mice 
and that the capacity of BM progenitors to generate colonies was severely 
impaired [7].
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In this study we first analyzed whether the severe progeria (overall aging) 
of the mice, which is associated with the defective NER, contributes to their 
bone marrow defect or whether it is specifically due to defective ICL repair 
at the replication fork (Chapter 2). Comparison with Xpa-/-Csb-/-  mice that 
lack NER but have intact ICL repair revealed that the severe progeria in 
Ercc1-/- mice does not cause aging of the BM compartment. 
The alternative explanation, that HSPCs are particularly sensitive to 
defects in ICL repair and stalled replication forks was supported by the 
fact that the quiescent stem cells of the HSPC population are relatively 
less affected once the mice become adult. Conditional knockout mice 
as well as hematopoietic repopulation studies in which Ercc1-defective 
BM was transplanted into irradiated hosts indicated progressive loss of 
Ercc1-deficient cells. This is in line with the hypothesis that proliferation is 
a disadvantage for cells with decreased DNA repair capacity (Chapter 3). 
Long term hematopoiesis could not be studied in Ercc1-/- mice due 
the fact that they die at three weeks of age. Mice with one hypomorph 
allele (Ercc1-/d) live for ~20 weeks and mice with two hypomorph alleles 
(Ercc1d/d) live for > 6 months. This difference in lifespan must be due to a 
dosage effect of their residual Ercc1 activity, and thus we next analyzed 
how small differences in Ercc1 activity affected parameters of progeria 
and hematopoiesis (Chapter 3). Although Ercc1-/d as well as Ercc1d/d 
mice liver significantly longer than Ercc1 full knockout mice, they are still 
50% smaller than their wildtype littermates. They also displayed signs of 
polyploidy in the liver which indicates that they age prematurely, however 
liver polyploidy decreased when the level of Ercc1 activity increased. The 
fraction of stem cells (LSK; lin-, Sca+, cKit+ cells) in the total BM of 3 and 
10 week old Ercc1-deficient animals correlated to Ercc1 levels.  Within 
the LSK compartment we detected a shift towards the more primitive 
cells (LT-HSC & ST-HSC) at the expense of lower number of mulitpotent 
progenitors in all Ercc1 deficient animals, which is associated with the 
largely quiescent state of primitive stem cells and the actively cycling state 
of MPP. Within the progenitor compartment there is a dramatic decrease of 
myeloid progenitors while lymphoid progenitors are not affected. Although 
low levels of Ercc1 increased the numbers of progenitors, these cells still 
failed to form BFU-E or CFU-G. Only the number of CFU-GM was slightly 
enhanced in Ercc1d/d mice, but wt numbers were never reached.  The fact 
that a low Ercc1 dose prolongs the lifespan of Ercc1 deficient mice while 
hematopoiesis is still severely affected renders mice with a hypomorphic 
Ercc1 allele suitable as a leukemogenesis model. 
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Progeria due to suppression of the hormonal growth axes has been linked 
to sustained DNA damage and defective TC-NER. As we established that 
the hematopoietic defect is independent of progeria and NER (Chapter 
2), we next examined which tumor suppressor genes were responsible for 
BM aging (Chapter 4). Expression of both the p53 target genes Puma and 
Noxa, and the genes encoded by the Cdkn2a locus, p16Ink4A and p19Arf was 
increased in Ercc1 defi cient bone marrow cells compared to their wildtype 
littermates. Deletion of either the Trp53 or Cdkn2a locus in Ercc1-defi cient 
mice revealed that p53 but not p16 or p19 contribute to loss of the HSPC 
compartment upon defective ICL repair. Intriguingly, loss of p53 enhanced 
the proliferative capacity of hematopoietic progenitors, but aggravated 
segmental progeria and liver polyploidy in Ercc1-defi cient mice. Loss of 
p53 did not alter the primary molecular response to stalled replication 
forks, which is the formation of phosphorylated Histon2A foci, nor did it 
change the hypersensitivity of Ercc1 defi cient cells to the DNA crosslinker 
MMC. It only affected the survival of cells, which is expected to have major 
consequences for leukemogenesis.  Indeed, transplantation of BM lacking 
Ercc1 and heterozygous for Trp53 effi ciently induced  leukemia, whereas 
mice transplanted with Trp53+/- BM remained healthy, and Ercc1-/d BM was 
impaired in its engraftment capacity. 
The observation that defective ICL repair underlies BM failure in 
Ercc1 defi cient mice render these mice a good model for Fanconi 
Anemia (FA). Several genes can be mutated in FA and their transcribed 
proteins constitute the FA-pathway which is involved in DNA repair at 
stalled replication forks. A particular problem in FA is the anemia due 
to unresponsiveness to erythropoietin (Epo). It is controversial whether 
this is due to the underlying DNA repair defi ciency or an independent 
aspect of FA. We analyzed Epo signalling in erythroblasts derived from 
mice lacking FancA, FancG or Ercc1 (Chapter 5).  At atmospheric 
oxygen levels Fanca-/- and Fancg-/- erythroid progenitors are impaired 
in their expansion capacity and show impaired Epo-induced Stat5 and 
Erk1/2 phosphorylation. However SCF-induced signal transduction and 
Epo-induced phosphorylation of the Epo-receptor and Jak2 were not 
affected, suggesting that the signaling defect occurs distal of the Epo-
receptor/Jak2 complex. We also saw this defective signal transduction 
in wild type erythroid progenitors that were challenged with a sub 
lethal dose of the DNA crosslinkers Mitomycin C (MMC) and in Ercc1-/- 
erythroid progenitors . Thus, the signalling defect is not specifi c for cells 
lacking specifi c Fanconi proteins. Interestingly impaired Epo-induced 
Stat5 and Erk phosphorylation upon MMC treatment of erythroblasts 
was p53 dependent. Therefore, attenuated Epo signaling is caused by
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accumulating ICLs and may contribute to Epo-resistance in the anemic 
phase of FA. It suggests that an impaired response to cytokines, which 
is often seen in BM failure syndromes, may contribute to impaired 
progenitor proliferation, but it is a secondary event to the activation of 
p53 and seems to be part of a more general senescence program.
So far we identified p53 as a major player that restricts HSPC proliferation 
when DNA damage stalls replication (Chapters 4 and 5). Since activated 
p53, or its related pathways, limit transient amplification, we wondered 
which factors abrogate this function to restore the proliferative capacity 
of cells and how such factors contribute to leukemogenesis. Wnt factors 
enhance transient amplification and may alter the function of tumor 
suppressor pathways (Chapter 6). Erythroblasts express low levels of 
various Wnt factors. In these erythroblast cultures p53 limits the transient 
expansion capacity. We showed that p53 controls β-catenin stabilization. 
Our data suggests that p53 activation and Wnt signalling may act as 
antagonizing pathways that control progenitor expansion. 
Relevance of Ercc1 deficient mice as a model system for bone 
marrow failure and subsequent leukemogenesis
The aberrant function of transcription factors due to translocations of 
the encoding genes such as t(8:21) or t(15:17) usually lead to a block 
in differentiation and factor-independent proliferation of progenitors [8]. 
These types of leukemias respond well to genotoxic agents. In contrast, 
the response to cytotoxic therapy is much less in leukemias arising from 
congenital bone marrow failures caused by genotoxic lesions or genotoxic 
therapy related secondary leukemias. This can be explained by the fact 
that these particular leukemias arise from mutations in gatekeeper genes 
(tumor suppressors). Initially mutations in these genes cause stress 
induced premature senescence (SIPS), which has to be overcome by 
additional mutations before cancer can occur. These leukemias respond 
poorly to cytotoxic therapy, because therapy is based on activation the 
same tumor suppressor systems. 
Several hereditary cancer syndromes, among which Fanconi Anemia 
(FA), Seckel syndrome and Bloom syndrome, initially develop bone marrow 
failure which progresses towards leukemia over time. All of the mentioned 
diseases are defective in the recognition as well as the processing of 
replication dependent lesions such as interstrand crosslinks (ICLs) which 
are induced by Mitomycin C (MMC) and Cisplatin [9]. This situation is not 
the only one in which an aplastic bone marrow progresses into leukemia. 
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Similar events occur in secondary or therapy-related MDS (t-MDS) 
and AML (t-AML).  Drugs used to treat solid cancers (such as Cisplatin 
and Pol-II inhibitors) frequently cause t-MDS resulting in subsequent 
leukemia [10]. Tumor suppressor genes deregulated in these cases are 
usually CHK1 [11], CHK2 [12], p53 [13] and p16 [14].
Mice defi cient in FancC are used to model this subset of leukemias. 
Hematopoietic progenitors as well as hematopoietic stem cells isolated 
from these mice have impaired functionality in vitro and show an 
increased sensitivity to MMC [15-16]. Interestingly this is only the 
case in progenitors isolated from adult BM and not from juvenile BM, 
indicating a progressive hematopoietic defect. This is confi rmed by the 
fact that BM cells isolated from FancC defi cient mice have signifi cantly 
reduced multi-lineage repopulating ability in competitive transplantation 
assays (short as well as long term) [15, 17-18]. Transplanted mice 
display a MDS like phenotype.  However the overall primary phenotype 
of FancC defi cient mice is relatively mild and spontaneous leukemias 
are not observed. For studying the transition of BM failure to leukemia 
it would be of use to employ a model which does develop leukemias 
without using bone marrow transplantation settings.
To study the transition of BM failure to leukemia development we 
choose to utilize an Ercc1 defi cient mouse model. The Ercc1-Xpf 
heterodimer functions as an endonuclease in NER as well as ICL repair. 
Mice lacking this gene develop the characteristics of bone marrow 
failure (similar to FA) at a very young age (3 weeks postnatal) as well 
as signs of progeria [7]. However their overall phenotype is much more 
severe and therefore this model is more robust than the Fanconi mouse 
models. 
The balance between aging and cancer is tightly associated with the 
type of DNA damage that is encountered as well as the level of damage. 
Although DNA damage can be expected to impair cell growth in general, 
different DNA repair defi ciencies result in distinct phenotypes. As we 
showed in chapter 2 defective ICL repair in Ercc1 defi cient mice results 
mainly in a hematopoietic defect while the NER defect contributes to 
their aging phenotype. As is hypothesized in FA, the ICL load is of great 
importance for the development of an aplastic bone marrow. Since 
mice completely defective in Ercc1 show such a severe phenotype that 
they do not survive weaning, this model is not suitable for studying 
leukemogenic development. However mice that are hypomorph for Ercc1 
do survive for longer and show the potential to become leukemogenic. 
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This effect in the dosage of Ercc1 has been described in chapter 3 of this 
thesis. Although it is not unlikely that deficiencies in other repair genes 
can also lead to such differences in phenotype. This reduced activity of 
caretakers can result in a pre-leukemic environment in which additional 
hits can lead to the development of clonal cell populations which can 
uncontrollably proliferate.
Leukemia types derived from an aplastic bone marrow 
environment
The type of leukemia that mainly develops in FA patients is acute myeloid 
leukemia (AML), only very rarely acute lymphoid leukemia (ALL) develops 
[19]. This suggests that the main hematopoietic defect is localized in the 
myeloid compartment. Which is in line with our findings in chapters 2, 3 
and 4 where we show that in FACS  analysis of total BM the CMPs as well 
as the GMPs are affected (in numbers as well as functionality) by the loss 
of Ercc1 while the CLP compartment is not influenced.  
In mouse models for leukemia development, mainly ALL develops. 
For example, in mice lacking p53 mostly lymphoma’s are formed [20]. In 
our Ercc1-/dTrp53+/- transplantation model the recipient mice developed 
heterogeneous leukemia’s (Chapter 4). The mice suffered from increased 
spleen and liver but leukemic BM cells also carried lymphoid markers such 
as CD3e and CD19. Loss of 1 allele of Trp53  increases the likelihood 
that these cells will completely lose Trp53 expression due to a secondary 
mutation. However a complete loss of Trp53 functionality itself is not 
sufficient for leukemic development as we showed that erythroblasts 
deficient in both Ercc1 and Trp53 are still capable of H2AX phosphorylation 
upon ICL induction and are also still completely growth factor dependent 
in addition to unchanged proliferative capacity (Chapter 4). Therefore loss 
of Trp53 expression in an Ercc1 deficient background will only facilitate 
mutagenesis by abrogating the senescence response to DNA damage 
but will not immediately contribute to factor independent proliferation or a 
block of differentiation. However it is still unclear which of the downstream 
targets of Trp53 is critical for the regulation of the hematopoietic stem cell 
response to continuous ICL damage. Our model could prove useful to 
identify the different players and their regulatory pathways by using next 
generation sequencing approaches in the different stages of leukemic 
development.  By identifying key players this information may be used to 
develop novel strategies that could be widely applicable to cancers arising 
from a genotoxic background.
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Mechanism of Trp53 activation upon detection of ICLs
Bone marrow failure in FA patients has been specifi cally linked to 
the extreme sensitivity of bone marrow cells to oxidative damage [21]. 
Primary cells from FA patients are uniquely sensitive to oxidative stress 
induced DNA damage and the following p53 induced growth arrest [22]. 
Although p53 induced growth arrest prevents the outgrowth of cells 
that accumulated damaged DNA, it also leads to depletion of stem 
and progenitor cells and subsequent bone marrow failure. In a hypoxic 
environment Fanc defi cient cells proliferate much better, which may be 
caused by a decrease in culture specifi c oxidative damage. 
However, there is also a possibility that lower cell division rate plays 
a role. The specifi c signaling pathway activated upon ICL detection is 
Trp53 dependent. Upon replication fork stalling, increasing amounts 
of single stranded DNA are formed that bind ATRIP, resulting in the 
activation of ATR kinase [23]. This will lead to phosphorylation of H2AX 
and subsequent activation of downstream effectors such as Chk1, 
Brca1 and p38. Phosphorylation of p53 by p38 or Chk1 will stabilize the 
protein, whereas Brca1 acts as a scaffold for the recruitment of DNA 
repair enzymes  that can remove the crosslink by either homologous 
recombination or non-homologous end joining. The requirement for stalled 
replication forks was supported by experiments in which we exposed cells 
for increasing time intervals to MMC. Short exposure to MMC does not 
infl uence cell viability and signaling, however prolonged exposure (>16hr) 
or exposure to high dosages leads to increased phosphorylation of Chk1. 
The number of cells with phospho-Chk1 foci in the nucleus correlated to 
the number of cells expected to reach S-phase in the same time interval 
(J.Verhagen-Oldenampsen. unpublished). 
Recently it has been shown that spontaneous abrogation of the G2 
checkpoint in a subset of FA patients indeed promotes leukemogenesis 
[24]. These patients expressed only very low levels of Chk1 and p53 
thereby preventing p53 induced cell death. Due to this they displayed 
only mild bone marrow defi ciencies (near normal blood counts) and 
as a result reached adulthood. However, several patients developed 
myelodysplasia and/or leukemia thus it is likely that these abrogated 
cell subsets contribute to leukemogenesis by promoting cell survival in a 
genetic background of constitutive genetic instability.
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Figure 1: CHK1 expression and phosphorylation is heterogeneous  in primary 
human AMLs with a normal karyotype.  Primary AML samples were defrosted and 
cultured under proliferative conditions. Cells were exposed overnight to MMC and 
harvested the next day. Cell lysates were made and blots were stained with anti-
PChk1 and total Chk1.
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Role of other tumor suppressor genes in bone marrow failure 
and leukemogenesis
Chemotherapeutic drugs, such as MMC, activate multiple pathways in 
addition to p53-induced targets, such as p73 activation by CHK1/CHK2 and 
subsequent transactivation of PUMA [25]. Also MAPKs such as p38 and 
FOXO1 [26] couple DNA damage to caspase-3 activation. In p53 profi cient 
cells MMC induces an increase in p53 protein which leads to activation of p53 
regulated genes and apoptosis. Many cancer cells are p53 defi cient and rely 
on the ATR/CHK1 checkpoint. If CHK1 would become inactive (e.g. due to 
mutations) these cells would become more sensitive to caspase-2 mediated 
cell death. In a recent study on DNA damage signaling in AML it was found 
that high levels of DNA damage signaling were present (phosphorylation of 
H2AX and CHK1) in complex karyotype AML samples and that this is already 
the case early on in leukemogenesis [27].  Upon Inhibition of CHK1 in these 
AML samples the authors found that progenitors with high DNA damage 
loads were sensitized to AraC treatment while normal progenitors were 
unaffected. The same protective effect of CHK1 against DSBs was seen in 
BCR/ABL leukemia cells which were treated with DNA crosslinking agents 
[28]. Therefore it seems that the checkpoint kinases pose an interesting 
target for cancer therapy. 
In addition, CHK1 inactivation may also be a step in leukemogenesis. In 
preliminary experiments we examined MMC-induced CHK1 phosphorylation 
in AML samples with a normal karyotype (Figure 1). This showed that patients 
differed in their sensitivity for MMC induced CHK1 phosphorylation. In two 
out of six samples (B, E) MMC induced strong phosphorylation of CHK1. Two 
others showed weak phosphorylation of CHK1 (C, D), whereas in two others 
MMC failed to induce any pCHK1 (A, F). Analysis of total CHK1 levels revealed 
that CHK1 was not expressed in sample A, whereas in sample F levels 
were normal, indicating that the upstream phosphorylation mechanism was 
abrogated. This shows that there is a high degree of heterozygosity between 
patients in their DNA damage response, and thus individual treatment regimes 
are of high importance. 
p19Arf (p14ARF in humans) and p16INK4a are both encoded by the Ink4a/
Cdkn2A locus [29]. p16INK4a impacts on the Rb pathway [30] while p19Arf targets 
the p53 tumor suppressor pathway [31]. This interaction is indirectly due to its 
interaction with Mdm2. As we showed in chapter 4, loss of the Cdkn2a locus 
did not affect the phenotype of Ercc1 defi cient mice, since deletion of this gene 
did not improve their severe hematopoietic phenotype. Interestingly, this also 
implies that p19Arf is dispensable for p53 activity in the BM of Ercc1/d mice. 
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Loss of both p16INK4a and p19Arf has little effect on HSC function since there is 
only a very subtle increase in serial repopulating ability [32]. In freshly isolated 
BM cells p19Arf is not expressed but it is induced during culture. The induction 
of p19Arf during culture impairs the formation of very early CFU-S colonies [32]. 
However in MEFs deletion of both proteins did effect proliferation capacity 
(Chapter 4), suggesting that the function of p16INK4a/p19Arf is cell type and 
tissue specific. 
p38 MAP kinases respond to a variety of cellular stress stimuli, including 
UV radiation and hypoxia [33]. They are also involved in developmental 
hematopoiesis. Mice lacking p38α are embryonic lethal because they have 
defects in placental angiogenesis and p38 inactivity is linked to a decrease 
in Epo gene expression [34-35]. In FancC deficient MEFs and progenitors, 
p38 inhibition has been shown to ameliorate apoptotic responses [36] and 
recently it was shown that p38 inhibitors improve multi lineage repopulating 
ability of FancC deficient HSCs [37]. There is a link between Cisplatin induced 
DNA damage (interstrand crosslinks) and p38 activation, NER defective 
mutants show higher levels of JNK and p38 activation compared to repair 
proficient cells [38].  Activation of p38 results in phosphorylation of human 
p53 on Ser33 and Ser46 after UV radiation [39], and on Ser15 and Ser392 
following DSB [40]). This phosphorylation leads to dissociation of p53 from 
MDM2 resulting in accumulation of p53 protein. In primary human erythroid 
progenitors the p38α  isoform is involved in induction of differentiation but 
not in apoptosis or cell proliferation [41]. We tested whether inhibition of p38 
could enhance transient proliferation of Ercc1-deficient erythroblasts. The p38 
inhibitor SB203580 indeed completely rescued the abrogated proliferation of 
Ercc1-deficient erythroblasts, however this was not specific for loss of Ercc1. 
In primary mouse erythroblasts we saw that inhibition of p38 by SB203580 
alleviated the spontaneous differentiation of wt cells as well, and induced 
extended proliferation similar to loss of Trp53. Thus p38 and p53 seem to 
function in the same pathway in erythroid cultures (Preliminary data, Figure 2). 
Role of Wnt signalling in hematopoiesis and leukemogenesis
Wnt signal transduction is very important for maintaining the balance between 
proliferation and differentiation throughout embryogenesis as well as postnatal 
life [42-43]. Its role in stem cell maintenance is especially well characterized 
and as such it can be regarded as antagonistic pathway of gatekeepers, since 
this pathway stimulates longevity of stem cells and increases the number of 
progenitor cells at the increased risk of tumor development. Enhanced Wnt 
signaling has been associated with may cancer types such as colon cancer 
[44], breast cancer [45], melanoma [46] as well as leukemia [47]. 
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Figure 2: p38 inhibitor prolongs proliferation of primary erythroblasts irrespective 
of their genotype. Primary erythroblasts were cultured under renewal conditions 
and counted daily. Dotted lines indicate addition of p38 inhibitor SB203580.
Under genotoxic stress conditions p53 is activated and a pathway for 
β-catenin degradation is initiated. p53 can directly induce Siah-1 expression 
and in turn formation of a unique SCF-like complex (SCF(TBL1)) consisting 
of Siah-1, Siah-1 interacting protein (SIP), SKP1, transducinβ-like1 
(TBL1) and APC [48-49]. Siah-1 (as a critical protein in this pathway) can 
effi ciently deplete β-catenin, thereby downregulating transcription of  Wnt 
target genes. In addition, Siah-1 also functions as an E3 ligase which is 
able to directly bind and poly-ubiquitinate β-catenin in vitro, although this 
interaction is very weak [50]. p53 overexpression induces transcriptional 
activation of Siah-1 genes in a variety of mammalian cell lines [51-53] and 
overexpression of Siah-1 can mimic the effects of p53 activation by inducing 
cell cycle arrest or apoptosis [54]. Following DNA damage, the p53 mediated 
induction of Siah-1 induces degradation of β-catenin independently of the 
GSK3β mediated pathway.  Since overexpression of β-catenin promotes 
cell cycle progression and inhibits cell cycle arrest induced by gamma 
irradiation [55], Siah-1 mediated β-catenin degradation may contribute to 
p53 dependent cell cycle arrest. Interestingly, accumulation of a β-catenin 
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mutant protein that is resistant to degradation by the GSK3β pathway induces 
activation of p53 [56]. Since overexpression of Siah-1 can induce degradation 
of wildtype or mutant forms of β-catenin, Siah-1 may function downstream of 
p53 in a pathway that senses and degrades oncogenic β-catenin and thereby 
contributes to tumor suppression.
The Wnt/β-catenin pathway is active in certain types of leukemia [57-60] 
as well as in normal HSCs [61-62]. The group of Zhao et al has shown that 
different β-catenin levels lead to varying effects in a BCR-ABL model of 
leukemogenesis [63] . Using conditional β-catenin deficient mice they showed 
that loss of β-catenin expression from the hematopoietic system decreased 
the incidence of CML. Interestingly they could rescue this phenotype by 
ectopically expressing low levels of β-catenin whereas high levels of β-catenin 
had adverse effects on leukemogenesis. This shows that the level of β-catenin 
expression as well as the activation status is of utmost importance for either its 
pro- or anti tumorigenic function. To date no β-catenin mutations are reported 
in AML or CML however via other ways it is still possible that deregulation 
of the Wnt/β-catenin pathway is involved in leukemogenesis. For example, 
increased FLT3 signaling (due to mutations or amplification) can lead to AKT 
mediated phosphorylation (and thus inactivation) of GSK3β. This will lead to 
stabilization of β-catenin and thus to increased Wnt signaling [64]. Certain 
Flt3 mutations lead to an increase in Frizzled-4 expression and also increase 
β-catenin signaling [65]. Translocation products such as AML-ETO and PLZF-
RARα can activate the Wnt/ β-catenin pathway by activating plakoglobins 
[66]. And lastly it is reported that abnormal promoter hypermethylation of Wnt 
inhibitors (such as DKK3) can enhance Wnt/ β-catenin signaling in ALL and 
AML [67-68]. 
Many different types of animal models have been developed for the 
Wnt signaling pathway. However many conventional knockout mice were 
embryonic lethal and thus studying the exact role of the Wnt factors was only 
possible since the development of conditional mouse models (using cre-lox 
technology). Today, mouse models are available for almost all Wnt genes and 
many of them are well characterized (for a list of their phenotypes see the Wnt 
homepage [69]). 
Erythroid progenitors isolated from wt mouse fetal livers can undergo a limited 
number of renewal divisions while Trp53 deficient erythroblasts can undergo 
indefinite renewal divisions without increased differentiation. We observed 
that Trp53 deficient erythroblasts display high levels of nuclear β-catenin while 
wt erythroblasts only express very low levels (Chapter 6). In Ercc1 deficient 
cultures we also found very low to absent levels of β-catenin which is interesting 
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since these cells show increased spontaneous differentiation compared to wt 
cells. It would be interesting to see if it is possible to alleviate the amount of 
spontaneous differentiation in Ercc1 defi cient erythroblast by introducing Wnt 
factors into the culture. For this purpose we aimed to transduce Ercc1 defi cient 
erythroblasts with a bi-cistronic retroviral vector harboring either Wnt3a or 
Wnt5a. While this process was successful in wt erythroblast (Chapter 6) we 
were unable to transduce Ercc1 defi cient erythroblast using this method. 
Probably these cells are already so fragile by their inability to repair damage 
that the process of transduction inevitably induces apoptosis in these cells. 
To circumvent this problem we decided to generate a conditional mouse 
model in which we are able to selectively choose when and where we activate 
the Wnt signaling pathway. Oocytes were injected with the pE/I vector carrying 
fl oxed eGFP in front of a Wnt5a-HA sequence, all under the control of the 
β-actin promoter. Without cre recombinase expression only eGFP will be 
expressed while in the presence of cre expression eGFP will be fl oxed out and 
WNT5a-HA will be expressed (see Figure 3 for a schematic representation 
and functionality tests). By using cre recombinase expressed under different 
promoters it is possible to regulate the place and timeframe of Wnt5a-HA 
expression. First we crossed the transgenic Wnt5a-HA mice with mice 
which expressed cre recombinase from the Cag locus [70]. This is a general 
germline promoter and Wnt5a-HA is expected to be expressed early on in 
all tissues. Using this technique 25% of the offspring is expected to carry the 
transgene, unfortunately only 2 viable pups harboring the vector were born 
out of 47 pups in total (4%).  Analysis of these mice indicated that there was 
no expression of Wnt5a-HA. It seems very likely that the cre recombinase 
expressed from the Cag locus is to abundant which leads to embryonic lethality 
of the embryos carrying the transgene. As a second approach we crossed the 
transgenic Wnt5a-HA mice with a cre recombinase expressed specifi cally in 
the hematopoietic system (C/EBPα-cre). C/EBPα is expressed in a signifi cant 
subset of multipotent hematopoietic progenitors which predominantly give rise 
to the myeloid lineage during steady state hematopoiesis [71]. In this setting 
the C/EBPα cre mice were crossed with YFP mice so that progeny of the 
cells which expressed cre is easy to trace using fl ow cytometry. Pups were 
born in the mendelian frequency, yet pups carrying the transgene showed 
no hematopoietic phenotype and no Wnt5a expression. Further work will be 
necessary to determine why no effect of Wnt5a expression is seen. Possibly the 
Wnt5a-HA transgene is non-functional or autocrine expression of Wnt5a has 
no effect on steady state hematopoiesis. Further research will be necessary to 
determine what the exact reason is, currently TOP/FOP reporter vectors are 
being used to transduce stroma cell lines on which C/EBPα-cre YFP+ Wnt5a-
HA cells can be plated to determine the YFP expression in stroma cells. 
Judith Proefschrift.indb   173 27-12-2012   16:34:07
Chapter 7174
Figure 3: Wnt5a-HA transgenic construct and testing in vitro and in vivo. (a) 
Schematic representation of the construct used for oocyte injections. (b) In vitro 
testing of the construct used for oocyte injection. Transient transfection of HELA cells 
with the pE/I-Wnt5a-HA construct with or without the addition of cre recombinase. 
(C) In vivo testing of construct activity. Bone marrow was harvested from two 
founder animals. Cells were cultured under erythroblast renewal conditions with or 
without the addition of Tat-Cre.
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Gedurende het hele leven van een organisme wordt het DNA blootgesteld 
aan condities die nucleotiden modificeren of de DNA strengen breken. 
Deze DNA schade veroorzaakt veroudering op het niveau van cellen en 
weefsels maar ook in het gehele organisme. Incorrect of foutief DNA herstel 
veroorzaakt mutaties welke kunnen leiden tot kanker. Het is daarom niet 
verbazend dat de incidentie van kanker toeneemt in oudere individuen. 
Er is al veel bekend over syndromen die gerelateerd zijn aan gebrekkig 
DNA schade herstel, er is echter weinig bekend over waarom bepaalde 
specifieke DNA schade herstel gebreken leiden tot specifieke fenotypes. 
Het DNA schade herstel netwerk bestaat uit een complex netwerk van 
eiwitten welke verantwoordelijk zijn voor herkenning van schade, signaal 
transductie, regulatie van de celcyclus en DNA herstel. Dit complexe 
netwerk zorgt voor een strikte balans tussen veroudering van het organisme 
en het ontstaan van kanker.
De cellen in ons bloed hebben een relatief korte overlevingstijd, 
om het aantal bloedcellen constant te houden is er een doorlopende 
productie van nieuwe cellen nodig vanuit de hematopoietische stam- en 
voorlopercellen (HSPCs) in het beenmerg. Door deze hoge delingsgraad 
is het hematopoietisch systeem zeer gevoelig voor geneesmiddelen die 
het DNA beschadigen. Cytotoxische anti kanker geneesmiddelen die 
veelvuldig gebruikt worden voor diverse soorten kanker hebben meerdere 
schadelijke neveneffecten op de hematopoiese. Het langdurig behandelen 
met een hoge dosering alkylerende middelen (bijv. cyclofosfamide gebruikt 
bij o.a. borstkanker behandeling) kan leiden tot een toenemende depletie 
van HSPCs met beenmerg hypoplasie als gevolg. Door deze hypoplasie 
kunnen de overgebleven HSPCs aangezet worden tot deling terwijl de 
mutaties, ontstaan door DNA schade in deze cellen, kunnen leiden tot een 
verhoogd risico op het ontstaan van leukemie.
De experimenten beschreven in dit proefschrift hadden tot doel de 
moleculaire mechanismen van beenmergfalen en de hierop volgende 
leukemogenese, zoals klinisch waargenomen in syndromen met een falend 
beenmerg door veroudering of aanhoudende DNA schade te identificeren. 
Voor deze experimenten hebben we muizen gebruikt die deficiënt zijn voor 
Ercc1. Ercc1 is een endonuclease betrokken bij de excisie van nucleotiden 
tijdens globaal en transcriptie gekoppeld nucleotide excisie herstel (NER) 
alsmede bij de excisie van crosslinks (ICL) tussen de twee DNA strengen 
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bij een replicatievork. Voorgaande studies hebben laten zien dat het 
aantal hematopoietische stamcellen in het beenmerg van Ercc1 deficiënte 
muizen verlaagd is, en dat de voorloper cellen verminderd in staat waren 
om kolonies te produceren.
In deze studie hebben we eerst bekeken of de ernstige veroudering 
(progeria) van de gehele muis, welke geassocieerd is met een verminderde 
NER functie, bijdraagt aan hun beenmergfalen of dat dit specifiek 
gerelateerd is aan een verminderde ICL reparatie op de replicatievork 
(hoofdstuk 2). Uit een vergelijking van Ercc1-/- muizen met Xpa-/-Csb-/- 
muizen, welke een geheel gebrek aan NER hebben maar wel functioneel 
zijn voor ICL reparatie, bleek dat de ernstige progeria in Ercc1-/- muizen 
niet bijdraagt aan het verouderen van het beenmerg compartiment. De 
alternatieve verklaring, dat HSPCs vooral gevoelig zijn voor defecten in 
ICL reparatie werd ondersteund door het feit dat de “quiescent” stamcellen 
van de HSPC populatie relatief gezien minder aangedaan waren zodra 
de muizen volwassen waren. Zowel conditionele knock out muizen als 
hematopoietische repopulatie studies waarin Ercc1 deficiënt beenmerg 
werd getransplanteerd in bestraalde ontvangers wezen uit dat er een 
progressief verlies is van Ercc1 deficiënte cellen. Dit is in overeenstemming 
met de hypothese dat proliferatie nadelig is voor cellen met een verminderde 
DNA reparatie capaciteit.
Lange termijn hematopoiese kon niet onderzocht worden in Ercc1 
muizen doordat ze drie weken na de geboorte overlijden. Muizen met één 
“hypomorph” allel (Ercc1-/d) leven ongeveer 20 weken en muizen met twee 
“hypomorph” allelen (Ercc1d/d) leven gemiddeld langer dan 6 maanden. 
Dit verschil in overlevingstijd moet bijna wel komen door een doserings 
effect van hun resterende Ercc1 activiteit. Daarom hebben we vervolgens 
onderzocht hoe kleine verschillen in Ercc1 activiteit parameters van progeria 
en hematopoiese beïnvloedden (hoofdstuk 3). Alhoewel zowel Ercc1-/d als 
Ercc1d/d muizen beide significant langer leven dan volledige Ercc1 knockout 
muizen zijn ze nog steeds 50% kleiner dan hun wildtype nestgenoten. 
Ze vertonen ook tekenen van polyploïdie in de lever wat aangeeft dat 
ze vroegtijdig verouderen. Echter de mate van polyploïdie nam af als de 
mate van Ercc1 activiteit toenam. LSK aantallen namen toe in het totale 
beenmerg van jonge dieren (3 en 10 weken oud) terwijl er geen verschil 
was in meer volwassen dieren van 20 weken oud. Hoogstwaarschijnlijk 
komt dit doordat er op 20 weken minder proliferatie plaatsvindt en derhalve 
er dus minder DNA schade opgelopen wordt welke gerepareerd moet 
worden. Binnen het LSK compartiment was er een verschuiving in het 
voordeel van de meer primitieve cellen (LT-HSC & ST-HSC) ten koste van 
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een lager aantal multipotente voorloper cellen. Deze verschuiving was 
zichtbaar in alle Ercc1 deficiënte dieren en wordt geassocieerd met de 
voornamelijk “quiescent” status van primitieve stamcellen en de actieve 
delingsstatus van multipotente voorlopercellen. Binnen het voorlopercel 
compartiment is er een drastische afname van myeloïde voorlopers terwijl 
er geen effect is op de lymfoïde voorlopers. Alhoewel een laag niveau van 
Ercc1 het aantal voorlopers verhoogde waren deze cellen nog steeds niet 
in staat om BFU-E of CFU-G te vormen. Alleen het aantal CFU-GM was 
licht toegenomen in Ercc1d/d muizen maar wildtype aantallen werden nooit 
bereikt. Deze resultaten wijzen erop dat het niveau van Ercc1 voornamelijk 
het verouderings fenotype van de Ercc1 deficiënte muizen verbeterd terwijl 
het hematopoietische fenotype niet veranderd is. 
Progeria veroorzaakt door onderdrukking van de hormonale groei-
as is gekoppeld aan aanhoudende DNA schade en niet werkende 
TC-NER. Omdat we vastgesteld hadden dat het hematopoietisch defect 
onafhankelijk was van progeria en NER (hoofdstuk 2) zijn we vervolgens 
gaan bekijken welke tumor suppressor genen verantwoordelijk zijn voor 
beenmerg veroudering (hoofdstuk 4). De expressie van de p53 target 
genen Puma en Noxa, en de genen liggend op het Cdkn2a locus, p16Ink4A 
en p19Arf was verhoogd in Ercc1-deficiënte beenmergcellen ten opzichte 
van wildtype cellen. Deletie van de Trp53 of de Cdkn2a locus in Ercc1 
deficiënte muizen bracht aan het licht dat p53 maar niet p16 of p19 
bijdroeg aan de afname van het HSPC compartiment door gebrekkige ICL 
reparatie. Fascinerend genoeg bleek dat verlies van p53 de proliferatie 
capaciteit van hematopoietische voorlopers verhoogde, maar dat het de 
segmentale progeria en lever polyploïdie in Ercc1 deficiënte muizen werd 
verergerd.  De primaire moleculaire response op vastgelopen replicatie 
vorken, gemarkeerd door de formatie van gefosforyleerde histon2A foci, 
en de extreme gevoeligheid van Ercc1 deficiënte cellen voor de DNA 
crosslinker MMC werden niet beïnvloed door het verlies van p53. Alleen de 
overleving van cellen werd beïnvloed, wat naar alle waarschijnlijkheid grote 
consequenties heeft voor leukemogenese. En inderdaad, transplantatie 
van Ercc1 deficiënt, p53 heterozygoot beenmerg zorgde efficiënt voor 
leukemie ontwikkeling terwijl de muizen die getransplanteerd werden 
met Trp53+/- beenmerg volledig gezond bleven en Ercc1-/d beenmerg een 
verminderde repopulatie capaciteit liet zien. 
De observatie dat gebrekkige ICL  reparatie de onderliggende oorzaak 
is van beenmergfalen in Ercc1 deficiënte muizen maken deze muizen 
zeer geschikt als model voor Fanconi Anemie (FA). Meerdere genen 
kunnen gemuteerd zijn in FA en hun bijbehorende eiwitten vormen de 
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FA-signaaltransductie route welke betrokken is bij DNA reparatie op 
vastgelopen replicatie vorken. Een veel voorkomend probleem in FA is 
anemie veroorzaakt door ongevoeligheid voor erythropoïetine (Epo). 
We hebben Epo signalering onderzocht in erythroblasten geïsoleerd uit 
muizen die deficiënt zijn voor FancA, FancG of Ercc1 (hoofdstuk 5). 
Bij atmosferische zuurstof niveaus zijn Fanca-/- en Fancg-/- erythroïde 
voorloper cellen verminderd in staat om te prolifereren en hebben ze een 
verminderde Epo-geïnduceerde Stat5 en Erk1/2 fosforylatie. De SCF 
geïnduceerde signaal transductie en Epo geïnduceerde fosforylatie van 
de Epo-receptor en Jak2 waren niet beïnvloed wat suggereert dat het 
signalerings defect zich distaal van het Epo-receptor/Jak2 complex bevindt. 
Hetzelfde defect werd gezien in wildtype erythroïde voorlopercellen die 
blootgesteld waren aan een subletale dosis van de DNA crosslinkers 
Mitomycin C (MMC) of Cyto-arabinoside (AraC). In Ercc1-/- erythroïde 
voorlopercellen, die in dezelfde DNA reparatie route werken, zagen we 
hetzelfde effect. Wat interessant is, is dat we ontdekten dat dit signalerings 
defect p53 afhankelijk was. Hierdoor is het mogelijk zo dat aanhoudende 
Epo signalering veroorzaakt door ophopende ICLs kan bijdragen aan Epo 
resistentie in de anemische fase van FA. Dus een verminderde respons op 
cytokines, wat vaak gezien wordt in syndromen met  beenmergfalen, kan 
mogelijk bijdragen aan verminderde voorlopercel proliferatie, maar is een 
secundaire gebeurtenis na de activatie van p53 dat deel lijkt te zijn van een 
meer algemeen “senescence” programma.
Tot nu toe hebben we p53 geïdentificeerd als een belangrijke speler 
welke HSPC proliferatie beperkt wanneer DNA schade de replicatie stillegt 
(hoofdstuk 5). Omdat geactiveerd p53, of de gerelateerde signalerings 
routes, kortdurende deling begrenst vroegen we ons af welke factoren 
deze functie van p53 kunnen opheffen om zo de proliferatie capaciteit 
van cellen te herstellen en hoe dit soort factoren kunnen bijdragen aan 
het ontstaan van leukemie. Wnt factoren versterken kortdurende deling 
en kunnen mogelijk de functie van tumor suppressor routes beïnvloeden 
en veranderen (hoofdstuk 6). Erythroblasten hebben zeer lage expressie 
niveaus van Wnt factoren. In erythroblast kweken begrenst p53 de 
kortdurende expansie capaciteit. We laten zien dat p53 de stabilisatie 
van β-catenin reguleert. Onze data suggereert dat p53 activatie en Wnt 
signalering antagonistisch kunnen werken om voorlopercel expansie te 
reguleren.
Nederandse samenvat t ing
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abbreViations
AA Aplastic Anemia 
ALL Acute Lymphoid Leukemia
AML Acute Myeloid Leukemia 
APC Adenomatous Polyposis Coli 
A-T Ataxia Telangiectasia 
ATF2 Activating Transcription Factor 2
A-T-LD Ataxia Telangiectasia Like Disorder
ATM Ataxia Telangiectasia Mutated 
ATR Ataxia Telangiectasia and Rad3 Related
ATRIP ATR Interacting Protein 
B-ALL B-lineage Acute Lymphoblastic Leukemia
BER Base Exchange Repair
BFU-E Erythroid Burst-Forming Units
BioEpo Biotinylated Erythropoetin
BM Bone Marrow 
Brca1 Breast Cancer 1
Brca2 Breast Cancer 2
BS Bloom Syndrome 
BSA Bovine Serum Albumin
C/EPB CCAAT/Enhancer Binding Protein
CDK4 Cyclin D1-Cyclin-Dependent Kinase 4
Cdkn2a Cyclin-Dependent Kinase Inhibitor 2A
cDNA Complementary DNA
CFU-G Granulocytic Colony Forming Unit 
CFU-GM Granulocyte-Macrophage Colony Forming Unit
Chk1 Checkpoint Kinase 1
Chk2  Checkpoint Kinase 2
CLL Chronic Lymphatic Leukemia
CLP Common Lymphoid Progenitor
CML Chronic Myeloid Leukemia
CMP Common Myeloid Progenitor
CPD Cyclobutane Pyrimidine Dimers 
CS Cockayne Syndrome 
CSF3R Colony Stimulating Factor 3 Receptor
DAPI 4’,6-Diamidino-2-Phenylindole
DBA Diamond-Blackfan Anemia 
DC Dyskeratosis Congenita 
DDR DNA Damage Response 
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Dex Dexamethasone
DNA Deoxyribonucleic Acid
DSB Double Strand Break 
dsDNA double strand DNA
Dsh Dishevelled 
DTT Dithiothreitol 
EMSA Electrophoretic Mobility Shift Assays 
Epo Erythropoetin
EpoR Erythropoetin receptor
Ercc1  Excision Repair Cross Complementing-group 1 
Erk1/2 Extracellular Signal-Regulated Kinase 1/2
ESEP Embryonic Stem Cell Derived Erythroid Progenitor
FA Fanconi Anemia 
FCS Fetal Calf Serum
FL Fetal Livers
Fz Frizzled
G-CSF  Granulocyte Colony-Stimulating Factor
GG-NER Global Genome NER 
GH Growth Hormone 
GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor
GMP Granulocyte-Monocyte Progenitors
GTP Guanosine Triphosphate
H2AX Histon 2AX 
HR Homologous Recombination
HSC Hematopoietic Stem Cell
HSPC Hematopoietic Stem- and Progenitor Cell
ICL Interstrand Crosslinks 
IGF-1 Insuline-Like Growth Factor
IgG Immunoglobuline G
IP Immune-Precipitated 
IR Ionizing Radiation 
Jak2 Janus Kinase 2
Km Kremen
LEF Lymphocyte Enhancer Factor
LMPP Lymphoid Primed Multi-Potent Progenitor
LRP Low Density Lipoprotein Receptor-related Protein
LSC Leukemic Stem Cells
LSK (Lin-)Sca1+cKit+
LT-HSC Long Term Repopulating Stem Cell
MDM2 Mouse Double Minutes 2 
Abbrev iat ioons
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MDS Myelodysplastic Syndrome 
MEF Mouse Embryo Fibroblasts
MEP Megakaryocyte–Erythroid Progenitor
miRNA microRNA 
MLL Mixed Lineage Leukemia
MMC Mitomycin C
MMR Mismatch Repair
MPP Multi-Potent Progenitor Cell
mRNA messenger RNA
NBS Nijmegen Breakage Syndrome 
NER Nucleotide Excision Repair
NHEJ Non-Homologous End-Joining
PBS Phosphate Buffered Saline
PCNA Proliferating Cell Nuclear Antigen
PCP Planar Cell Polarity pathway
PCR Polymerase Chain Reaction
PI Propidium Iodide
Q-PCR Quantitative Polymerase Chain Reaction
Rb Retinoblastoma
RBC Red Blood Cell
RNA  Ribonucleic Acid
RNAi RNA interference 
ROS Reactive Oxygen Species 
RPA Replication Protein A
RT-PCR Real Time PCR
SCF Stem Cell Factor
SCN Severe Congenital Neutropenia 
SDS Shwachmann-Diamond Syndrome 
SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel
 Electrophoresis
SEM Standard Error of Mean
shRNA  short hairpin RNA
Siah-1 Seven-In-Absentia homologue-1
SIP Siah-1-Interacting Protein
SIPS Stress Induced Premature Senescence
siRNA small interfering RNA
SSB Single Strand Breaks 
ssDNA single stranded DNA 
Stat5 Signal transducer and activator of transcription 5
ST-HSC Short Term Repopulating Stem Cell
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T-ALL T-lineage Acute Lymphoblastic Leukemia
tAML therapy related AML
TCF T-Cell Factor
TC-NER Transcription Coupled NER 
tMDS therapy related Myelodysplastic Syndrome 
TSG Tumor Suppressor Genes 
TTD Trichothiodystrophy 
UV Ultraviolet 
WBC White Blood Cell
WCL Whole Cell Lysates
WT Wildtype
XP Xeroderma Pigmentosum 
γH2AX  phosphorylated Histon 2AX 
Abbrev iat ioons
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dankwoord
Eindelijk is het dan zover! Na 7,5 jaar is hier dan toch eindelijk het 
laatste hoofdstuk aangebroken dat geschreven mag worden voor mijn 
proefschrift. De voltooiing van 4,5 jaar onderzoek binnen de afdeling 
hematologie van het Erasmus MC en nog bijna 3 jaar van bikkelen, hopen, 
vrezen en doorzetten. Het moge duidelijk zijn dat dit resultaat niet behaald 
was zonder de hulp van vele anderen. Graag wil ik enkele mensen in het 
bijzonder bedanken voor hun bijdrage aan dit proefschrift.
Als eerste mijn promotor ivo touw. Ondanks dat we niet altijd op één lijn 
zaten heb je altijd geprobeerd om het grote plaatje in de gaten te houden 
zodat er uiteindelijk toch een mooi proefschrift tevoorschijn is gekomen. 
Lieve marieke, de “moeder” van de Von Lindern groep. Bedankt dat 
je mij de mogelijkheid hebt geboden om onderzoek te doen in jouw 
onderzoeksgroep. Jouw tomeloze enthousiasme is iets waar weinig 
mensen onaangeraakt door blijven. Van jou heb ik geleerd hoe ik om 
moest gaan met vele lastige situaties die zich voordoen in de wondere 
wereld van de wetenschap. Verder wil ik je bedanken voor alle inzet en 
motivatie die je me nog hebt gegeven nadat we beiden de hematologie 
afdeling verlaten hadden. Menig weekend heb ik aan jouw eetkamertafel 
gezeten om artikelen en hoofdstukken te herschrijven. Heel veel succes 
bij Sanquin! Ik wil ook freek bedanken voor de uitermate goede catering 
tijdens deze weekenden en voor alle biologie lessen en mooie verhalen die 
ik tussen het schrijven door heb mogen aanhoren. 
Ook wil ik dr. wim Vermeulen, dr. erik wiemer en prof. dr. ellen van 
der schoot, de leden van de kleine commissie, bedanken voor het kritisch 
doorlezen van dit proefschrift. Prof. dr. elaine dzierzak thank you for 
being an opponent in my committee. Prof. dr. Jan hoeijmakers en prof. 
dr. ruud delwel bedankt voor het als opponent plaatsnemen in de grote 
commissie.
Lieve Jurjen, jij was de eerste die ik leerde kennen toen ik binnenwandelde 
op de afdeling. Samen hebben we 4 jaar lang de afdeling onveilig gemaakt, 
menig persoon heeft er zich dood aan geërgerd maar wij hadden de 
grootste lol. Onze uitgebreide lunches staan nog in mijn geheugen gegrift. 
En hoe het lot het heeft gedaan snappen we nog steeds niet, maar indirect 
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werken we toch weer vaak samen, ook al gaat het ditmaal om hele andere 
zaken dan cellen. Ik hoop dat we in de toekomst nog vele weekenden naar 
het puntje van Nederland zullen reizen om onze kids met elkaar te laten 
spelen. marijke, ook jij bedankt voor de vele gezellige weekenden en je 
positieve inslag!
Mijn rechterhand paulette kan ook niet zomaar vergeten worden. Vele 
uren hebben we beneden in de stallen doorgebracht bij onze piepers 
(waarvan minimaal 1 uur dweilend met Calinda over de vloer om houdini 
muizen te vangen). En minstens zoveel uren hebben we gekluisterd gezeten 
aan de flow en FACS. Zonder jouw hulp was er nooit een eind gekomen 
aan de enorme hoeveelheid experimenten die er gedaan moesten worden. 
En ook in de afgelopen jaren zagen we elkaar nog regelmatig onder het 
genot van een witte chocolademelk en grote bak koffie om weer even alle 
roddels door te nemen. Ontzettend bedankt voor al jouw inzet! Ik ben blij 
dat je vandaag mijn paranimf wilt zijn!
En dan mijn bijna derde paranimf! Helaas op het laatste moment 
gesneuveld door administratieve tegenwerking maar dat mag de pret niet 
drukken toch? Ook al heb je maar 1 keer voet gezet in het lab (wat een 
uitzicht voor de Red Bull air race), deze dag kan niet voorbij gaan zonder 
dat jij erbij bent lieve arian. Mijn maatje door dik en dun. Ontelbare films 
zijn al door ons bekritiseerd en kilo’s m&m’s zijn daarbij verorberd. Hopelijk 
zullen er nog vele bioscoop avonden volgen. Ik wens je heel veel geluk 
met Malika!
En natuurlijk werd er niet alleen maar hard gewerkt op het lab. Vele 
feestjes hebben er plaatsgevonden; filmavonden, bowlen, stapavonden 
en etentjes. Ook de koffie was een vaste prik ‘s middags. Vele gesprekken 
(zowel wetenschappelijk als onzinnig) hebben plaatsgevonden onder 
het genot van een heavenly hazel. irene, Joyce, menno, merel, onno, 
marijke, simone, su ming, natalie, annelieke, iris, Judith, fatima, eva, 
Marieke B., tamara, kim, Janine, mahban, arthuro, lucilla, karishma, 
saman, goran, marije, renée, andrzej, rasti, Jasper, martijn, sophie, 
Yvonne en tanja bedankt voor alle gezelligheid op het lab.
Beste Jurgen, halverwege mijn promotietraject kwam jij het Ercc1 team 
versterken. Ik heb ontzettend veel van je geleerd, onder andere hoe je 
een FACS Aria moet temmen en hoe je het beste Madonna mee kan 
zingen terwijl je op een belachelijk laat tijdstip nog aan het FACSen bent. 
Dankzij jouw inzet zijn er nog bergen mooie data ontstaan die we konden 
publiceren. Heel veel succes in het mooie Groningen/Amsterdam!
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Beste anne ook buiten het lab konden wij het prima vinden. Vele avonden 
buiten bij de bbq, filmpjes op de bank en later kinderboerderij bezoekjes 
met onze ukken. Ik ben blij dat we elkaar nog steeds zien en ik hoop dat we 
met z’n allen nog vele gezellige middagen/avonden gaan hebben.
Verder wil ik (nogmaals) alle Von Lindern/Touw mensen bedanken voor 
hun hulp en alle gezelligheid in onze straatjes: godfrey (Good Morning!), 
hanna, Jurjen (Homie!), andrzej (Ohhh no!), rasti (Weekend breaks? No 
way! Cell culture rules!), marleen, astrid, bart, mahban, Judith (zonder 
jou was er geen JO!), Jurgen (hoeveel minuten moeten we nog in die 
koude kelder staan??), albert, renée, tanja (Queen of the microscope), 
arthuro, karishma (heavenly cooking!), onno (Gronings proefkonijn), 
marijke (bij de ster naar links (of was het nou rechts?), sylvana (chiquita), 
stefan (hebbie haar ook weer) en paulette (bedankt voor de tip “ik zou dat 
voorlopig maar niet meer aan doen als ik jou was”!).
ans, monique, Cevilay en Jan zonder jullie inzet zou de afdeling niet 
hetzelfde zijn. Jan, de beeldende foto’s van je weekend activiteiten staan 
me nog steeds bij (de bijbehorende smaak was toch beter!). Eric B. bedankt 
voor alle hulp bij mijn eerste pogingen tot kloneren en jouw briljante kijk op 
de wereld. Calinda dank je wel voor alle goede zorgen voor onze piepers. 
Heel veel geluk met je jongste vierbenige aanwinst, en we zien elkaar vast 
nog wel eens op een Kane concert! Janneke ik wil je bedanken voor het 
lay outen van mijn proefschrift en voor het ontwerpen van de schitterende 
kaft. Heel veel succes met je bedrijf!
Junda, inge en ed, het was altijd lachen, gieren, brullen bij TNO. Junda, 
de verdeel en heers techniek heeft jammerlijk gefaald maar hopelijk vindt 
je dat niet al te erg. Inge jij hebt me de fijne kneepjes van het muizenvak 
geleerd, Mickey Mousen mag wat mij betreft in de dikke Van Dale. ED, 
inmiddels zijn we allebei een hele andere kant opgegaan maar we zien 
elkaar nog steeds, vaak onder het genot van gebak en (veel) koffie! Ik wens 
je veel geluk met Arya, Yannick en Menno. Op naar de eerste vrouwelijke 
kippen professor!
Mijn huidige collega’s van het Clinical Research Bureau wil ik ook 
bedanken voor hun medeleven de laatste 2 jaar. harry bedankt dat je die 
rare overgekwalificeerde labrat een kans wilde geven als monitor binnen 
jouw trialbureau. Heel veel succes in Canada! irene, edith en elke, bedankt 
voor alle positieve opbeurende woorden de afgelopen tijd, ze hebben zeker 
geholpen om vol te houden! ludi en pauline, we gaan er samen voor zorgen 
dat jullie mooie data uit de lopende studies gaan krijgen voor jullie proefschrift!
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Verder wil ik alle vrienden en (schoon)familie bedanken voor hun bijna 
eindeloze geduld. Ook al hadden veel van jullie geen idee wat ik in dat 
lab aan het uitspoken was of waarom alles ging zoals het is gegaan, toch 
bleven jullie vragen of er al schot in zat en bleven de opbeurende woorden 
mijn kant op komen. Bedankt daarvoor! elly en gerard, bedankt voor alle 
dagen dat jullie op de kinders hebben gepast zodat ik door kon gaan met 
schrijven. 
marianne, rogier, Jeanette, tom, angela, Chris, bernie, rob, diana, 
henry en wendy ik hoop dat we nog vele relaxte middagen en avonden 
voor de boeg hebben samen!
Lieve pap en mam, zonder jullie steun om door te zetten had dit 
proefschrift er niet gekomen. Ik ben jullie dankbaar voor de schop onder 
m’n kont om na het eerste (niet bijster succesvolle) jaar universiteit niet 
op te geven maar opnieuw te gaan beginnen met een schone lei. Na de 
zoveelste “en hoe staat het met…..” kon ik dan eindelijk zeggen dat het 
klaar is. Op naar vele vrije weekenden om samen leuke dingen met de 
ukkies te doen!
En dan mijn 2 best gelukte kloneringsexperimenten ooit, fynn en gwen. 
Onze twee wervelwinden in huis. We zullen elkaar in de toekomst nog 
regelmatig dwars gaan zitten lieve schatten, maar ik ben enorm trots op 
jullie! May all of your wishes come true for life!
En last but not least, niels. Wie zegt er dat mannen niet kunnen 
multitasken? Die van mij kan dat anders zeker wel! Variërend van 
aanstichter van dit hele gebeuren (ach joh het is toch gewoon werk?) tot 
psycholoog (niet zeiken maar doen!), cellen teller, oppas papa, betonnen 
muur, taxi chauffeur (sorry, alweer de laatste bus gemist) en personal 
coach. Lieve schat, zonder jou had ik al ontelbare keren het bijltje erbij 
neergegooid, maar iedere keer dat ik er doorheen zat heb je me kunnen 
motiveren om door te gaan. Doe het goed of doe het niet, is en blijft ons 
motto. Whatever is gonna happen, I belong to you!
JO
Dankwoord
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CurriCulum Vitae
De auteur van dit proefschrift werd geboren op 1 juni 1981 te 
’s-Gravenhage. Zij behaalde haar atheneum diploma in 1999 aan het Atlas 
College, te Rijswijk. Vervolgens heeft zij haar doctoraal  Bio-Farmaceutische 
Wetenschappen in 2005 behaald aan de Universiteit Leiden. Tijdens deze 
opleiding heeft zij 1 jaar in vivo onderzoek gedaan naar de dynamiek van 
cel adhesie eiwitten tijdens renale schade en regeneratie onder leiding 
van Prof. Dr. B. Van de Water, Dr. M. De Grauw en Dr. M. Alderliesten. 
Aansluitend hierop heeft zij  nog  11 maanden onderzoek gedaan binnen 
TNO Quality of Life te Leiden, naar de functie van C-type lectinen in een in 
vivo model voor auto-immuun encephalomyelitis (EAE) onder begeleiding 
van Dr. L.  Nagelkerken en Dr. J.M. Kel.  In augustus 2005 is zij begonnen 
als promovenda in de groep van Dr. M. Von Lindern en Prof. Dr. I.P. Touw 
op de afdeling hematologie van het Erasmus MC. Het werk dat voor dit 
promotietraject is uitgevoerd, staat beschreven in het proefschrift dat 
nu voor u ligt. In april 2010 is zij begonnen als monitor bij het Clinical 
Research Bureau van de afdeling Maag-, Darm- en Leverziekten binnen 
het Erasmus MC. Sinds april 2011 is zij werkzaam als projectmanager 
binnen hetzelfde onderzoeksbureau. 
Judith Proefschrift.indb   193 27-12-2012   16:34:11
194 Publicat ions
publiCations
Loss of Ercc1 results in a time- and dose-dependent reduction of 
proliferating early hematopoietic progenitors. Judith h.E. Verhagen-
oldenampsen, Jurgen R. Haanstra, Paulina M.H. van Strien, Marijke 
Valkhof,  Ivo P. Touw and Marieke von Lindern. Anemia 2012 Article ID 
783068
Critical role of p53 in interstrand-crosslink induced bone marrow failure 
and associated leukemic transformation . Jurgen R. Haanstra, Judith 
Verhagen-oldenampsen, Paulina M.H. van Strien, Marijke Valkhof, Björn 
Schumacher, Ivo P. Touw and Marieke von Lindern. Submitted
Attenuated expansion and erythropoietin-induced signal transduction 
in Fanca and Fancg knockout erythroblasts is a p53-mediated response 
to defective repair of interstrand crosslinked DNA. Emile van den Akker, 
Henri J. van de Vrugt, Judith Verhagen-oldenampsen, Godfrey Grech, 
Ivo Touw, Fré Arwert, Marieke von Lindern. Submitted
Wnt-signaling in erythroblasts is controlled by p53. Judith Verhagen-
oldenampsen, Sarah Duit, Pavel Vaclavik, Nuno Andrade, Ernst W. 
Müllner, Johannes Nimpf and Marieke von Lindern. Submitted
Extracellular signal-regulated kinase activation during renal ischemia/
reperfusion mediates focal adhesion dissolution and renal injury. Maaike 
Alderliesten, Marjo de Graauw, Judith oldenampsen, Yu Qin, Chantal 
Pont, Liesbeth van Buren and Bob van de Water . Am J Pathol. 2007 
Aug;171(2):452-62.
Soluble mannosylated myelin peptide inhibits the encephalitogenicity of 
autoreactive T cells during experimental autoimmune encephalomyelitis. 
Junda Kel, Judith oldenampsen, Mariken Luca, Jan Wouter Drijfhout, 
Frits Koning, Lex Nagelkerken. Am J Pathol. 2007 Jan;170(1):272-80.
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phd portfolio summary 
summary of phd training and teaching activities
Name PhD student: Judith Verhagen-Oldenampsen              PhD period: 01-08-2005 to 1-2-2010
Erasmus MC Department: Hematology                                  Promotor: Prof. Dr. I.P. Touw
Research School: Molecular Medicine (MM)                          Co-promotor: Dr. M. Von Lindern
1. Phd training    
Year (eCts)
Courses 
- In Vivo Imaging – from cell to Organism
- Basic and Translational Oncology
- Annual Course Molecular Medicine
- Biomedical Research Techniques V
- Signal Transduction and Disease (MGC)
- Genome Maintenance and Cancer (MGC)
- Transgenesis and Gene Targeting (MGC)
- Development, stem cells and disease (MGC)
2005
2005
2006
2006
2006
2007
2007
2007
1.8
1.8
0.7
1.5
1.1
1.0
1.5
1.0
workshops and seminars
- Workshop Molecular Therapeutics in Acute Leukemia
- Workshop Browsing Genes and Genomes with Ensembl
- Workshop Indesign
- Erasmus Hematology Lectures
2005
2007
2011
2005-2010
0.5
0.6
0.3
3.0
oral presentations
- Hematology presentations
- Journal Club presentations
- 3rd Dutch hematology Congres
- 4th Dutch hematology Congres
poster presentations (5x)
 
2005-2010
2005-2010
2009
2010
2005-2010
 
5.0
1.5
0.5
0.5
3.0
(inter) national conferences
- 6 Symposia and Congresses
 
2005-2010
 
7.0
2. teaching activities      
 Year eCts
lecturing
- Hematopoiesis course for 1st year Medicine Students
- Supervising Master student Rotation (1 week)
2007
2010
0.5
0.5
total 33.3
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